<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
January 1, 1999
(Date of Report - earliest event reported)
DURA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-19809 95-3645543
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
7475 LUSK BLVD., SAN DIEGO, CALIFORNIA 92121
(Address of principal executive offices) (Zip Code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE IS (619) 457-2553
<PAGE>
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS
On January 1, 1999, Dura Pharmaceuticals, Inc. (the "Company") acquired from
Bristol-Myers Squibb Company ("BMS") the exclusive U.S. distribution rights
for the patented hospital antibiotic products Maxipime-Registered Trademark-
IV/IM (cefepime hydrochloride) and Azactam-Registered Trademark- IV/IM
(aztreonam) (collectively, the "Products"), pursuant to a Distribution
Agreement effective such date. The purchase price consisted of $60 million
paid in cash at closing, payments totaling $4 million due in 1999, and a
payment of $70 million due in 2003, plus additional contingent payments due
from 1999 through 2003 based on sales of the Products during that period.
The initial cash payment was funded from the Company's existing cash and the
Company expects to fund future payments from existing cash balances.
BMS will manufacture and supply the Products under a separate Supply
Agreement effective January 1, 1999 (the "Supply Agreement"). The Company
will establish a hospital-based sales force to market the Products. Pursuant
to an interim services agreement between BMS and the Company, BMS will
co-promote the Products during 1999 as the Company builds its hospital sales
force.
The Products generated combined U.S. sales for BMS for the years ending
December 31, 1996, 1997, and 1998, of approximately $43 million, $50 million,
and $59 million, respectively. Based on the terms of the Supply Agreement,
the Company expects that direct cost of sales of the Products will be
approximately 23 % of net sales, which is consistent with the cost of sales
incurred by BMS during the periods discussed above.
2
<PAGE>
ITEM 7. EXHIBITS
2.1 Distribution Agreement for Maxipime-Registered Trademark- and
Azactam-Registered Trademark- between Bristol-Myers Squibb Company and
Dura Pharmaceuticals, Inc.* The exhibits referenced in the Distribution
Agreement have not been included because they are either disclosed in
such agreement or would not be material to an investment decision; they
will be provided to the Commission upon request.
2.2 Supply Agreement for Maxipime-Registered Trademark- and Azactam-Registered
Trademark- between Bristol-Myers Squibb Company and Dura Pharmaceuticals,
Inc.* The exhibits referenced in the Supply Agreement have not been
included because they are either disclosed in such agreement or would not
be material to an investment decision; they will be provided to the
Commission upon request.
99.1 Press Release dated December 22, 1998 issued by the Company.
*Certain confidential portions of this Exhibit were omitted by means of marking
such portions with an asterisk (the "Mark"). This Exhibit has been filed with
the Secretary of the Commission without the Mark pursuant to the Company's
application requesting confidential treatment under Rule 24b-2 under the
Securities Exchange Act of 1934, as amended.
3
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report on Form 8-K to be signed on its behalf
by the undersigned hereunto duly authorized.
DURA PHARMACEUTICALS, INC.
Date: January 15, 1999 /s/ MICHAEL T. BORER
---------------------------
Michael T. Borer
Sr. Vice President and
Chief Financial Officer
4
<PAGE>
DURA PHARMACEUTICALS, INC.
FORM 8-K
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
2.1 Distribution Agreement for Maxipime-Registered Trademark- and
Azactam-Registered Trademark- between Bristol-Myers Squibb
Company and Dura Pharmaceuticals, Inc.* The exhibits referenced
in the Distribution Agreement have not been included because they
are either disclosed in such agreement or would not be material
to an investment decision; they will be provided to the
Commission upon request.
2.2 Supply Agreement for Maxipime-Registered Trademark- and
Azactam-Registered Trademark- between Bristol-Myers Squibb
Company and Dura Pharmaceuticals, Inc.* The exhibits referenced
in the Supply Agreement have not been included because they are
either disclosed in such agreement or would not be material to an
investment decision; they will be provided to the Commission upon
request.
99.1 Press Release dated December 22, 1998 issued by the Company.
*Certain confidential portions of this Exhibit were omitted by means of marking
such portions with an asterisk (the "Mark"). This Exhibit has been filed with
the Secretary of the Commission without the Mark pursuant to the Company's
application requesting confidential treatment under Rule 24b-2 under the
Securities Exchange Act of 1934, as amended.
<PAGE>
Exhibit 2.1*
DISTRIBUTION AGREEMENT
FOR MAXIPIME-Registered Trademark- AND AZACTAM-Registered Trademark-
This AGREEMENT is made between Bristol-Myers Squibb Company, a
corporation duly organized and existing under the laws of the state of
Delaware, having offices at Route 206 and Province Line Road, Princeton, New
Jersey 08543-4000 ("BMS") and Dura Pharmaceuticals, Inc., a corporation duly
organized and existing under the laws of the State of Delaware, and having
offices at 7475 Lusk Boulevard, San Diego, CA 92121 ("DURA").
RECITALS
A. BMS markets two products known as Maxipime-Registered
Trademark-(Cefepime Hydrochloride) and Azactam-Registered Trademark-
(Aztreonam) in various formulations and strengths.
B. DURA wishes to obtain the right to distribute, market, and sell
these two products in the United States and to use BMS's trademarks for such
two products in such country, and BMS wishes to grant such rights to DURA, on
the terms and conditions set forth in this Agreement.
C. By separate agreement of even date herewith, DURA has agreed to
purchase from BMS, and BMS has agreed to supply to DURA, DURA's entire
requirements of each Product (as hereinafter defined), for use in the United
States only, pursuant to the terms and conditions set forth in such separate
Supply Agreement (as defined below).
NOW, THEREFORE, in consideration of the foregoing recitals and the
mutual covenants and agreements of the Parties contained in this Agreement,
the Parties agree as follows:
1. DEFINITIONS.
For all purposes of this Agreement, (i) the terms defined in this
Article 1 will have those meanings set forth in this Article 1, unless the
context in the text of the Agreement dictates otherwise; and (ii) all dollar
amounts refer to United States dollars.
"ABBOTT LICENSE AGREEMENT" means the Agreement executed in 1985 between
Abbott Laboratories, Inc. ("Abbott") and Bristol-Myers Squibb Company, as
heretofore amended and as the same may be amended hereafter, covering, among
other matters, the license by Abbott to make and use ADD-Vantage-TM- Vials
containing certain BMS drugs, including Maxipime-Registered Trademark-,
within the Territory.
"AFFILIATE", with respect to any Party, means any Person controlling,
controlled by, or under common control with, such Party. For these purposes,
"control" shall refer to: (a) the possession, directly or indirectly, of the
power to direct the management or policies of a Person or to veto any
material decision relating to the management or policies
1
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
of a Person, in each case, whether through the ownership of voting
securities, by contract or otherwise, or (b) the ownership, directly or
indirectly, of at least 50% of the voting securities of a Person.
"AGREEMENT" means this agreement, together with all appendices, exhibits
and schedules hereto, and as the same may be amended or supplemented from
time to time hereafter by a written agreement duly executed by authorized
representatives of each Party hereto.
"AGREEMENT QUARTER" means each three-month period commencing on the
first day of January, April, July, or October, as the case may be, during the
Term.
"AGREEMENT YEAR" means each 12-month period commencing on January 1
during the applicable Term for any Product.
"AZACTAM-Registered Trademark- TERM" has the meaning set forth in
Section 13.1 hereof.
"BAXTER SUPPLY AGREEMENT" means the Agreement dated June 6, 1986 between
Travenol Laboratories, Inc. ("Baxter") and E.R. Squibb & Sons, Inc., as
heretofore amended and as the same may be amended hereafter, covering, among
other matters, the supply by Baxter to BMS of Azactam-Registered Trademark-
in packaged, premixed, sterile filled and frozen form in Baxter's
VIAFLEX-Registered Trademark- plastic container delivery system (now know as
the GALAXY-Registered Trademark- system) within the Territory.
"BMS ENTITIES" means BMS and those BMS entities that (i) distribute,
sell, or market any of the Products in the Territory; (ii) own or control any
of the rights licensed to DURA hereunder; (iii) own or control any of the
assets that are used in and are material to the conduct of the Business;
and/or (iv) are party to any Third Party contracts that are material to the
conduct of the Business.
"BUNDLED CONTRACTS" has the meaning set forth in Section 3.5.
"BUSINESS" means the manufacture, distribution, sale and marketing of
the Products within the Territory as conducted by BMS and its Affiliates as
of the Execution Date. The Business does not include any of the operations,
technology, intellectual property rights, research or assets relating to (A)
any other product of BMS or any of its Affiliates or (B) the manufacture,
distribution, marketing or sale of the Products for use outside the
Territory.
"CLINICAL TRIALS COMMITTEE" has the meaning set forth in Section 5.2
hereof.
"COMMERCIALLY REASONABLE EFFORTS" of a Party shall mean those efforts
consistent with the exercise of its prudent scientific and business judgment
as applied to other research, development and commercialization efforts for
products of similar scientific and commercial potential within the research
programs and relevant product lines of such Party.
2
<PAGE>
"CONFIDENTIAL INFORMATION" has the meaning set forth in Article 12
hereof.
"CONFIDENTIALITY AGREEMENT" has the meaning set forth in Section 12.1.3
hereof.
"CONTROL" or "CONTROLLED BY" means, with respect to a right or license
granted hereunder, possession by a Party or its Affiliates of the ability to
grant a license or sublicense or to supply a Product in accordance with the
terms of this Agreement, and without violating the terms of any agreement by
such Party with any Third Party.
"EFFECTIVE DATE" means January 1, 1999.
"EXECUTION DATE" means the date that this Agreement is signed by the
last Party to sign below.
"FDA" means the United States Food and Drug Administration.
"FUJISAWA LICENSE AGREEMENT" means the Agreement dated September 1,
1984, as amended heretofore and from time to time hereafter, between Fujisawa
Pharmaceutical Company, Ltd, a Japanese corporation, and BMS covering the
license to BMS of certain U.S. and foreign patents covering certain
monocyclic beta-lactam compounds, including Aztreonam, starting materials,
intermediates and manufacturing processes thereof.
"IND" means an Investigational New Drug application filed with the FDA
for any Product requesting permission to perform human clinical studies in
accordance with 21 CFR Part 312, as the same may be amended or supplemented
from time to time hereafter.
"INITIAL TRAINING SESSION" has the meaning set forth in Section 4.3.1
hereof.
"INTERIM PERIOD" has the meaning set forth in Section 7.3 hereof.
"INTERIM SERVICES AGREEMENT" means the separate agreement of even date
herewith (as the same may be amended from time to time hereafter in
accordance with the terms thereof), under which BMS has agreed to provide
certain interim services and Product co-promotion services to DURA, as more
fully set forth therein.
"KNOW-HOW" means, for each Product, any and all technical data,
information, material and other know-how currently owned or controlled by BMS
and its Affiliates or that may hereafter during the relevant Term for such
Product be owned or controlled by BMS and its Affiliates and which relates to
preclinical and clinical development, use and marketing of such Product;
PROVIDED, however, that the foregoing shall not extend to any formulation or
Manufacturing Know-How (including without limitation manufacturing processes
and techniques and quality control assays and reference standards) owned or
controlled by BMS or any of its Affiliates.
3
<PAGE>
"LAWS" has the meaning set forth in Section 6.5 hereof.
"MAJOR PHARMACEUTICAL ENTITY" means (i) a Person for whom more than
fifty percent (50%) of the consolidated gross revenues of such Person and its
Affiliates are derived, as applicable, from (A) the sale, licensing and/or
distribution of drug products (whether prescription, generic or over-the
counter), nutritional agents and medical devices, and (B) the provision of
drug or device management services (such as a Pharmaceutical Benefits
Management (PBM) entity), and where such consolidated gross revenues have
exceeded, in any of the three most recent fiscal years for such Person, One
Billion Dollars ($1,000,000,000), and (ii) any Affiliate of a Person falling
within the scope of (i).
"MANUFACTURING KNOW-HOW" means, for each Product, any and all technical
data, information, material and other know-how currently owned or controlled
by BMS and its Affiliates or that may hereafter during the relevant Term for
such Product be owned or controlled by BMS and its Affiliates and which
relates to the formulation or manufacture of such Product (including without
limitation manufacturing processes and techniques, bulk actives,
intermediates and excipients, and quality control assays and reference
standards).
"MAXIPIME-Registered Trademark- TERM" has the meaning set forth in
Section 13.1 hereof.
"NDA" means a New Drug Application or Product License Application for
any Product, as appropriate, requesting permission to place a drug on the
market in accordance with 21 CFR Part 314, and all supplements filed pursuant
to the requirements of the FDA, including all documents, data and other
information concerning a Product which are necessary for FDA approval to
market a Product in the Territory.
"NET SALES" means, for a given Product for an applicable period, the
gross amount invoiced for such Product by DURA or its Affiliates to Third
Parties in the Territory, less the following amounts to the extent deducted
on such invoice or absorbed by DURA: (i) quantity, trade, and/or cash
discounts, allowances, rebates, and price adjustments or reductions allowed
or given; (ii) credits, rebates, chargebacks, or refunds allowed for
rejected, outdated or returned Products; and (iii) sales and other excise
taxes and duties directly related to the sale, to the extent that such items
are included in the gross invoice price (but not including taxes assessed
against the income derived from such sale). Deductions shall be determined in
accordance with Generally Accepted Accounting Principles, consistently
applied. If a Product is sold for compensation other than cash, Net Sales
shall be calculated based on the gross list price of the Product on the date
of sale in cash.
Notwithstanding the foregoing, if any Product is sold under a bundled
arrangement with other products, then, solely for the purpose of calculating
Net Sales for Other Payment purposes under Section 8.2 hereof, any discount
or rebate on Products sold under such an arrangement shall not exceed the
smallest discount or other rebate for any other product included within such
bundled arrangement for the applicable accounting period.
"PARTY" means BMS or DURA and, when used in the plural, shall mean BMS
and DURA.
4
<PAGE>
"PERSON" means any natural person, corporation, firm, business trust,
joint venture, association, organization, company, partnership, limited
liability company, or other business entity, or any government or any agency
or political subdivision thereof.
"PRODUCT" means: (i) any of the products listed on EXHIBIT 1.1A,
filled, packaged and labeled in accordance with applicable law and the
applicable Product Registration, including all strengths and packaging
configurations of the final finished dosage form presentations existing on
the Execution Date, (ii) and any new products, dosage forms, or other
presentations composed of either of the compounds Cefepime Hydrochloride or
Aztreonam, whether formulated with or without arginine, as may be added to
this Agreement pursuant to Section 4.8 hereof.
"PRODUCT CONTRACTS" has the meaning set forth in Section 3.5.
"PRODUCT REGISTRATIONS" means the approvals or registrations for each
Product which have been received by BMS in the Territory, including without
limitation each IND, Drug Master File (DMF), and NDA for each Product.
"RECALL" has the meaning set forth in Section 6.4 hereof.
"RELATED AGREEMENTS" means the Supply Agreement and the Interim Services
Agreement.
"SALES/MARKETING COMMITTEE" has the meaning set forth in Section 5.1
hereof.
"SPECIFICATIONS" for each Product means such specifications for each
Product as set forth in EXHIBIT 1.1B, as the same may be changed or
supplemented by mutual written agreement of the Parties from time to time
hereafter.
"SUPPLY AGREEMENT" means the separate agreement of even date herewith
(as the same may be amended or supplemented from time to time hereafter in
accordance with the terms thereof), under which DURA has agreed to purchase
from BMS, and BMS has agreed to supply to DURA, DURA's entire requirements of
each Product, for use in the United States only, pursuant to the terms and
conditions set forth in such separate agreement.
"TAKEDA LICENSE AGREEMENT" means the Agreement dated May 7, 1991, as
amended heretofore and from time to time hereafter, between Takeda Chemical
Industries, Ltd, a Japanese corporation, and BMS covering the license to BMS
of certain U.S. and foreign patents covering cephalosporins, including
Cefepime, starting materials, intermediates and manufacturing processes
thereof.
"TERM", without any other qualification, means the last to expire or
terminate of the Azactam-Registered Trademark- Term or the
Maxipime-Registered Trademark- Term, as set forth in Article 13 hereof.
"TERRITORY" means all fifty states of the United States of America. For
sake of clarity and avoidance of doubt,
5
<PAGE>
Puerto Rico and any U.S. possessions and territories are not part of the
Territory.
"THIRD PARTY" means any Person who or which is neither a Party nor an
Affiliate of a Party.
"TO THE KNOWLEDGE OF" of a specified entity or any similar term means to
the actual knowledge of the officers and key employees of the specified
entity having operating responsibility for the business of such entity.
"TRADEMARKS" means the trademarks registered by BMS for the marketing of
the Products in the Territory, as more fully set forth on EXHIBIT 1.1A
attached hereto. For sake of clarity and avoidance of doubt, the Trademarks
do not include any of the names (or variants thereof) of Bristol-Myers Squibb
Company and any of its Affiliates or any marks customarily associated with
such names.
2. RIGHTS AND TRANSFER.
2.1 GRANT OF DISTRIBUTION RIGHTS. Subject to the terms and conditions
of this Agreement, BMS hereby grants to DURA an exclusive (including, except
as set forth in the Interim Services Agreement, as to BMS) right to
distribute, market, sell, and promote each Product in the Territory,
commencing as of the Effective Date, during the applicable Term for such
Product. DURA may distribute, market, sell, and promote each Product only in
the Territory and for use only in accordance with applicable law, each
Product's labeling, and the applicable Product Registrations for such Product
in the Territory as the same are in force and effect from time to time during
the applicable Term for such Product. DURA may not use, re-export, sell or
transfer the Products outside the Territory. BMS or its designee shall have
the right to inspect at reasonable times, during business hours upon
reasonable advance notice to DURA, DURA's Product inventory, its shipping
records, and its facilities designated for storage and shipping of Products
to ensure compliance with the foregoing and with any other terms and
conditions of this Agreement.
2.2 GRANT OF TRADEMARK LICENSE.
2.2.1 Subject to the terms and conditions of this Agreement,
BMS hereby grants to DURA the exclusive (including, except as set forth in a
Related Agreement, even as to BMS) right and license, without the right to
sublicense, to use the Trademarks during the applicable Term for the Products
associated with such Trademarks in the Territory solely to the extent
necessary to distribute, market, promote and sell Products within the
Territory in accordance with this Agreement.
2.2.2 Provided that this Agreement has not been terminated,
either in whole or, as to a given Product, in part, prior to the end of the
applicable Term for a given Product, then, at the end of such Term, DURA
agrees to buy, and BMS agrees to sell, all rights, title and interests owned
by BMS in and to all Trademarks for such Product in the Territory, for a
payment of One Hundred Dollars ($100.00). Nothing in the foregoing shall be
construed as giving DURA any right or license, express or implied, to use
such Trademarks outside the Territory for any purpose.
6
<PAGE>
2.2.3 If, after acquisition of a Trademark in accordance with
Section 2.2.2, DURA permanently ceases to market a Product in the Territory
or desires to sell or license a Trademark to a Third Party for use within the
Territory, then BMS shall have the first right and option, exercisable within
sixty (60) days following receipt of a written notice from DURA that one of
the foregoing conditions has occurred, to purchase from DURA all rights,
title and interests owned by DURA in and to such Trademark in the Territory,
for a payment of One Hundred Dollars ($100.00).
2.2.4 BMS will book all sales for Product orders received by it
prior to the Effective Date; DURA will book all sales for Product orders
received after the Effective Date.
2.3 NO SUBLICENSING.
2.3.1 Subject to Section 2.3.2, DURA shall not be entitled to
sublicense any of the rights granted to it under this Article 2 or to grant
sub-distribution rights to any Product to any Third Party (including without
limitation co-promotion rights), without the prior written consent of a
Vice-President or higher of BMS, to be given or withheld in BMS' sole and
absolute discretion. No right or license under any patent rights or know-how
owned or controlled by BMS or any of its Affiliates to make and/or have made
any Product or any active ingredient therein is granted under this Agreement
to DURA. Subject to Section 2.2.3 and provided that this Agreement has not
been terminated, either in whole or, as to a given Product, in part, prior to
the end of the Term for a given Product, then, at the end of such Term, the
restrictions on sublicensing and sub-distribution set forth in this Section
2.3.1 for the corresponding Product shall expire.
2.3.2 DURA shall have the right to sublicense the rights
granted in this Article 2 to its Affiliates (and to Third Parties where any
required prior written consent of BMS has been obtained in accordance with
Section 2.3.1), provided that: (i) DURA hereby unconditionally guarantees,
and shall be jointly and severally responsible and liable, for the making of
all payments due and the making of reports under this Agreement by reason of
sales of any Product by its Affiliates or such approved Third Parties and
their compliance with all applicable terms of this Agreement; and (ii) each
Affiliate and such Third Party shall have first agreed in writing with DURA
and BMS to keep all necessary books and records and to permit BMS to review
such books and records pursuant to this Agreement and to observe all other
applicable obligations and terms imposed on DURA under this Agreement in the
same manner as DURA hereunder. In the event of a breach by an Affiliate or
an approved Third Party in the observance of applicable terms of this
Agreement, BMS shall be entitled to proceed directly against DURA, in
addition to BMS being entitled to proceed directly or concurrently against
such Affiliate or Third Party, to enforce this Agreement or to pursue any
remedies available to it, at law or in equity. In the event of a termination
of this Agreement prior to applicable Term for a given Product where DURA has
sublicensed rights with respect to such Product in accordance with this
Section 2.3.2, such sublicensee's rights shall terminate at the same time as
DURA's rights under this Article 2 to such Product shall terminate.
3. DURA RESPONSIBILITIES.
7
<PAGE>
3.1 DILIGENCE. During the applicable Term for a given Product and
subject to the terms and conditions of this Agreement, DURA shall use
commercially reasonable efforts to (i) distribute, market, sell, and promote
such Product within the Territory and (ii) create and maintain a market for
and to increase the sales of Products in the Territory. In the performance
of such obligations, DURA shall:
3.1.1 use commercially reasonable efforts to maintain and provide at
its expense an organization of qualified, professional
salespersons as set forth in Section 3.2;
3.1.2 maintain and provide at its expense suitable storage in
accordance with the Specifications and labeling and other
appropriate facilities and services reasonably satisfactory to
BMS, as needed for the storage and continuous sale and
distribution of Products within the Territory;
3.1.3 use commercially reasonable efforts to solicit new customers and
to maintain existing customers for the Products;
3.1.4 use commercially reasonable efforts to ensure that sufficient
stock of each Product will be available in its inventory to fill
orders from the trade in accordance with normal industry
practices, including maintaining reasonable levels of inventory
in light of customary industry practice and historical sales
patterns;
3.1.5 use commercially reasonable efforts to conduct at its expense
appropriate promotional activities for the Product sufficient for
DURA to achieve adequate and reasonably rapid market penetration;
3.1.6 provide, at its expense, an adequate Product traceability system
(e.g. lot level traceability, readily accessible format),
reasonably satisfactory to BMS;
3.1.7 ensure that its sales force personnel do not make representations
or claims with respect to the safety, efficacy or uses for a
Product that are not contained within such Product's applicable
Product Registration and/or labeling and/or that are not
permitted by applicable law;
3.1.8 market and sell Products only on the basis of quality, service,
price and other legitimate marketing attributes, and without the
payment of bribes or any similar inducements;
3.1.9 observe and perform all provisions of this Agreement, and comply
with all pertinent laws and regulations in force in the
Territory; and
3.1.10 use commercially reasonable efforts not to take any action which
would have a material adverse impact on (i) the commercialization
of the Products in the Territory or (ii) the then existing
business
8
<PAGE>
of BMS, its Affiliates and licensees with respect to the
Products in other countries of the world (taken as a whole).
3.2 SALES FORCE. Except as the Parties may otherwise separately agree
to in writing, DURA shall be solely responsible for the costs and expenses of
establishing and maintaining its sales force and conducting its other
activities under this Agreement and shall have sole authority to control its
sales force and direct the activities of its sales force. Although DURA's
sales force may consist of employees, individual contractors, and individual
telemarketers, DURA agrees that it will not contract with any Person to
provide sales force personnel to assist DURA in marketing a Product (and
whose activities shall be controlled or coordinated by DURA) without the
prior written consent of BMS (such consent not to be unreasonably withheld
for any entity that is not a Major Pharmaceutical Company); provided that:
(i) (A)DURA hereby unconditionally guarantees, and shall be jointly and
severally responsible and liable, for the compliance by any such Person with
their compliance with all applicable terms of this Agreement; and (B) each
such Third Party shall have first agreed in writing with DURA and BMS to
keep all necessary books and records and to permit BMS to review such books
and records pursuant to this Agreement and to observe all other applicable
obligations and terms imposed on Dura under this Agreement, and (ii) DURA
does not breach Article 2 of this Agreement in contracting with such entity
to provide such sales force personnel. Upon payment by DURA of all amounts
required to be paid under Article 8 hereof and so long as Article 2 hereof is
not violated, then DURA shall not thereafter be required to obtain BMS' prior
written consent as set forth in this paragraph (but shall continue to be
subject to (i) and (ii) above) with respect to any such Person with which it
may contract to provide sales force personnel for a Product.
DURA acknowledges that BMS is not, and shall not be, responsible to
DURA, to DURA's employees, agents, representatives or contractors, or to any
governmental entity for any compensation or benefits (including, without
limitation, vacation and holiday remuneration, health care coverage or
insurance, life insurance, pension or profit-sharing benefits and disability
benefits), payroll-related taxes or withholdings, or any governmental charges
or benefits (including without limitation unemployment and disability
insurance contributions or benefits and workmen' compensation contributions
or benefits) that may be payable to, imposed upon, or be related to the
performance of this Agreement by, DURA's employees, agents, representatives
or contractors, all of which shall be solely a matter between DURA and such
Persons and governmental entities. All such matters of compensation,
benefits and other terms of employment for any employee, agent,
representative or contractor used by DURA in the performance of this
Agreement shall be solely a matter between DURA and such Person(s).
DURA acknowledges and agrees that any individual employees, agents,
representatives, contractors or other Persons used by DURA to perform its
obligations under this Agreement (i) are not employees of Bristol-Myers
Squibb Company or any of its Affiliates, and that such Persons are not
eligible to participate in any "employee benefit plans", as such term is
defined in Section 3(3) of the Employee Retirement Income Security Act of
1974, as amended ("ERISA"), that are sponsored by BMS or any of its
Affiliates, and (ii) is, and shall be deemed to have been, engaged solely by
DURA and not by BMS, even if it is subsequently determined by any court, the
IRS or any other governmental agency that such individual may be a common law
employee of BMS or any of its affiliates or subsidiaries.
9
<PAGE>
3.3 PROMOTIONAL MATERIALS.
3.3.1 DURA shall be solely responsible for designing, preparing
and distributing at its sole expense all promotional materials and
advertisements used in the promotion and marketing of the Products within the
Territory. DURA will ensure that such materials and advertisements comply
with, and DURA will be solely responsible and liable for any failure of such
materials to comply with, the applicable labeling and Product Registration
for a given Product and with applicable law and regulations, notwithstanding
any prior review and/or approval of such materials by BMS and notwithstanding
that such materials may have been previously reviewed or used by BMS. DURA
shall be solely responsible for submitting all promotional and advertising
materials prepared by or for it to FDA for review and approval following
review by BMS and for negotiating with FDA for approvals of such materials;
PROVIDED, that BMS has submitted to FDA such authorization as may be required
by law for DURA to submit such promotional and advertising materials (which
BMS will use commercially reasonable efforts to effect as promptly as
reasonably practicable after the Effective Date); and PROVIDED, FURTHER, that
DURA shall promptly inform BMS of the substance of any responses received to
such materials (and provide a copy of any written responses received from or
sent to FDA with respect thereto). DURA shall absorb and be solely
responsible for any lost profits, lost revenues, damages, losses and costs
incurred by DURA, its Affiliates, BMS, or any Third Party arising from the
failure of any promotional materials developed by DURA to comply with the
applicable labeling and Product Registrations and with applicable law and
regulations.
3.3.2 BMS shall provide DURA with all current and available
advertising and promotional materials used by BMS relating to the Products,
and shall permit DURA, subject to compliance by DURA with applicable law and
regulation and to the following paragraph, to adapt and use such materials in
the Territory in developing new promotional materials (subject to the prior
written approval of BMS in accordance with Section 3.3.3 of any adapted or
revised materials, not to be unreasonably withheld, and subject to Section
3.3.1 and to any copyrights or other rights reserved to BMS, its Affiliates
and to Third Parties in such materials).
BMS reserves and retains title and all rights, including copyright
rights, in and to all written, visual and electronic works and other
materials (including without limitation training materials, promotion
materials, brochures and other detail literature) provided by it to DURA
under this Agreement, as well as any adaptions thereof or "derivative works"
(as such term is defined in the U.S. Copyright Code, 17 U.S.C. Section 101
ET. SEQ.) derived or developed by DURA from or with such works and materials.
Subject to the foregoing, DURA is granted the nonexclusive right under this
Section to use, copy, modify, and distribute such materials only in
furtherance of this Agreement and the rights granted to it hereunder, for the
applicable Term for a given Product to which such works and materials relate.
DURA will ensure that all copyright notices and this permission notice
appear on all copies of the written materials provided by BMS and all
adaptations and derivative works thereof.
3.3.3 All detail brochures and other printed materials, all print,
television, radio, and other media advertising materials, and all training
materials shall be subject to the prior review and written approval of BMS (not
10
<PAGE>
to be unreasonably withheld). The individual to whom these shall be sent
will be designated by BMS upon execution of this Agreement and from time to
time thereafter upon written notice to DURA. BMS shall have fifteen (15)
working days from receipt of the material to respond with any objections; and
if no objections are received, DURA may proceed with its planned use of the
materials as submitted for approval. After BMS has achieved a level of
comfort with DURA's ability to prepare such materials in compliance with
applicable law and the Product labeling (which the Parties will review
periodically, but not less often semi-annually), BMS agrees to consider (but
without any obligation to so agree) mechanisms to limit thereafter the
materials that need to be reviewed in advance by BMS.
With respect to any brochures, training materials, or
promotional or advertising materials (or pertinent portions thereof)
developed by DURA that compare or position a Product to (or involve Product
strategy vis-a-vis) BMS' gatifloxacin product or other compounds within
gatifloxacin's class of compounds, BMS shall designate a single individual
within its Promotional Compliance or Regulatory Affairs Department to review
such materials (or the pertinent portions thereof relating to such comparison
or positioning) and shall use commercially reasonable efforts to limit access
to such materials (or the pertinent portions thereof relating to such
comparison or positioning) by individuals within its marketing and sales
groups (except where review by an individual within such group is necessary
to ensure compliance by such materials with applicable law and the Product
labeling).
3.3.4 During the first two (2) years of this Agreement, DURA
shall provide BMS, within five (5) working days of transmission, complete
copies and/or transcripts of all home office generated (for example, those
sent out by DURA's Sales, Marketing and Sales Training departments)
communications (whether written, electronic or visual aids) sent to a
majority of DURA sales representatives concerning the promotion of any
Product, as well as all written, electronic and visual communications
provided to a majority of DURA sales representatives regarding Product
strategy, positioning or selling messages. The individual to whom these shall
be sent will be designated by BMS upon execution of this Agreement.
Following such two-year period, DURA shall provide all such transmissions and
materials to BMS not less frequently than once per calendar quarter.
3.3.5 DURA shall have strategic responsibility and sole
authority and responsibility at its expense for conducting and developing
symposia, seminars, technical and scientific exhibits and other professional
relations events with respect to the Products within the Territory.
3.4 USE OF TRADEMARKS. Until such time as DURA may have acquired
ownership of a Trademark pursuant to Section 2.2.2 (at which time, all of the
obligations set forth below in this Section 3.4 on the part of BMS shall
become the responsibility of DURA with respect to such Trademark):
3.4.1 DURA shall use the Trademarks, and no other trademarks, to
promote, sell and distribute the Products within the Territory. DURA shall be
identified as the distributor of each Product on the Product label as the same
may be required and specified under applicable law, or if applicable law does
not specify how the distributor shall be indicated on a Product's label, then as
determined (including without limitation as to size and placement) by BMS
11
<PAGE>
in consultation with DURA. The use of the Trademarks by DURA shall be
subject to the prior review and written approval of BMS as set forth in this
Section 3.4, which shall not be unreasonably withheld.
3.4.2 DURA shall permit duly authorized representatives of BMS
to inspect, on the premises of DURA, at reasonable times during normal
business hours and on reasonable advance notice, Product inventory, DURA's
quality control records, and DURA's facilities used in or relating to the
storage, distribution or sale of the Products to ensure compliance with
quality control standards and with applicable terms of this Agreement
pertaining to the use of the Trademarks.
3.4.3 Whenever DURA uses the Trademarks in advertising or in
any other manner in connection with the Product, DURA shall clearly indicate
BMS's ownership of the Trademarks. DURA shall provide to a person designated
by BMS samples of all literature and advertising using the Trademarks
prepared by or for DURA and intended to be used by DURA, for approval of such
use by BMS (which consent shall not be unreasonably withheld). If no
objection is received from BMS within 15 business days of receipt by BMS of
such samples, DURA may use the Trademarks in the manner used in the samples
submitted to BMS for approval. When using the Trademarks under this
Agreement, DURA undertakes to comply with all laws pertaining to Trademarks
in force at any time in the Territory.
3.4.4 If applicable law permits, BMS shall make an application
to register DURA as a Permitted User or Registered User of the Trademarks
and, if necessary, or if requested by BMS, DURA undertakes to join in such
application and to take such action as may be necessary or requested by BMS
to implement such application or retain, enforce or defend the Trademarks.
3.4.5 DURA acknowledges that BMS is the owner of the
Trademarks. DURA shall not at any time do, cause to be done, or permit any
act or thing inconsistent with, contesting or in any way impairing or tending
to impair such ownership. DURA agrees that all use of the Trademarks by DURA
shall inure to the benefit of and be on behalf of BMS. DURA acknowledges
that nothing in this Agreement shall give DURA any right, title or interest
in the Trademarks other than the right to use the Trademarks within the
Territory in accordance with this Agreement. DURA agrees that it will not
challenge the title or ownership of BMS to the Trademarks or attack or
contest the validity of the Trademarks. All goodwill accruing to the
Trademarks as a result of the use of the Trademarks in the performance of
this Agreement shall belong solely to BMS.
3.5 CONTRACT ASSUMPTION.
3.5.1 BMS will provide to DURA, either before or promptly
following the Execution Date, subject to any confidentiality obligations it may
have to Third Parties, a copy of all written agreements as of the Execution Date
between BMS (or any of its Affiliates) and a Third Party specifically relating
to the supply of Products, and only the Products, to such Third Party within the
Territory ("PRODUCT CONTRACTS"). All such contracts represent Confidential
Information of BMS. To the extent transferable or assignable, and subject to
any required consents of Third Parties, all
12
<PAGE>
rights, interests, covenants, and obligations of BMS or any of its Affiliates
in and under such Product Contracts, as the same shall be in force and effect
as of the Effective Date, shall be assigned by BMS (or such BMS Affiliate, as
applicable) to DURA and DURA shall accept such assignment and assume all
rights, interests, covenants, and obligations of BMS thereunder thereafter,
except: (i) to the extent that (A) such rights, interests and obligations
shall have accrued prior to the Effective Date (in which event such rights,
interests and obligations shall remain with BMS), or (B) such rights,
interests, covenants and obligations relate to any liability or obligation
which DURA is not assuming or agreeing to perform under this Agreement, or
(ii) as provided in the Interim Services Agreement.
DURA acknowledges that certain Product Contracts may require
consents to the assignment thereof to DURA. Each Party will use commercially
reasonably efforts, and will cooperate with the other, to obtain such
consents under such Product Contracts as expeditiously as reasonably
practicable, such consents to be effective, where possible, as of the
Effective Date. DURA agrees that the failure to obtain any such consent as
of the Effective Date or any resulting breach under any such Product Contract
by reason of the execution and performance of this Agreement by BMS and DURA
shall not constitute a breach of this Agreement. BMS shall use its
commercially reasonable efforts to provide to DURA the benefits from the sale
of Products under such Product Contracts from and after the Effective Date
for orders received after the Effective Date, and, to the extent that BMS
receives such benefits after the Effective Date, BMS shall, subject to
Section 7.1.2 hereof and any applicable terms of the Interim Services
Agreement, pay to DURA the net amount BMS receives from the sale of any
Product under any Product Contracts (based on the amount received by BMS with
respect to such sales of such Product and, except where otherwise specified
in the Interim Services Agreement, such reasonable costs as are allocated by
BMS to its efforts on behalf of DURA with respect to such Product Contract
and Product in accordance with BMS' normal accounting practices) until such
time as DURA enters into an agreement with such customer for the sale by it
of any such Product to such customer in lieu of such Product Contract. In
the event that a Product Contract requires that BMS pay an administrative or
marketing fee, or make any other payment (or grant any discounts), to such
Third Party on account of such Product Contract with respect to the services
provided by such Third Party, or, in cases where the Product Contract sets
the pricing for certain institutions that are part of such Third Party's
purchasing group, with respect to the volume level of purchases achieved by
such participating institutions, then DURA shall be responsible for all such
payments or discounts to be made or granted for such administrative and other
services provided by such Third Party after the Effective Date (and which, if
paid by BMS because such Product Contract is not immediately assignable on
the Effective Date, will be reimbursed by DURA to BMS or deducted by BMS from
the net amount payable to DURA hereunder with respect to such Product
Contract).
Nothing in this Section 3.5.1 shall require DURA to assume,
and DURA does not assume, any obligation or liability under any such Product
Contract with respect to the manufacture of a given Product.
3.5.2 DURA acknowledges that BMS possesses certain written
agreements as of the Execution Date between BMS (or any of its Affiliates) and a
Third Party that cover both the supply of one or more Products, as well as other
BMS products, to such Third Party within the Territory ("BUNDLED CONTRACTS").
Subject to Section 3.5.3, such contracts will not be assigned to DURA. EXHIBIT
3.6.2 sets forth a listing of such contracts, to the extent known by BMS'
13
<PAGE>
Office of Pricing Administration as of the day before the Execution Date.
BMS shall use its commercially reasonable efforts to provide to DURA the
benefits from the sale of Products under such Bundled Contracts from and
after the Effective Date for orders received by BMS after the Effective Date,
and, to the extent that BMS receives such benefits after the Effective Date,
BMS shall, subject to Section 7.1.2 hereof and any applicable terms of the
Interim Services Agreement, pay to DURA the net amount BMS receives from
such sale of any Product under any Bundled Contracts (based on the amount
received by BMS with respect to sales of such Product and, except where
otherwise specified in the Interim Services Agreement, such reasonable costs
as are allocated by BMS to its efforts on behalf of DURA with respect to such
Bundled Contract and Product in accordance with BMS' normal accounting
practices) until such time as DURA enters into an agreement with such
customer for the sale by it of any such Product to such customer in lieu of
such Bundled Contract. In the event that a Bundled Contract requires that
BMS pay an administrative or marketing fee, or make any other payment (or
grant discounts), to such Third Party on account of such Bundled Contract
with respect to the services provided by such Third Party, or, in cases where
the Bundled Contract sets the pricing for certain institutions that are part
of such Third Party's purchasing group with respect to the volume level of
purchases achieved by such participating institutions, then DURA shall be
responsible for all such payments or discounts to be made or granted for such
administrative and other services provided by such Third Party after the
Effective Date with respect to the Products only (and which, if paid by BMS
because such Bundled Contract is not immediately assignable on the Effective
Date, will be reimbursed by DURA to BMS or deducted by BMS from the net
amount payable to DURA hereunder with respect to such Bundled Contract).
3.5.3 DURA and BMS acknowledge that certain regulatory
requirements for Product Contracts with governmental agencies and
instrumentalities do not permit DURA, even though it may be entitled to ship
Products under such contract to such customer, to bill such customers for
Product shipped to such customer by DURA until DURA is approved in accordance
with applicable procedure for such governmental agency or instrumentality as
a distributor of the Product. In such event, BMS shall bill such customers
on behalf of DURA at the price and terms agreed to by DURA. BMS shall,
subject to Section 7.1.2 hereof and any applicable terms of the Interim
Services Agreement, pay to DURA the net amount BMS receives from the sale of
any such Product (based on the amount received by BMS with respect to sales
of such Product and such reasonable costs as are allocated by BMS to its
efforts on behalf of DURA with respect to such Contract and Product in
accordance with BMS' normal accounting practices) until such time as DURA is
approved as a distributor by such governmental agency or authority and is
able to bill such entity directly. DURA shall use commercially reasonable
efforts to obtain such approval as expeditiously as reasonably practicable,
and BMS will reasonably cooperate with DURA in connection therewith.
3.5.4 BMS and Dura shall cooperate with each other in notifying
all customers and other interested Third Parties who have a need to know of
the consummation of the transactions contemplated by this Agreement.
3.5.5 DURA and BMS shall reasonably cooperate to obtain all
necessary governmental approvals and to revise, redesign, and prepare all
necessary packaging and labels in accordance with applicable law and this
14
<PAGE>
Agreement so that DURA's NDC number may appear on all Product sold by it as
expeditiously as reasonably practicable after receipt of all such approvals.
3.5.6 DURA and BMS acknowledge that certain Product Contracts
and/or Bundled Contracts may require that future pricing under such contracts
for a given Product are based on market share/penetration obtained by the
contractee for such Product. Except as may be provided in the Interim
Services Agreement, DURA shall be responsible after the Effective Date for
obtaining, and for the cost of obtaining, all market share data, including
IMS America data where required by such contracts.
3.6 NONCOMPETE. * DURA and its Affiliates shall not market, promote,
distribute, or sell any injectable (i.v. or i.m.) cephalosporin antibiotic
product other than Maxipime-Registered Trademark- or any injectable (i.v. or
i.m.) monobactam product other than Azactam-Registered Trademark- without the
prior written consent of BMS; PROVIDED, that (i) the foregoing shall not
prevent DURA from acquiring, or being acquired by, a company that is actively
developing (i.e., in Phase II studies or later), marketing promoting, or
distributing any such product; and (ii) where DURA can clearly and
convincingly demonstrate that the marketing, promotion, distribution or sale
of any such product will not materially cannibalize sales from, and otherwise
will not have the effect of preventing DURA from maximizing sales of, any
Product, then BMS agrees not to unreasonably withhold its consent to the
marketing, promotion, distribution, and sale of such product.
3.7 COMPLIANCE WITH BAXTER SUPPLY AGREEMENT. In order to ensure
compliance by BMS with the terms of the Baxter Supply Agreement, DURA agrees,
during the term of the Baxter Supply Agreement, that it will comply with any
obligations imposed upon BMS under such agreement that can only be met by
DURA following the Effective Date as the distributor and marketer of the
Product, including but not limited to:
3.7.1 DURA will not market a frozen or premixed presentation of
any Azactam-Registered Trademark- Product within the Territory other than one
manufactured for BMS by Baxter under the terms of the Baxter Supply
Agreement; and
3.7.2 DURA will use, in addition to any other obligations
imposed upon it hereunder, its best efforts to market the Azactam-Registered
Trademark-Products in the Territory and reasonably cooperate with Baxter to
support and facilitate the sale of such Products.
3.8 COMPLIANCE WITH ABBOTT LICENSE AGREEMENT. In order to ensure
compliance by BMS with the terms of the Abbott License Agreement, DURA
agrees, during the term of the Abbott License Agreement, that it will comply
with any obligations imposed upon BMS under such agreement that can only be
met by DURA following the Effective Date as the distributor and marketer of
each Product covered by the license rights granted under such Agreement,
including but not limited to:
3.8.1 DURA will share non-confidential, NDA-related information
with Abbott so that the NDA
15
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
submissions by Abbott for its Add-Vantage Vials can be supported by Abbott;
and
3.8.2 DURA will share pertinent market research information
associated with the ADD-Vantage System (including but not limited to focus
group studies, quantitative market surveys, time and motion pharmacy studies
and drug waste studies), excluding, however, any market research data
relating to (i) information or data obtained by DURA from Third Parties which
is subject to a confidential commitment which prohibits disclosure to Abbott
and (ii) pricing or market research data, the disclosure of which either
Party in good faith believes would violate applicable law.
3.9 RESALE OF PRODUCT IN SAME PACKAGING. DURA shall not alter in any
manner each Product or its packaging as sold to it by BMS and shall resell
each Product without alteration in the form sold to it by BMS.
4. BMS RESPONSIBILITIES.
4.1 SUPPLY OF PRODUCT. In order to ensure the quality of the Products
to be sold by DURA under the Trademarks, DURA shall purchase, and BMS shall
supply to DURA, subject to the terms and conditions as set forth in the
Supply Agreement. DURA's requirements of the Product(s) for marketing, sale
and distribution by DURA in the Territory during the applicable Term for such
Product. All Products supplied to DURA shall be in finished dosage form,
filled, labeled, and packaged for commercial sale in accordance with
applicable law and the applicable Product Registrations in the Territory and
in accordance with the terms of this Agreement and any Related Agreement.
4.2 RETENTION OF REGISTRATIONAL DOSSIER.
4.2.1 BMS shall retain all rights, title and interests in and
to the Product Registrations for each Product in the Territory. DURA shall
not at any time do, cause to be done, or omit or permit any act inconsistent
with the Product Registration for any Product in the Territory. In the event
that any filings are required to be made with or approvals required to be
obtained from applicable regulatory authorities in order to sell a Product to
DURA or for DURA to initiate marketing and sale of a Product in the
Territory, the Parties shall cooperate fully to ensure that such filings and
approvals are obtained or made as expeditiously as reasonably practicable.
4.2.2 BMS shall have sole responsibility for maintaining, and
shall use commercially reasonable efforts to maintain, the Product Registrations
in the Territory at its expense, including without limitation filing IND and NDA
Annual Reports. BMS shall keep DURA informed on a timely basis as to any
developments that would have a material adverse effect on a Product
Registration. Subject to such limitations as BMS may have under the Abbott
License Agreement and the Baxter Supply Agreement with respect to access to and
disclosure of information contained in the product registrations filed by such
Third Parties with respect to their plastic container systems used in the
manufacture of a Product, BMS shall provide DURA, upon request after reasonable
notice from DURA, with access to copies of all filings submitted by BMS to the
NDA for each Product (other than to the CMC section) and, with respect to
clinical trials for the Products sponsored by BMS that are included in the NDA
for a given Product, copies of the
16
<PAGE>
Application Summary for such Product, which provides a comprehensive summary
of all clinical trials conducted under the NDA for such Product. Nothing set
forth herein shall permit DURA to photocopy or otherwise make a reproduction
of the NDAs without the prior written consent of a Vice President of BMS.
DURA shall cooperate with BMS with respect to obtaining and/or maintaining
the Product Registrations, and shall execute, acknowledge and deliver such
further instruments at BMS' request and expense, and use commercially
reasonable efforts to do all such other acts, as promptly as possible, which
may be necessary or appropriate to obtain and maintain the Product
Registrations in the Territory. DURA shall, on a timely basis, provide to
BMS all information that DURA has from time to time during the applicable
Term for each Product that BMS does not have that is reasonably necessary and
relevant to BMS's obligations hereunder to fulfill such Product Registration
maintenance requirements (including, but not limited to, providing sales
distribution information concerning the Products), and shall otherwise
cooperate with BMS as reasonably necessary in connection therewith. BMS
shall have the final decision-making authority in every case on whether and
how to supplement, amend or otherwise alter the Product Registrations and any
other issues in connection with such Product Registrations (including, but
not limited to, decisions to recall the Products) and on whether and how to
communicate with the FDA and other applicable governmental agencies or
authorities in connection therewith; PROVIDED, that BMS will not, except
where required by, or to fulfill its obligations under, applicable law or
except where required by a governmental agency or authority acting within the
scope of its authority, supplement, amend or otherwise alter a Product
Registration so as to materially and adversely alter the rights granted to
DURA hereunder that are derived from such Product Registration.
4.2.3 BMS shall provide DURA with reasonable written notice
of, and DURA shall be entitled to be present at, all meetings with the FDA
with respect to any Product (other than meetings and audits pertaining to
manufacturing processes and manufacturing issues), provided that such
participation does not result in any undue delay or interfere with BMS'
relationship with FDA.
4.2.4 BMS and Dura each shall make its facilities available at
reasonable times during business hours for inspection by representatives of
governmental agencies. BMS and Dura each shall notify the other within
twenty-four (24) hours of receipt of any notice or any other indication
whatsoever of any FDA or other governmental agency inspection, investigation
or other inquiry, or other material governmental notice or communication of
any type, involving the sale, manufacture, or use of the Products within the
Territory. Dura and BMS shall cooperate with each other during any such
inspection, investigation or other inquiry including, but not limited to,
allowing upon request a representative of the other to be present during the
applicable portions of any such inspection, investigation or other inquiry
and providing copies of all relevant documents (it being understood that BMS
shall not be required to provide Dura with, and shall be entitled to redact
from any writing, any information relating to Manufacturing Know-How and that
DURA shall not be entitled to be present at inspections that would involve
access to or disclosure of BMS Manufacturing Know-How). Dura and BMS shall
discuss any response to observations or notifications received in connection
with any such inspection, investigation or other inquiry and each shall give
the other an opportunity to comment upon any proposed response before it is
made. In the event of disagreement concerning the form or content of such
response, however, BMS shall be responsible for deciding the appropriate form
and content of any response with
17
<PAGE>
respect to any of its cited activities and Dura shall be responsible for
deciding the appropriate form and content of any response with respect to any
of its cited activities. DURA will provide BMS with copies of all
correspondence received by it from, or filed by it with, any federal, state
or local regulatory authority to the extent pertaining to each Product and/or
its distribution, promotion, or sale in the Territory.
4.2.5 All Product sold after the Effective Date will be sold
under a BMS label, whereby the Product will be identified as a BMS Product
with DURA identified as the distributor thereof (except for Product supplied
pursuant to the Baxter Supply Agreement, under which Baxter will be indicated
as the manufacturer). BMS shall control all package inserts and labeling
(and any changes or supplements thereto) for each Product in the Territory,
and shall have the responsibility at its expense for securing any approvals
required by FDA to any such changes or supplements thereto (except for
Product supplied under the Baxter Supply Agreement to the extent Baxter
retains any such responsibility). DURA shall not at any time do, cause to be
done, or omit or permit any act inconsistent with the then existing package
inserts and labeling for any Product in the Territory. In the event that any
filings are required to be made with or approvals required to be obtained
from applicable regulatory authorities in order to change or supplement the
package inserts and labeling, BMS shall have the sole right and discretion on
how to effect such changes at BMS' expense (and Baxter shall have such right,
to the extent it retains same under the Baxter Supply Agreement, to effect
such changes, at DURA's or Baxter's expense, as provided in said Baxter
Supply Agreement). BMS shall consult with DURA with respect to any such
changes or supplements to the label for any Product, and DURA shall cooperate
fully with BMS with respect to any actions or decisions taken or made by BMS
with respect thereto; PROVIDED, that BMS will not, except where required by,
or to fulfill its obligations under, applicable law or except where required
by a governmental agency or authority acting within the scope of its
authority, supplement, amend or otherwise alter a Product's package insert or
labeling so as to materially and adversely alter the rights granted to DURA
hereunder that are derived from such Product's package insert and/or labeling.
4.2.6 Subject to the terms and conditions of this Agreement and
any Related Agreement, BMS will consider in good faith proposals (including
without limitation new delivery systems) by DURA to maximize sales of the
Products (but without any obligation, express or implied, on BMS' part to
agree to same). Nothing in this Agreement shall require BMS, expressly or
impliedly, to participate in or agree to participate in such proposal put
forth by DURA for maximizing sales of the Products without BMS' prior written
consent (to be given or withheld in BMS' sole and absolute discretion).
4.3 TRAINING OF DURA SALES FORCE.
4.3.1 The Parties intend that BMS will provide DURA's sales force
with the same or substantially similar training with respect to promotion of the
Products as has been given traditionally to BMS's sales force in the Territory
(it being understood that such training shall be specific to each Product itself
and its uses, as opposed to general sales skills training). BMS and DURA will
hold * training sessions ("INITIAL TRAINING SESSIONS") for the DURA
sales force, which shall be held on * mutually convenient dates within twelve
(12) months after the Effective Date of
18
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
this Agreement, and which will be held at a location mutually acceptable to
BMS and DURA. The Sales/Marketing Committee will determine the content of
each such Initial Training Session, and shall review the Product-related
training materials and make recommendations for any revisions and updates
thereto as the Committee may deem appropriate; PROVIDED, that BMS shall
determine and be solely responsible for the content, development, and
associated cost of all training materials. All members of the DURA sales
force (including management and representatives) shall attend a
Product-related training program, whether as part of an Initial Training
Session or a subsequent training program conducted by DURA or BMS. DURA
shall bear the full cost and expense of all of its sales force and other
personnel who attend a Product-related training program, without contribution
from BMS. BMS shall bear the costs and expenses of its training personnel
provided for the Initial Training Sessions. DURA shall reimburse BMS for any
out-of-pocket costs incurred by BMS for any subsequent training programs for
which participation by BMS personnel has been requested by DURA and approved
by BMS.
4.3.2 Training of DURA sales representatives and other
personnel following the * Training Sessions shall be the responsibility of
DURA and at its cost and expense. The contents of any training provided by
DURA that relates to the Products shall be coordinated by DURA (subject to
BMS' prior review and prior written approval of such training materials in
the same manner as, and subject to the same terms and conditions as, BMS
reviews and approves promotional materials pursuant to Section 3.3). From
time to time as training materials for the Products may be revised by either
Party (the timing and content of which shall be determined by a Party in the
exercise of its sole and absolute discretion or as mandated by regulatory
agencies), such Party will make such training materials available to the
other Party and its Affiliates for its own internal training use thereafter.
4.4 PROSECUTION AND MAINTENANCE OF PATENTS AND TRADEMARKS. Until such
time as DURA may have acquired ownership of a Trademark pursuant to Section
2.2.2 (at which time, all of the obligations set forth in Sections 4.4.1 and
4.4.2 below on the part of BMS shall become the responsibility of DURA with
respect to such Trademark):
4.4.1 BMS shall use commercially reasonable efforts to register
and maintain, or cause to be registered and maintained, at its cost and
expense, the Trademarks in the Territory during the Term of this Agreement.
If DURA learns of any unauthorized use of the Trademarks by others in the
Territory, DURA agrees to promptly notify BMS of such unauthorized use.
4.4.2 BMS shall use commercially reasonable efforts to
prosecute and maintain, at its cost and expense, any patent rights covering
the composition, formulation, and use of a Product in the Territory during
the applicable Term for such Product. In the event that any extension,
registration, confirmation, reissue, renewal, reexamination or
continuation-in-part is to be filed with respect to any such patent within
the Territory, BMS shall provide DURA with the opportunity to review such
extension, registration, confirmation, reissue, renewal, reexamination or
continuation-in-part and provide input thereto.
4.4.3 Notwithstanding any other provision of this Agreement that
may imply or provide to the
19
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
contrary, BMS shall have the sole right, but not the obligation, at its sole
discretion and expense, to prosecute, maintain, enforce, defend or abandon
any patent rights and know-how owned or controlled by BMS covering the
manufacture of a Product, except that BMS shall use commercially reasonable
efforts to maintain, at its cost and expense, its rights under the patent
rights, know-how, and/or trademarks licensed to it under (i) the Takeda
License Agreement, (ii) the Fujisawa License Agreement, and (iii) the Abbott
License Agreement. DURA understands and accepts that Takeda, Fujisawa, and
Abbott are entitled in their sole and absolute discretion to prosecute,
maintain, enforce, defend or abandon (or license to Third Parties, to the
extent same is nonexclusively licensed to BMS) any patent rights, trademarks,
and/or know-how licensed by any of them to BMS under the Takeda License
Agreement, the Fujisawa License Agreement and/or the Abbott License
Agreement, as applicable. The foregoing shall not require BMS to grant
additional rights or to provide any additional consideration to Takeda,
Fujisawa or Abbott, as the case may be, beyond that which BMS is obligated
to pay or provide under the terms of the current applicable agreement.
4.4.4 Notwithstanding any provision of this Agreement that may
imply or provide to the contrary, BMS shall have the sole right, but not the
obligation, at its sole discretion and expense, to maintain and enforce any
contract entered into by BMS covering the supply of any compounds,
intermediates, biomaterials, packaging components, containers and other
materials used in the manufacture of a Product, except that BMS shall use
commercially reasonable efforts to maintain, at its cost and expense, the
supply of premixed, frozen Azactam-Registered Trademark- Product under the
Baxter Supply Agreement. DURA understands and accepts that Baxter is
entitled in its sole and absolute discretion to prosecute, maintain, enforce,
defend or abandon (or license to Third Parties, to the extent same is
nonexclusively licensed to BMS) any patent rights, trademarks, and/or
know-how licensed by Baxter to BMS under the Baxter Supply Agreement, or
which Baxter may own or control with respect to the supply of any plastic
container or other component used by Baxter in making the premixed, frozen
presentation of the Azactam-Registered Trademark-Product. The foregoing
shall not require BMS to extend such Baxter Supply Agreement, to grant
additional rights to Baxter, or to provide any additional consideration to
Baxter beyond that which BMS is obligated to pay or provide under the terms
of the current applicable agreement.
4.5 NO RESTRICTION ON BMS BUSINESS. Nothing in this Agreement is
intended to limit or restrict BMS or its Affiliates in any way, expressly or
impliedly, from marketing during the applicable Term for a Product any
product that is competitive with a Product, other than a product containing
Cefepime Hydrochloride or Aztreonam. Except to the extent provided in
Section 4.6, nothing in this Agreement is intended to limit or restrict BMS
or its Affiliates in any way, expressly or impliedly, from developing during
the Term of this Agreement or any Related Agreement any product that is
competitive with a Product, including without limitation any product
containing Cefepime Hydrochloride or Aztreonam for commercial sale as a
generic product following expiration of the applicable Term for such Product.
4.6 NO DIRECT COUNTERDETAILING. BMS will instruct its sales force
personnel not to, and will use commercially reasonable efforts to ensure that
its promotional materials do not, counterdetail or promote * directly and
specifically against any Product for a period of * years following the
Effective Date (after which date such restriction shall lapse). It is
understood and agreed that the foregoing restriction does not,
20
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
and shall not be construed to, prevent BMS from counterdetailing or promoting
* directly and generally against products within the class of compounds of
which a Product is part.
In the event that both Parties desire for BMS to extend its
co-promotion efforts under the Interim Services Agreement beyond the one-year
term provided for therein, then the Parties agree to discuss in good faith
whether the term set forth in the preceding paragraph should be extended by
the same period of such co-promotion extension.
4.7 TAKEDA LICENSE. Under the Takeda License Agreement, BMS' license
rights to exclusively use the patents licensed to it thereunder in the
manufacture of Cefepime Hydrochloride are converted to nonexclusive rights
after April 30,2002. It is understood that BMS is under no obligation,
express or implied, to negotiate or reach any such agreement) for the
extension of exclusive rights under such patents for the manufacture and use
of Cefepime Hydrochloride within the Territory for the period after April
30, 2002 and extending beyond the applicable Maxipime-Registered Trademark-
Term, although at DURA's written request prior to January 1, 2000, BMS agrees
to approach Takeda to determine the terms of any such extension of
exclusivity under such Takeda patent rights within the Territory (it being
understood that BMS may also approach Takeda on its own to determine the
terms of any such extension within and/or outside the Territory). In the
event that BMS is able to reach tentative, non-binding agreement with Takeda
as to the terms of any such extension of exclusivity under such Takeda patent
rights within the Territory, then BMS shall notify DURA in writing of the
terms of such tentative agreement with respect to the Territory (which
tentative terms shall be kept in confidence by DURA). Such Notice shall also
include the additional costs, fees and other compensation payable by BMS to
Takeda that BMS would expect DURA to bear and any compensation requested by
BMS for obtaining an extension in the Territory. DURA shall have thirty (30)
days thereafter in which to notify BMS in writing ("Notice") as to whether
DURA would like BMS to pursue a binding agreement with Takeda for such
extension of exclusivity under such Takeda patent rights within the
Territory. If DURA fails to so notify BMS within such 30-day period, BMS
shall have no obligation thereafter, express or implied, under this Agreement
or any Related Agreement to negotiate any such extension of exclusivity under
the Takeda patent rights within the Territory following April 30, 2002.
If DURA timely provides a Notice to BMS, BMS shall use commercially
reasonable efforts to conclude a binding agreement with Takeda for the
extension of exclusivity under the Takeda patent rights within the Territory
following April 30, 2002 and beyond the Maxipime-Registered Trademark- Term,
subject to the following: BMS shall not be obligated in any way to enter
into a binding agreement with Takeda for such extension of exclusivity under
such Takeda patent rights within the Territory beyond April 30, 2002, unless
and until BMS and DURA shall have first agreed in writing: (i) that DURA will
pay or reimburse BMS for all additional costs, royalties, fees and other
compensation payable by BMS to Takeda (and that were disclosed by BMS to
DURA) under the Takeda License Agreement with respect to the use of the
licensed rights within the Territory that BMS would not otherwise have been
required to pay under the then existing Takeda License Agreement, and (ii)
upon such additional compensation as the Parties may mutually agree to in
writing that DURA will pay to BMS with respect to the period of time that
generic competition does not enter the market within the Territory following
the Maxipime-Registered Trademark- Term as a result of such extension of
exclusivity under the Takeda
21
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
patent rights beyond the Maxipime-Registered Trademark- Term.
Nothing herein shall limit BMS' ability or right to secure an
extension of such Takeda patent rights outside the Territory, as BMS may
determine in its sole discretion.
4.8 NO OBLIGATION TO DEVELOP NEW FORMULATIONS; CONVERSION TO DRY POWDER
FOR AZACTAM-Registered Trademark-.
4.8.1 BMS shall have no obligation, express or implied, to
develop new formulations, dosages, forms of administration, or preparations
for the Product, other than those in effect as of the Effective Date.
4.8.2 DURA acknowledges and accepts that BMS may, at BMS'
discretion and expense, pursue or conduct such studies as are necessary to
convert Azactam-Registered Trademark- (other than the frozen, premixed
presentation prepared by Baxter) from a lyophilized product to a crystalline,
sterile dry powder fill product. BMS shall be responsible for making any
regulatory filings and conducting any studies as are necessary, at its
expense, to obtain regulatory approval for such dry powder fill product for
Azactam-Registered Trademark-. Upon receipt of all regulatory approvals
needed to manufacture and market a dry powder fill product for
Azactam-Registered Trademark-, such product shall replace the lyophilized
Azactam-Registered Trademark- product as set forth in the Exhibits attached
to this Agreement and to any Related Agreement.
4.9 ORANGE BOOK UPDATE. BMS will use commercially reasonable efforts
at its expense to correct the Orange Book listing with FDA for
Azactam-Registered Trademark- to reflect that the formulation currently sold
by BMS includes arginine in the formulation as promptly as reasonably
practicable following the Execution Date. If any new formulations for a
Product are developed by BMS and BMS has received all necessary regulatory
approvals for the manufacture and marketing of same, BMS will commercially
reasonable efforts at its expense to update the Orange Book listing with FDA
to reflect the change in formulation for such Product as promptly as
reasonably practicable after receipt of all such necessary approvals. Except
as provided in the preceding two sentences, the Parties will cooperate and
appropriately allocate responsibilities for the purpose of making any
semi-annual updates to the Orange Book.
4.10 PHYSICIAN DESK REFERENCE (PDR). DURA will be responsible after the
Effective Date at its expense for all updates and corrections to the
Physician Desk Reference with respect to each Product (and shall list the
Product under DURA's name in the PDR), subject to prior review and approval
by BMS (not to be unreasonably withheld). BMS will reasonably cooperate with
DURA in connection therewith.
4.11 USP MONOGRAPH. BMS shall not update the USP Monograph (or the
Standards and Specifications contained therein) for a Product without the
prior written consent of DURA, nor shall BMS be obligated to update the USP
Monograph (or the Standards and Specifications contained therein) for a
Product except as DURA and BMS may mutually agree. If the Parties shall have
agreed upon a revision to be proposed to the USP Monograph, BMS shall be
22
<PAGE>
responsible for coordinating same, and shall use commercially reasonable
efforts to effect such revision. DURA will reimburse BMS for any reasonable
costs and expenses incurred by BMS in using commercially reasonable efforts
to effect such revision.
4.12 NO AMENDMENTS WITHOUT CONSENT. BMS agrees not to amend the Abbott
License Agreement, the Baxter Supply Agreement, the Fujisawa License
Agreement or the Takeda License Agreement in any manner that would materially
and adversely affect the rights of Dura within the Territory under this
Agreement or a Related Agreement, without the prior written consent of DURA
(not to be unreasonably withheld). The foregoing shall not apply to such
changes, if any, that BMS and the party to such other agreement may be
required to make in order to comply with applicable law or the labeling for a
given Product.
5. JOINT COMMITTEES.
5.1 SALES/MARKETING COMMITTEE.
5.1.1 A marketing committee for each Product will be
established promptly by BMS and DURA after execution of this Agreement (such
committee being referred to herein as the "SALES/MARKETING COMMITTEE"). The
principal purpose of the Sales/Marketing Committee shall be to create a forum
for enabling the Parties to coordinate, as appropriate, their respective
marketing strategies in an effort to maximize global sales of the Products.
In furtherance of such goal, each Party will consider in good faith (but
without any obligation to agree or participate), where appropriate and upon
presentation by the other Party, coordination and/or support of specific
marketing initiatives (such as the development of joint promotional programs)
by either or both Parties to build and maximize the global market for each
Product. Any sharing of costs or dedication of personnel to such coordinated
efforts shall require the unanimous written approval of all members of the
Sales/Marketing Committee, and any proposal made by a Party that would result
in costs incurred by the other Party shall be subject to prior written
approval of all members appointed by the other Party to the Sales/Marketing
Committee.
The Sales/Marketing Committee shall also be a forum for (i)
discussing revisions to, and the preparation of any new, materials directly
related to each Product that are to be used to train the Party's respective
sales forces; (ii) discussion of symposia, seminars and other professional
relations events of specific interest to customers; (iii) discussion of the
design and implementation of programs to encourage and improve cooperation
between BMS and DURA with respect to maximizing sales of the Product; and
(iv) performing such duties as are assigned to it under the Interim Services
Agreement..
5.1.2 The Sales/Marketing Committee shall be composed of six
(6) persons, with DURA and BMS each being entitled to designate three (3)
individuals. The initial members shall be designated by each Party in
writing promptly following execution of this Agreement. Each Party may
change its designated members at any time upon advance written notice to the
other Party (for BMS, notice must be sent to its Vice President, Infectious
Diseases
23
<PAGE>
Marketing; for DURA, notices must be sent to its Vice President, Marketing, of
any substitution of a member.
5.1.3 The Sales/Marketing Committee shall meet not less than
once in each Agreement Quarter during the Term or as otherwise agreed by the
Parties in the writing, at such locations as are designated by each Party
alternatingly. Each Party shall bear the costs and expenses of its designated
members that are incurred in connection with the Sales/Marketing Committee
meetings.
5.2 CLINICAL TRIALS COMMITTEE.
5.2.1 A clinical trials committee for the Products will be
established promptly by BMS and DURA after execution of this Agreement (such
committee being referred to herein as the "CLINICAL TRIALS COMMITTEE").
Subject to each of Sections 5.2.2 through 5.2.6 below, the principal purpose
of the Clinical Trials Committee shall be to create a forum for enabling the
Parties to coordinate, as appropriate, Phase I through V clinical trial
strategies in an effort to obtain approvals for the broadest and/or most
commercially important indications for each Product throughout the world and
to review and share results and data that may be obtained by each Party in
clinical trials sponsored by it for the Products throughout the world. In
furtherance of such goal, each Party will consider in good faith (but without
any obligation to agree or participate), where appropriate and upon
presentation by the other Party, coordination and/or support of specific
Phase I through V clinical trial initiatives by either or both Parties;
provided, that any sharing of costs for, or dedication of personnel to, any
joint efforts shall require the unanimous written approval of all members of
the Clinical Trials Committee, and any proposal made by a Party that would
result in costs incurred by the other Party shall be subject to prior written
approval of all members appointed by the other Party to the Clinical Trials
Committee.
The Clinical Trials Committee shall be composed of four (4)
persons, with DURA and BMS each being entitled to designate two (2)
individuals. The initial members shall be designated by each Party in writing
promptly following execution of this Agreement. Each Party may change its
designated members at any time upon advance written notice to the other
Party (for BMS, notice must be sent to its Vice President, Infectious
Diseases - Clinical; for DURA, notices must be sent to its Senior Vice
President, Clinical Development and Regulatory Affairs, of any substitution
of a member.
The Clinical Trials Committee shall meet not less than once in
each Agreement Quarter during the Term or as otherwise agreed by the Parties
in the writing, at such locations as are designated by each Party
alternatingly. Each Party shall bear the costs and expenses of its designated
members that are incurred in connection with the Clinical Trials Committee
meetings.
5.2.2 BMS shall be responsible for performing and completing at
its expense all Phase I through V clinical trials in the Territory that are
ongoing as of the Effective Date, and shall provide to DURA any results obtained
by BMS therefrom during the applicable Term for a Product at the same time as
such results are made available to BMS' senior management (it being understood
that, except as provided in Section 5.2.8 below, DURA shall not have access
24
<PAGE>
to the database from any such studies and, with respect to clinical trials
for the Products sponsored by BMS that are included in the NDA for a given
Product, copies of the Application Summary for such new studies for such
Product only shall be provided from the NDA). A list of all ongoing studies
within the Territory that are being conducted by BMS as of the Effective Date
will be provided to DURA within 30 days after the Effective Date. Except as
may be expressly set forth in the Interim Services Agreement, DURA shall be
solely responsible, at DURA's expense, for symposiums/speaker programs
pertaining to, and for working with the investigators/opinion leaders to
publish the results of, any such studies after the Effective Date. Any
clinical trials to be conducted within the Territory that are currently
planned but which have not yet begun to enroll subjects shall require DURA's
prior written consent for enrollment to commence, and any such studies for
which such enrollment is approved by DURA shall be conducted by BMS at DURA's
expense.
5.2.3 BMS shall be entitled to conduct any Phase I through V
clinical trials with respect to the Products outside the Territory, at BMS'
sole expense, as BMS may determine, sponsor, and structure in its sole and
absolute discretion. BMS shall not initiate any Phase I through V clinical
trials or studies within the Territory after the Effective Date except with
DURA's prior written consent (not to be unreasonably withheld). BMS will
consult with DURA with respect to any Phase I-III studies that BMS may wish
to initiate after the Effective Date and conduct outside the Territory
through meetings of the Clinical Trials Committee. BMS shall provide to DURA
the results obtained by BMS during the applicable Term for a Product from any
such Phase I through V studies initiated by BMS after the Effective Date at
the same time as such results are made available to BMS' senior management
(it being understood that, except as provided in Section 5.2.8 below, DURA
shall not have access to the database from any such studies and, with respect
to clinical trials for the Products sponsored by BMS that are included in the
NDA for a given Product, copies of the Application Summary for such new
studies for such Product only shall be provided from the NDA).
DURA shall be entitled to use all results obtained by BMS in
any such Phase IV or V clinical trials that are sponsored by BMS for any
appropriate advertising or promotional purpose within the Territory, without
restriction and without payment to BMS; PROVIDED, that DURA shall remain
solely responsible for the use of such results in promoting and advertising
the Products in the Territory in compliance with, and shall be solely
responsible and liable for any failure to so comply in the use thereof with,
applicable law and the applicable labeling and Product Registrations.
5.2.4 DURA shall not be entitled to conduct any Phase I through V
clinical trials with respect to the Products within the Territory, except where
it shall have obtained the prior written consent of BMS (which shall not be
unreasonably withheld by BMS with respect to Phase IV and Phase V studies that
DURA proposes to conduct within the Territory) as to the Study Protocol (and as
to any amendments or supplements thereto), any Investigator's brochure, the
investigators to be used for the conduct of the Study, and any compensation or
cost reimbursement to be provided to BMS in connection therewith. As between
BMS and DURA, DURA shall be solely responsible and liable for the conduct and
cost of any such Phase I through V clinical trials conducted and/or sponsored by
DURA that are approved by BMS (including without limitation for all payments to
be made to any clinical sites/investigators with respect to such studies, and
for all injuries, including death, suffered by, and for all damages payable to,
any patient in any such studies,
25
<PAGE>
except to the extent that the same may be the responsibility of BMS as set
forth in Articles 6, 7 and/or 8 of the Supply Agreement with respect to the
Product supplied by BMS). DURA shall provide the results, any case report
forms, any analyses, and the database obtained from any such Phase I through
V studies to BMS at the same time as the same are made available to DURA's
senior management. BMS shall be entitled to use, and to permit others to
use, all such results, case report forms, analyses, and data for any
appropriate advertising or promotional purpose outside the Territory and for
any regulatory filing purpose (including seeking approvals for new
indications for the Product) within or outside the Territory, without
restriction and without compensation to DURA; PROVIDED, that BMS shall remain
solely responsible for the use of such results in promoting and advertising
the Products outside the Territory in compliance with, and shall be solely
responsible and liable for any failure to so comply in the use thereof with,
applicable law and the applicable labeling and Product Registrations.
5.2.5 BMS shall have sole and absolute discretion in
determining whether to use any data obtained by DURA or by BMS from clinical
trials sponsored by either in filings with regulatory authorities in any
country within or outside the Territory. Subject to Section 5.2.4, BMS will
give good faith consideration to any request by DURA to file for additional
indications for any Product in the Territory where appropriate data to
support such filing is available; PROVIDED that DURA shall be responsible for
all out-of-pocket costs incurred by BMS in preparing and making any such
filings agreed to by BMS within the Territory.
5.2.6 In the event that any governmental authority in the
Territory having jurisdiction over the Product Registrations requires
additional clinical study(ies) to be performed on a Product, BMS shall be
sponsor and be responsible for the conduct of such study(ies), and the
Parties shall evenly bear the out-of-pocket costs of such studies. In such
event DURA and BMS will meet to review the reasons for such governmental
requirement and will confer on the best methods of complying with the request.
5.2.7 BMS maintains a database of Phase I-V studies for the
Products called the SENTRY database. Except as BMS and DURA may otherwise
agree to in writing, BMS shall be responsible, at its sole discretion, for
maintaining and updating the SENTRY database from time to time hereafter as
BMS may determine, it being understood that BMS shall not be obligated,
expressly or impliedly, to so maintain and update such database (BMS will
give DURA three months notice of any decision by BMS to cease maintenance or
update of such database, in which event BMS agrees to discuss with DURA, at
DURA's request, the transfer of such obligations to DURA). BMS shall bear
the cost of any such maintenance and updates. BMS will provide DURA with
access to BMS' SENTRY database so that DURA may use same to develop, at
DURA's expense, promotional and advertising materials and to conduct symposia
and speaker programs in accordance with the terms of this Agreement and with
applicable law. Such SENTRY database, and all intellectual property rights
pertaining thereto, shall remain the exclusive property of BMS.
5.2.8 BMS agrees to provide DURA with reasonable and
appropriate access to its clinical studies database for each Product to the
extent necessary for DURA to fulfill the Medical Information Services
obligations assumed by DURA pursuant to Section 6.2.
26
<PAGE>
6. ADVERSE REACTION REPORTING AND PRODUCT COMPLAINTS; MEDICAL INFORMATION
SERVICES; PRODUCT RETURNS; COMPLIANCE WITH LAW; COMPLIANCE AUDITS.
6.1 ADVERSE REACTION REPORTING; PRODUCT COMPLAINTS. DURA and BMS have
jointly developed written procedures for the reporting of adverse drug
experiences, as set forth on EXHIBIT 6.1. DURA and BMS shall each comply
with the provisions thereof.
6.2 MEDICAL INFORMATION SERVICES. DURA and BMS have jointly developed
written procedures for the administration of and response to medical
inquiries concerning the Products by consumers, physicians, pharmacists and
other health care professionals, as set forth in EXHIBIT 6.2. DURA and BMS
shall each comply with the provisions thereof.
6.3 PRODUCT RETURNS. DURA shall be responsible for all chargebacks and
returns of Products (and the financial impact thereof) sold on or after the
Effective Date, and BMS shall be responsible for all chargebacks and returns
of Products (and the financial impact thereof) sold prior to the Effective
Date in accordance with BMS' customary practices therefor; PROVIDED, however,
that if the Parties are unable to determine whether a particular Product was
sold before or after the date of this Agreement, then with respect to any
such Product, the Parties shall abide by the procedures and responsibilities
as set forth in the Interim Services Agreement. DURA shall be solely
responsible for the processing and disposal of all returned or rejected
Product for which it is financially responsible as provided in this Section
6.3.
6.4 PRODUCT RECALL. In the event that DURA obtains information that a
Product or any portion thereof should be alleged or proven not to meet the
Specifications, the labeling, or the Product Registration for such Product
in the Territory, DURA shall notify BMS immediately and both Parties shall
cooperate fully regarding the investigation and disposition of any such
matter. BMS and Dura shall each maintain such traceability records as are
sufficient and as may be necessary to permit a recall or field correction of
any Products. In the event (a) any applicable regulatory authority of a state
or country in the Territory should issue a request, directive or order that
a Product be recalled, or (b) a court of competent jurisdiction orders such a
recall, or (c) BMS determines that any Product already in interstate commerce
in the Territory presents a risk of injury or gross deception or is otherwise
defective and that recall of such Product is appropriate (a "RECALL"), each
Party shall give telephonic notice (to be confirmed in writing) to the other
within twenty-four (24) hours of the receipt of any event. BMS shall have
sole responsibility for determining all corrective action to be taken and for
carrying out the Recall. DURA will provide full cooperation and assistance to
BMS in connection therewith as may be requested by BMS. BMS shall be
responsible for all expenses of effecting any such Recall (including any
out-of-pocket expenses incurred by DURA in connection with such cooperation),
except (i) to the extent such Recall is attributable to any negligence on the
part of DURA or any material breach by DURA of its obligations under this
Agreement or any other agreement then in force and effect between DURA and
BMS, in which event DURA will reimburse BMS for its reasonable costs and
expenses incurred that are so attributable to such actions by DURA or (ii)
where the Product was manufactured by or for DURA (other than by BMS), in
which event DURA will reimburse BMS for its reasonable costs and expenses
incurred in effecting such Recall. Credits to DURA's customers
27
<PAGE>
for any recalls or withdrawals that are required by reason of BMS' failure to
manufacture a Product in accordance with its warranty set forth in Section
5.2.1 of the Supply Agreement shall be borne solely by BMS; credits to DURA's
customers for any other recalls or withdrawals shall be the solely the
responsibility of DURA.
6.5 COMPLIANCE WITH LAW. Each Party shall use commercially reasonable
efforts to maintain in full force and effect all necessary licenses, permits
and other authorizations required by law to carry out its duties and
obligations under this Agreement. Each Party shall comply with all laws,
ordinances, rules and regulations (collectively, "LAWS") applicable to its
activities under this Agreement and any Related Agreement, including without
limitation, any requirements of any product license applicable to the
Products in the Territory; PROVIDED, that DURA shall be solely responsible
for compliance with those Laws pertaining to the activities conducted by it
hereunder and any Related Agreement (including, without limitation, those
Laws that apply to documentation and records retention pertaining to the
distribution and use of Products within the Territory), notwithstanding that
FDA may, as a matter of law, be entitled to hold BMS accountable or
responsible (whether primarily or secondarily) for failure of DURA to comply
with such Laws. Records retention schedules by DURA shall be subject to BMS'
prior written approval (not to be unreasonably withheld). Without limiting
the generality of the foregoing, Dura shall not promote the Products for any
indications not contained in the approved NDAs or in any manner in conflict
with the approved labeling and all applicable Laws. DURA shall store and
distribute the Products and trade forms in compliance with all applicable
Laws, including, without limitation, applicable guidelines and policies of
the PDMA. BMS and DURA each shall keep all records and reports required to
be kept by applicable laws and regulations. The Parties will reasonably
cooperate with one another with the goal of ensuring full compliance with
Laws. Each Party will cooperate with the other to provide such letters,
documentation and other information on a timely basis as the other Party may
reasonably require to fulfill its reporting and other obligations under
applicable Laws to applicable regulatory authorities. Except for such
amounts as are expressly required to be paid by a Party to the other under
this Agreement or any Related Agreement, each Party shall be solely
responsible for any costs incurred by it to comply with its obligations under
applicable Laws.
6.6 REASONABLE COOPERATION. BMS and DURA each hereby agrees to use
commercially reasonable efforts to take, or cause to be taken, all actions
and to do, or cause to be done, all things necessary or proper to make
effective the transactions contemplated by this Agreement, including such
actions as may be reasonably necessary to obtain approvals and consents of
governmental Persons and other Persons (including, without limitation, all
NDA notifications to the FDA identifying DURA as a distributor of the
Products); PROVIDED, that no Party shall be required to (i) pay money (other
than as expressly required pursuant to this Agreement or a Related
Agreement), or (ii) assume any other material obligation not otherwise
required to be assumed by this Agreement or any Related Agreement.
6.7 COMPLIANCE AUDITS.
6.7.1 From time to time as BMS may elect during the applicable
Term for a given Product, during normal business hours and upon reasonable
notice from BMS (but not less than 10 days notice), DURA shall permit duly
authorized representatives of BMS to review and inspect the premises,
facilities, Product inventory, records and
28
<PAGE>
documentation maintained by DURA for the purpose of determining compliance by
DURA with its obligations under this Agreement and any Related Agreement.
6.7.2 From time to time as DURA may elect during the applicable
Term for a given Product, during normal business hours and upon reasonable
advance notice from DURA (but not less than 10 days notice), BMS shall permit
duly authorized representatives of DURA to inspect, on the premises of BMS
where such records and inventory are kept, finished Product inventory and
BMS' quality control records relating to the storage of the finished Products
to ensure compliance with quality control standards and the labeling for each
such Product and with applicable terms of this Agreement pertaining to the
use of the Trademarks; PROVIDED, that nothing in the foregoing shall allow or
be construed to allow DURA to have access to any Manufacturing Know-How of
BMS or any records containing or pertaining to same.
7. PRICING; REVENUE RECOGNITION; BEST PRICE ISSUES; CONDUCT OF BUSINESS BY BMS
AFTER EXECUTION DATE.
7.1 PRICING; BEST PRICE ADJUSTMENT.
7.1.1 From and after the Effective Date and subject to Section
7.1.2, DURA shall have the sole authority to determine the price of a Product
sold by it during the applicable Term for such Product, including price
increases or decreases and the timing thereof as determined by DURA. DURA
will use commercially reasonable efforts to provide reasonable advance
notice to BMS prior to implementing any price change, but such consultation
shall not restrict or limit DURA's sole authority and discretion to implement
changes.
7.1.2 In the event that the price, discount or other terms of
sale charged or applied by DURA for any Product sold by it after the
Effective Date should create a refund, rebate or other payment obligation on
the part of BMS or any of its Affiliates to a Third Party under any contract
for such Product entered into by BMS with such Third Party prior to the
Effective Date (e.g., under best price provisions applicable to Medicaid
contracts entered into by BMS) beyond and in addition to that which BMS would
have been obligated to refund, rebate or reimburse using the prices charged
by BMS and without regard to the price, discount or other terms of sale
charged or applied by DURA, DURA shall repay to BMS such additional amount
required to be paid or paid by BMS within 30 days after receipt of written
notice from BMS with respect to same and of a reasonably detailed calculation
of how such amount was determined.
7.1.3 BMS shall keep for three (3) years from the date of each
payment by DURA to BMS under Section 7.1.2 complete and accurate records of
sales and all other information necessary to accurately calculate such payment.
DURA shall have the right through its representatives or an independent,
certified public accountant to audit such records at the place or places of
business where such records are customarily kept in order to verify the accuracy
of same. Such audits may be exercised once per year during normal business
hours upon fifteen (15) days' advance written notice to BMS. DURA shall bear
the full cost of such audit unless such audit discloses a variance of more than
29
<PAGE>
five percent (5%) from the amount due, in which event, BMS shall bear the
full cost of such audit. DURA may not disclose confidential information
concerning such payment and reports, any contract information upon which such
payments are determined, and all other information learned in the course of
any audit or inspection, except to the extent necessary for DURA to reveal
such information in order to enforce its rights under this Agreement or if
disclosure is required by law. Any amounts that are determined to be due and
owing by BMS to DURA or by DURA to BMS following such audit shall be paid
within ten (10) business days thereafter, together with any interest due
thereon (as determined in accordance with Section 8.3.4) for amounts owing by
BMS to DURA only. Any non-employee representatives of DURA shall execute an
appropriate confidentiality agreement reasonably acceptable to BMS.
7.2 REVENUE RECOGNITION. From and after the Effective Date, except as
may be otherwise set forth in the Interim Services Agreement, DURA will book
all sales of each Product made by it, with all sales to be made pursuant to a
contract between DURA and the customer. Except as may be otherwise set forth
in the Interim Services Agreement, from and after the Effective Date DURA
shall have the sole responsibility, at its cost and expense, for shipping
(except as provided in the Baxter Supply Agreement) and distribution of each
Product to its customers, for warehousing, for the invoicing and billing of
purchasers of the Product, for order confirmation (if any) in accordance with
DURA's customary practices, and for the collection of receivables resulting
from sales of the Product.
7.3 CONDUCT OF BUSINESS BY BMS AFTER THE EXECUTION DATE THROUGH
EFFECTIVE DATE. From and after the Execution Date through the end of the
business day immediately preceding the Effective Date (the "INTERIM PERIOD"):
7.3.1 BMS shall conduct its business pertaining to the Products
in the ordinary course conducted by it prior to the Execution Date; and
7.3.2 BMS will book all sales of each Product made by it during
the Interim Period, with all sales to be made pursuant to a contract between
BMS and the customer. BMS shall have the sole responsibility, at its cost
and expense, for shipping and distribution of a Product to its customers, for
warehousing, for the invoicing and billing of purchasers of the Product, for
order confirmation (if any) in accordance with BMS's customary practices, and
for the collection of receivables resulting from sales of the Product.
8. FEES AND OTHER PAYMENTS
8.1 FEES. DURA shall pay to BMS the following sums:
8.1.1 Sixty Million Dollars (US$60,000,000) on or before December
31, 1998. This payment shall be non-refundable, and shall not be creditable
against any future payments of any character made by DURA under this Agreement.
8.1.2 Except as provided in Section 8.1.3, Seventy Million Dollars
(US$70,000,000) on December
30
<PAGE>
31, 2003. Except as provided in Section 8.1.3, this payment shall be
non-refundable, and shall not be creditable against any prior or future
payments of any character made by DURA under this Agreement.
8.1.3 In the event that BMS terminates this Agreement as to a
given Product pursuant to Section 13.4.2, and such termination is made by BMS
voluntarily and not in response to a request by FDA to initiate action and/or
in reasonable anticipation of an action or a request by FDA that would
require or result in such an action by BMS to withdraw such Product from the
market, then, the Parties agree that if such decision is made by BMS prior to
the expiration of the applicable Term for such Product, then BMS shall repay
to DURA (or, where the payment required by Section 8.1.2 has not yet been
made, then DURA shall be entitled to deduct from such payment to be made)
such amount as determined in accordance with the Schedule attached as EXHIBIT
8.1.3 hereto.
8.1.4 DURA shall pay to BMS the sum of One Million Dollars
($1,000,000) on each of March 31, 1999, June 30, 1999, September 30, 1999 and
December 31, 1999; PROVIDED, that if DURA loses marketing exclusivity for
the Products in the Territory at any time during 1999, DURA shall not be
required to make the remaining payments that would otherwise be made in 1999
under this Section 8.1.4.
8.2 OTHER PAYMENTS. DURA shall make the following additional payments
("Other Payments") to BMS, as follows:
- * of Net Sales of all Products for calendar year 1999;
- * of Net Sales of all Products for calendar year 2000;
- * of Net Sales of all Products for calendar year 2001;
- * of Net Sales of all Products for calendar year 2002;
- * of Net Sales of all Products for calendar year 2003.
Upon payment by DURA of all amounts due by it under Sections 7.1.2, 8.1 and 8.2,
DURA shall have a fully paid-up license to use the rights granted to it
hereunder for the remainder of each of the Azactam-Registered Trademark- Term
and the Maxipime-Registered Trademark- Term, as applicable, subject to Sections
4.7 and 5.2 hereof, as applicable.
8.3 PAYMENT; RECORDS; AUDITS; TAXES
8.3.1 PAYMENT; REPORTS. All Other Payments due under this
Agreement shall be calculated and paid in U.S. dollars within 60 days of the end
of each calendar quarter (or particular quarter) during the Term hereof, unless
otherwise specifically provided herein. Each payment of Other Payments shall be
accompanied by a report of Net Sales of each Product in sufficient detail to
permit confirmation of the accuracy of the Other Payment made. DURA shall
report such information concerning such Net Sales with at least as much
information as set forth in the template attached as Exhibit 8.3.1 hereto.
8.3.2 MANNER AND PLACE OF PAYMENT. All payments owed under
Sections 8.1 and 8.2 of this
31
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
Agreement shall be made by wire transfer to an account specified by BMS.
8.3.3 RECORDS. DURA shall keep for three (3) years from the
date of each payment of any Other Payment hereunder complete and accurate
records of sales and all other information necessary to accurately calculate
the Net Sales of each Product used in determining such payment. BMS shall
have the right through its representatives or an independent, certified
public accountant to audit such records at the place or places of business
where such records are customarily kept in order to verify the accuracy of
the reports of Net Sales and Other Payments made for the preceding three
years. Such audits may be exercised once per year during normal business
hours upon fifteen (15) days' advance written notice to DURA. BMS shall bear
the full cost of such audit unless such audit discloses a variance of more
than five percent (5%) from the amount of the Other Payments due under this
Agreement, in which event, DURA shall bear the full cost of such audit. BMS
may not disclose confidential information concerning such payments and
reports, and all information learned in the course of any audit or
inspection, except to the extent necessary for BMS to reveal such information
in order to enforce its rights under this Agreement or if disclosure is
required by law. Any amounts that are determined to be due and owing by DURA
to BMS or by BMS to DURA following such audit shall be paid within ten (10)
business days thereafter, together with any interest due thereon (as
determined in accordance Section 8.3.4) for amounts owing by DURA to BMS
only. Any non-employee representatives of BMS shall execute an appropriate
confidentiality agreement reasonably acceptable to DURA.
8.3.4 LATE PAYMENTS. In the event that any payment due under
this Agreement is not made when due, the payment shall accrue interest from
the date due at the rate of twelve percent (12%) per annum; PROVIDED, that in
no event shall such rate exceed the maximum legal annual interest rate. The
payment of such interest shall not limit a Party from exercising any other
rights it may have as a consequence of the lateness of any payment.
8.3.5 TAXES. All turnover, income and other taxes levied on
account of any Other Payments and other payments made or accruing to BMS
under this Agreement shall be paid by BMS.
8.3.6 SALES FORECAST. DURA will provide to BMS at the
beginning of each calendar quarter beginning with the Effective Date and
ending September 30, 2003, with its good faith forecast of its sales for each
Product by SKU# for each of the immediately following four calendar quarters
(but in any event not beyond the quarter ending December 31, 2003.
9. REPRESENTATIONS AND WARRANTIES.
9.1 REPRESENTATIONS AND WARRANTIES OF BOTH PARTIES. Except as may be
set forth in EXHIBIT 9.1, each Party hereby represents and warrants that, as
of the Execution Date:
9.1.1 GOOD STANDING. Such Party is duly organized, validly
existing and in good standing under
32
<PAGE>
the laws of the state of its incorporation, is duly qualified to transact the
business in which it is engaged in each jurisdiction where failure to be so
qualified would have a material adverse effect upon its business as currently
conducted, and has full corporate power and authority to enter into this
Agreement and the Related Agreements and to carry out the provisions of this
Agreement and the Related Agreements.
9.1.2 POWER AND AUTHORITY. Such Party has the requisite power
and authority and the legal right to own and operate its property and assets,
to license and lease the property and assets it operates or uses under lease
or license, and to carry on its business as it is now being conducted. Such
Party has the requisite power and authority and the legal right to enter into
this Agreement and the Related Agreements, and to perform its obligations
hereunder and thereunder, and has taken all necessary corporate action on its
part to authorize the execution and delivery of the Agreement and the Related
Agreements and the performance of its obligations hereunder and thereunder.
All persons who have executed this Agreement or a Related Agreement on behalf
of such Party, or who will execute on behalf of such Party any agreement or
instrument contemplated hereby or thereby, have been duly authorized to do so
by all necessary corporate action.
9.1.3 BINDING OBLIGATION. This Agreement and the Related
Agreements have been duly executed and delivered on its behalf and (assuming
the due execution and delivery hereof and thereof by the other Party) each
such agreement is a legal and valid obligation binding upon it and is
enforceable in accordance with its terms, except that (i) such enforcement
may be subject to bankruptcy, insolvency, reorganization, moratorium or other
similar laws now or hereafter in effect relating to creditors rights
generally and (ii) the remedy of specific performance and other forms of
equitable relief may be subject to equitable defenses and to the discretion
of the court or arbitrator before which any proceeding therefor may be
brought.
9.2 REPRESENTATIONS AND WARRANTIES OF BMS. Except as set forth in
EXHIBIT 9.2, BMS hereby represents and warrants to DURA that:
9.2.1 NO VIOLATION OF INSTRUMENTS OR CONTRACTS. The execution
and the delivery of this Agreement and the Related Agreements and the
consummation of the transactions contemplated hereby and thereby will not:
(i) violate the Certificate of Incorporation or By-Laws of any of the BMS
Entities; (ii) to the knowledge of BMS, materially conflict with or result
in a material breach of any of the material terms, conditions or provisions
of, or constitute an express event of default under, any material instrument,
agreement, mortgage, judgment, order, award, or decree specifically relating
to the Business to which any BMS Entity is a party or by which it is bound
and which would have a material adverse effect upon the conduct of the
Business as currently conducted by such BMS Entity (it being understood that
certain contracts pertaining to the sale of Products to Third Parties may
require the consent of such Third Party for assignment of same to DURA),
(iii) to the knowledge of BMS, require the affirmative approval, consent,
authorization or other order or action of any court, governmental authority
or regulatory body or of any creditor of any of the BMS Entities, or (iv) to
the knowledge of BMS, give any Third Party the right under any material
instrument,
33
<PAGE>
agreement, mortgage, judgment, order, award or decree specifically relating
to the Business the right to terminate, modify or otherwise change the rights
or obligations of any of the BMS Entities under such material instrument,
agreement, mortgage, judgment, order, award or decree, the effect of which
would be materially adverse to the conduct of the Business as currently
conducted by such BMS Entity, or (v) conflict with or result in any
violation of or constitute a breach of any of the terms or provisions of, or
result in the acceleration of any obligation under, or constitute a default
under, any contract that is material to the conduct of the Business and to
which any BMS Entity is a party or to which it is subject or bound, except
for such conflict, acceleration, default, breach or violation that is not
reasonably likely to have a material adverse effect on such BMS Entity's
ability to perform its obligations under this Agreement or any Related
Agreement.
9.2.2 COMPLIANCE WITH LAW. Each BMS Entity is in compliance
with all requirements of applicable law within the Territory, except to the
extent that any noncompliance would not have a material adverse effect on the
conduct of the Business as currently conducted by such BMS Entity and would
not materially and adversely affect BMS's ability to perform its obligations
under this Agreement or any Related Agreement.
9.2.3 LITIGATION AND CLAIMS. There is no litigation,
arbitration, claim, governmental or other proceeding (formal or informal),
or, to the knowledge of BMS, governmental investigation pending or threatened
in writing within the Territory relating to the Business (it being understood
that this sentence does not relate in any way to the subject matter of
Sections 9.2.5 and 9.2.6 of this Agreement), which, if adversely determined,
would have a material adverse effect upon BMS' ability to perform its
obligations under this Agreement or any Related Agreement. None of the BMS
Entities is in violation of, or in default with respect to, any law, rule,
regulation, order, judgment, or decree relating to the Business or to the
Trademarks, which violation or default would materially and adversely affect
the Business; nor is any of the BMS Entities required to take any action
outside of the ordinary course of business in order to avoid such violation
or default.
9.2.4 NDAS. BMS has furnished DURA with access to a complete
copy of each of the NDAs, including all material amendments and supplements
thereto, relating to the Products in the Territory, other than information
contained in the CMC section of each NDA. BMS is the lawful holder of all
rights under each of the NDAs. BMS has complied in all material respects
with all applicable laws and regulations in connection with the preparation
and submission to the FDA of each of the NDAs, and each of the NDAs has been
approved by, and nothing has come to the attention of BMS in writing which
has, or reasonably should have, led BMS to believe that any of the NDAs are
not in good standing with, the FDA. To its knowledge, BMS has filed with the
FDA all required notices, supplemental applications and annual or other
reports, including adverse experience reports, with respect to each NDA which
are material to the conduct of the Business as currently conducted by BMS.
There is no pending FDA proceeding, or to the knowledge of BMS any action
threatened in writing by the FDA, which, if adversely determined, would have
a material adverse effect on the conduct of the Business as currently
conducted.
34
<PAGE>
9.2.5 TRADEMARKS.
9.2.5.1 It is the owner of all of the issued Trademark
registrations listed in Exhibit 1.1A, and has the exclusive right to grant
licenses therefor within the Territory in accordance with the terms of this
Agreement. BMS has not entered into any agreement with any Third Party that
prohibits BMS from licensing the Trademarks to DURA in accordance with this
Agreement.
9.2.5.2 The Trademarks are in full force and effect and have
been maintained to date in the Territory.
9.2.5.3 To the knowledge of BMS, none of the Trademarks
infringes upon any trademark or other proprietary rights of any other Third
Party in the Territory. There is no action, suit or proceeding pending or,
to the knowledge of BMS, that has been threatened in writing by any Third
Party in the Territory against BMS which, if adversely determined, would have
a material adverse effect upon the ability of BMS to use the Trademarks in
connection with the marketing or sale of the Products in the Territory as
currently conducted by BMS.
9.2.6 PATENTS.
9.2.6.1 All patents owned or controlled by any BMS Entity
pertaining to the composition of matter or use of any Product in the
Territory ("BMS Patents") are in full force and effect and have been
maintained to date. BMS has not entered into any agreement with any Third
Party under which BMS has licensed to such Third Party within the Territory
any rights under such BMS Patents to use or sell any Product, other than as
set forth in the Baxter Supply Agreement.
9.2.6.2 BMS has not received any written notice of any claim
that the manufacture, use or sale of any Product infringes any patent rights
of any Third Party in the Territory.
9.2.6.3 There is no action, suit or proceeding pending or, to
the knowledge of BMS, that has been threatened in writing by any Third Party
against BMS in the Territory which, if adversely determined, would have a
material adverse effect upon the ability of BMS to use the BMS Patents in
connection with the manufacture, use or sale of the Products in the Territory
as currently conducted by BMS.
9.2.7 NO BROKER FEES. BMS has not incurred any liability or
obligation to any broker, finder, or agent for any brokerage fees, finder's
fees, or commissions with respect to the transactions contemplated by this
Agreement which may be directly or indirectly asserted against DURA.
9.3 REPRESENTATIONS AND WARRANTIES OF DURA. Except as set forth in
EXHIBIT 9.3, DURA hereby represents
35
<PAGE>
and warrants to BMS that:
9.3.1 NO VIOLATION OF INSTRUMENTS OR CONTRACTS. The execution
and the delivery of this Agreement and the Related Agreements and the
consummation of the transactions contemplated hereby and thereby will not:
(i) violate the Certificate of Incorporation or By-Laws of DURA; (ii) to the
knowledge of DURA, materially conflict with or result in a material breach of
any of the material terms, conditions or provisions of, or constitute an
express event of default under, any material instrument, agreement, mortgage,
judgment, order, award, or decree to which DURA is a party or by which it is
bound and that would have a material adverse effect upon DURA's ability to
perform its obligations under this Agreement or any Related Agreement, (iii)
to the knowledge of DURA, require the affirmative approval, consent,
authorization or other order or action of any court, governmental authority
or regulatory body or of any creditor of DURA or any of its Affiliates, or
(iv) to the knowledge of DURA, give any Third Party the right under any
material instrument, agreement, mortgage, judgment, order, award or decree
the right to terminate, modify or otherwise change the rights or obligations
of DURA or any of its Affiliates under such material instrument, agreement,
mortgage, judgment, order, award or decree, which would have a material
adverse effect upon DURA's ability to perform its obligations under this
Agreement or any Related Agreement, or (v) conflict with or result in any
violation of or constitute a breach of any of the terms or provisions of, or
result in the acceleration of any obligation under, or constitute a default
under, any contract to which DURA or any of its Affiliates is a party or to
which it is subject or bound, except for such conflict, acceleration,
default, breach or violation that is not reasonably likely to have a material
adverse effect on DURA's ability to perform its obligations under this
Agreement or any Related Agreement.
9.3.2 COMPLIANCE WITH LAW. DURA and its Affiliates are in
compliance with all requirements of applicable law within the Territory,
except to the extent that any noncompliance would not have a material adverse
affect upon its ability to perform its obligations under this Agreement or
any Related Agreement.
9.3.3 LITIGATION AND CLAIMS. There is no litigation,
arbitration, claim, governmental or other proceeding (formal or informal),
or, to the knowledge of DURA, governmental investigation pending or
threatened in writing within the Territory against DURA or any of its
Affiliates where an adverse outcome would have a material adverse affect upon
DURA's ability to perform its obligations under this Agreement or any Related
Agreement. DURA and its Affiliates are not in violation of, or in default
with respect to, any law, rule, regulation, order, judgment, or decree, which
violation or default would have a material adverse affect upon DURA's ability
to perform its obligations under this Agreement or any Related Agreement; nor
is DURA or any of its Affiliates required to take any action outside of the
ordinary course of business in order to avoid such violation or default.
9.3.4 NO BROKER FEES. DURA has not incurred any liability or
obligation to any broker, finder, or agent for any brokerage fees, finder's
fees, or commissions with respect to the transactions contemplated by this
Agreement which may be directly or indirectly asserted against BMS.
36
<PAGE>
9.4 DISCLAIMER OF WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS
AGREEMENT, THERE ARE NO OTHER REPRESENTATIONS OR WARRANTIES, EXPRESS OR
IMPLIED, MADE OR GIVEN BY EITHER PARTY HEREUNDER, INCLUDING, WITHOUT
LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OR USE OF ANY PRODUCT.
9.5 NO RELIANCE BY THIRD PARTIES. The representations and warranties
of a Party set forth in this Agreement are intended for the sole and
exclusive benefit of the other Party hereto, and may not be relied upon by
any Third Party.
10. INDEMNIFICATION AND INSURANCE.
10.1 BMS INDEMNITY. BMS shall defend, indemnify and hold DURA, its
Affiliates, and its and their employees, agents, officers, and directors (a
"DURA PARTY") harmless from and against any and all losses, liabilities,
damages, fees (including, until such time as BMS has notified DURA in writing
that it will assume control of a given DURA Claim, reasonable attorneys fees
and costs of litigation pertaining to such DURA Claim), and expenses paid or
payable by a DURA Party to a Third Party and that result from or arise in
connection with a claim, suit or other proceeding made or brought by such
Third Party (a "DURA CLAIM") against a DURA Party based on (i) the breach of
any obligation, covenant, agreement, representation or warranty of BMS
contained in this Agreement, or (ii) any Third Party litigation, arbitration,
claim, governmental or other proceeding (formal or informal) or investigation
arising out of or based upon the conduct of the Business by BMS or its
Affiliates, including without limitation any sale by or through BMS or any of
its Affiliates, and any use of any Product (including without limitation
Claims based on or relating to product liability), prior to the Effective
Date, or (iii) any sale of a Product by BMS or any of its Affiliates outside
the Territory, and any use outside the Territory of any such Product that was
sold by BMS or any of its Affiliates outside the Territory (including without
limitation Claims based on or relating to product liability), whether sold by
BMS or its Affiliates prior to or following the Effective Date; or (iv)
infringement of a Third Party's patent rights or trademarks by reason of the
purchase of a Product by DURA under the Supply Agreement (and which was
manufactured by or for BMS) and/or its sale by DURA in accordance with the
provisions of this Agreement (other than infringement of Third Party patent
rights or trademarks by reason of the manufacture, use or sale of plastic
containers, vials, or other components for any Azactam-Registered Trademark-
Product used or provided by Baxter under the Baxter Supply Agreement and the
manufacture, use or sale of the Abbott fluid containers or vials for any
Maxipime-Registered Trademark- Product pursuant to the rights granted under
the Abbott License Agreement and other than infringement of a Third Party's
trademark based on the use of a Trademark assigned by BMS to DURA pursuant to
Section 2.2.1); PROVIDED, however, that BMS shall not be obligated to
indemnify a DURA Party under (i), (ii), (iii) or (iv) above for any loss,
liability, damages, fees or expenses incurred by such DURA Party to the
extent attributable to a breach by DURA of any obligation, covenant,
agreement, representation or warranty of DURA contained in this Agreement or
any Related Agreement, to any act or omission constituting negligence,
recklessness, gross negligence, or wilful misconduct on the part of DURA or a
DURA Party, and/or to any failure of DURA to identify a Product defect or
nonconformity with Specifications known or that should
37
<PAGE>
reasonably have been known to DURA prior to the use of such Product by a
Third Party.
10.2 DURA INDEMNITY. DURA shall defend, indemnify and hold BMS, its
Affiliates, and its and their employees, agents, officers, and directors (a
"BMS PARTY") harmless from and against any and all losses, liabilities,
damages, fees (including, until such time as DURA has notified BMS in writing
that it will assume control of a given Claim, attorneys fees and costs of
litigation pertaining to such Claim), and expenses paid or payable by a BMS
Party to a Third Party (including without limitation payments that BMS may be
required to make to its licensors of any rights pertaining to any Product
(including without limitation Fujisawa, Abbott, and Takeda) and suppliers of
any components of any Product (including without limitation, Baxter)) that
result from or arise in connection with a claim, suit or other proceeding
made or brought by a Third Party ("BMS CLAIM") against a BMS Party resulting
from or arising in connection with (i) the breach by DURA of any obligation,
covenant, agreement, representation or warranty of DURA contained in this
Agreement; (ii) the conduct of the Business by DURA and its Affiliates in the
Territory after the Effective Date, including without limitation any sale by
or through DURA or any of its Affiliates, and any use of any Product
(including without limitation Claims based on or relating to product
liability), after the Effective Date; and/or (iii) infringement of a Third
Party's trademarks by reason of the use of "DURA" or any variant thereof on
the labeling for a Product or in any materials used in promoting or
advertising a Product or the use of a Trademark following the assignment of
such Trademark to DURA in accordance with Section 2.2.1; PROVIDED, however,
that DURA shall not be obligated to indemnify a BMS Party for any loss,
liability, damages, fees or expenses incurred by such BMS Party to the extent
attributable to a breach by BMS of any obligation, covenant, agreement,
representation or warranty of BMS contained in this Agreement or any Related
Agreement, or to any act or omission constituting negligence, recklessness,
gross negligence, or wilful misconduct on the part of BMS or a BMS Party.
10.3 CONTROL OF PROCEEDINGS. To receive the benefits of the indemnity
under Sections 10.1 or 10.2, as applicable, an indemnified Party must (i)
give the indemnifying Party written notice of any Claim or potential Claim
promptly after the indemnified Party receives notice of any such Claim; (ii)
allow the indemnifying Party to assume exclusive control of the defense and
settlement (including all decisions relating to litigation, defense and
appeal) of any such Claim (so long as it has confirmed its indemnification
obligation responsibility to such indemnified Party under this Section 10.3
with respect to a given Claim); PROVIDED THAT the controlling Party may not
settle such Claim in any manner that would require payment by the other
Party, or would materially adversely affect the rights granted to the other
Party hereunder, or would materially conflict with the terms of this
Agreement, without first obtaining the other Party's prior written consent;
and (iii) so long as such cooperation does not vitiate any legal privilege to
which it is entitled, reasonably cooperate with the indemnifying Party in its
defense of the Claim (including, without limitation, making documents and
records available for review and copying and making persons within
its/his/her control available for pertinent testimony). If the indemnifying
Party defends the claim, an indemnified Party may participate in, but not
control, the defense of such Claim using attorneys of its/his/her choice and
at its/his/her sole cost and expense. An indemnifying Party shall have no
obligation or liability under this Article 10 as to any Claim for which
settlement or compromise of such claim or an offer of settlement or
compromise of such Claim is made by an indemnified Party
38
<PAGE>
without the prior written consent of the indemnifying Party.
If the Party entitled to control the defense of such Claim notifies
the other in writing that it will not defend the other Party against such
Claim asserted against the other Party, or if the Party entitled to control
the defense of such Claim fails to defend or take other reasonable, timely
action, in response to such Claim asserted against the other Party, the other
Party shall have the right, but not the obligation, to defend or take other
reasonable action to defend its interests in such proceedings, and shall have
the right to litigate, settle or otherwise dispose of any such Claim;
provided, however, that the other Party shall not have the right to settle
such Claim in a manner that adversely affects the rights granted to the other
Party hereunder, or would materially conflict with this Agreement, or would
require a payment by the Party entitled to control the defense to such Third
Party, without the prior written consent of Party entitled to control the
defense of such Claim.
10.4 DURA INDEMNITY AS TO COMPENSATION. DURA will indemnify, defend,
and hold harmless each BMS Party from and against any damages, liability,
loss and costs that may be paid or payable by any such BMS Party resulting
from or in connection with any claim or other cause of action asserted by:
(i) any employees, agents, contractors, telemarketers, or other
personnel of DURA used by it to perform its obligations under
this Agreement, or
(ii) by any Third Party (including federal, state or local
governmental authorities)
with respect to:
(iii) any payment or obligation to make a payment to any
employees, agents, contractors, telemarketers, or other
personnel used by DURA to perform its obligations under this
Agreement with respect to any compensation, benefits of any
type under any employee benefit plan (as such term is
defined above), and any other bonus, stock option, stock
purchase, incentive, deferred compensation, supplemental
retirement, severance and other similar fringe or employee
benefit plans, programs or arrangements that may be
sponsored at any time either by BMS or any of its Affiliates
or by DURA or any of its Affiliates, even if it is
subsequently determined by any court, the IRS or any other
governmental agency that any such employee, agent,
contractor, telemarketer, and other person used by DURA to
discharge its obligations hereunder may be a common law
employee of BMS or any of its Affiliates; and
(iv) the payment or withholding of any contributions, payroll taxes,
or any other payroll-related item by or on behalf of DURA or any
of its employees, agents, contractors, telemarketers, and other
personnel with respect to which BMS, DURA or any of DURA's
employees,
39
<PAGE>
agents, contractors, telemarketers, and other personnel may be
responsible hereunder or pursuant to applicable law to pay,
make, collect, withhold or contribute, even if it is subsequently
determined by any court, the IRS or by any other governmental
agency that any such employee, agent, contractor, telemarketer,
and other person used by DURA to discharge its obligations
hereunder may be a common law employee of BMS or any of its
Affiliates.
10.5 INFRINGEMENT BY THIRD PARTIES.
10.5.1 If either Party becomes aware that a Third Party is
infringing any rights in any patent rights owned or controlled by BMS or any
of its Affiliates covering the composition or use of a Product or any
Trademark used in connection with a Product, such Party shall give written
notice to the other Party describing in detail the nature of such
infringement. Subject to Section 10.5.2, BMS and its Affiliates shall have
the sole right, but not the obligation, to enforce any such patent rights and
Trademarks against such Third Party infringer and to settle or compromise any
such possible infringement by taking such action as BMS or its Affiliates may
determine in their sole and absolute discretion; PROVIDED, however, that BMS
may not settle any such potential infringement in a manner that materially
adversely affects the rights granted to DURA hereunder or the title, rights
and interests in any patent rights, Trademarks or other intellectual property
rights owned or controlled by BMS or any of its Affiliates relating to the
composition or use of any Product, or that would materially conflict with
this Agreement, or that would require a payment by DURA to such Third Party,
or that would require the grant of any right or license by BMS to any Third
Party in conflict with the rights granted to DURA hereunder, without the
prior written consent of DURA. So long as such cooperation does not
vitiate any legal privilege to which it is entitled, DURA agrees to provide
BMS all reasonable assistance (including, without limitation, making
documents and records available for review and copying and making persons
within its control available for pertinent testimony), at BMS' expense, in
such enforcement.
10.5.2 In the event that BMS fails to institute an infringement
suit or take other reasonable action in response to such infringement
referred to in 10.5.1 within one hundred eighty (180) days after notice of
such infringement has been brought to its attention, DURA shall have the
right, but not the obligation, to institute such suit or take other
appropriate action in its own name to enforce such BMS patent rights (but not
any BMS patents pertaining to the manufacture of a Product) against such
Third Party and to settle or compromise any such possible infringement by
taking such action as DURA or its Affiliates may determine in their sole and
absolute discretion; PROVIDED, however, that DURA may not settle any such
potential infringement in a manner that would materially adversely affect any
title, rights and interests in any patents, Trademarks or other intellectual
property rights owned or controlled by BMS or any of its Affiliates relating
to the composition or use of any Product, or that would materially conflict
with any terms of this Agreement, or that would require a payment by BMS to
such Third Party, or that would require the grant of any right or license by
BMS to any Third Party, without the prior written consent of BMS. So long
as such cooperation does not vitiate any legal privilege to which it is
entitled, BMS agrees to provide DURA all reasonable cooperation and
assistance (including, without limitation, making documents and records
available for review and copying and making persons
40
<PAGE>
within its control available for pertinent testimony), at DURA's expense, in
such enforcement.
10.5.3 Regardless of which Party brings an action to enforce a
BMS Patent or a Trademark that is being infringed by a Third Party as
provided in Section 10.5.1 or 10.5.2 above, the Party not bringing the action
shall have the right to participate in such action at its own expense with
its own counsel. Any damages or other recovery, whether by settlement or
otherwise, from an action hereunder to enforce such BMS Patents or Trademarks
shall be paid to the Party controlling the conduct of the litigation.
10.5.4 Upon assignment by BMS of a Trademark to DURA in
accordance with Section 2.2.2 hereof, the Parties' rights and
responsibilities under Section 10.5.1 and 10.5.2 shall be reversed, MUTATIS
MUTANDIS, with respect to infringement of such Trademark by a Third Party
following such assignment.
10.5.5 In the event that a Third Party files an ANDA for a
Product certifying that it does not infringe any patents owned or controlled
by BMS relating to such Product, the Party receiving a copy of such ANDA
shall promptly forward a copy of same to the other Party. The Parties shall
meet and confer within thirty (30) days following the filing of such ANDA for
the purpose of determining what action should be taken with respect to such
certification should both Parties conclude that such Third Party would
violate Patent Rights owned or controlled by BMS. As the NDA holder, BMS
shall be responsible for filing and coordinating any mutually agreed
responses to FDA. DURA shall reimburse BMS for any reasonable costs incurred
by BMS in connection with such filings, and will reimburse BMS for any
reasonable out-of-pocket costs incurred by BMS in any legal proceedings
undertaken by BMS based on the Parties mutually agreed upon course of action.
10.6 INSURANCE. DURA shall maintain at all times during the period that
any Product is being distributed or sold by or through DURA hereunder, and
for fifteen (15) years thereafter, comprehensive general liability insurance,
with endorsements for contractual liability and product liability with
coverage limits of not less than Twenty Million Dollars ($20,000,000). The
minimum level of insurance set forth herein shall not be construed to create
a limit on DURA's liability with respect to its indemnification obligations
hereunder. Prior to the Effective Date (and each anniversary thereof), DURA
shall furnish to BMS a certificate of insurance evidencing such coverage as
of the Effective Date (and each anniversary thereof) and upon request by BMS
at any time hereafter. Each such certificate of insurance shall include a
provision whereby sixty (60) days' written notice must be received by BMS
prior to coverage modification or cancellation by either DURA or the insurer.
BMS will maintain at all times during the period that any Product
is being supplied to DURA by BMS and is being manufactured by or for BMS, and
for fifteen (15) years thereafter, a commercially reasonable program of
self-insurance/insurance with respect to its obligations under this Agreement
and any Related Agreement.
11. FORCE MAJEURE.
41
<PAGE>
11.1 FORCE MAJEURE. Any delays in performance by any Party under this
Agreement shall not be considered a breach of this Agreement if and to the
extent caused by occurrences beyond the reasonable control of the Party
affected, including but not limited to acts of God, embargoes, governmental
restrictions, materials shortages or failure of any supplier, where such
shortage or failure is attributable to a supplier's breach of its agreement
with BMS or with a Third Party subcontractor or to an event of force majeure
suffered by such supplier), fire, flood, explosion, earthquake, hurricanes,
storms, tornados, riots, wars, civil disorder, failure of public utilities or
common carriers, failure of Baxter to supply Product, labor disturbances,
rebellion or sabotage. The Party suffering such occurrence shall immediately
notify the other Party as soon as practicable immediately notify the other of
such inability and of the period for which such inability is expected to
continue, and any time for performance hereunder shall be extended by the
actual time of delay caused by the occurrence; provided, that the Party
suffering such occurrence uses commercially reasonable efforts to mitigate
any damages occurred by the other Party. The Party giving such notice shall
thereupon be excused from such of its obligations under this Agreement as it
is thereby disabled from performing, and shall have no liability for such
non-performance, for so long as it is so disabled and the 30 days thereafter.
12. CONFIDENTIALITY.
12.1 CONFIDENTIALITY.
12.1.1 Each Party acknowledges that it may receive confidential
or proprietary information of the other Party in the performance of this
Agreement. Each Party shall use commercially reasonable efforts to safeguard
and to hold such information received by it from the other Party in
confidence, and shall limit disclosure of the furnishing Party's information
to those employees and consultants of the receiving Party and its Affiliates
who are bound by a written obligation of confidentiality to the receiving
Party that is consistent with the terms of this Article 12. Each Party shall
not, directly or indirectly, disclose, publish or use for the benefit of any
Third Party or itself, except in carrying out its duties hereunder, any
confidential or proprietary information of the other Party, without first
having obtained the furnishing Party's written consent to such disclosure or
use. "CONFIDENTIAL INFORMATION" shall include, INTER ALIA, know-how,
scientific information, the terms of this Agreement, clinical data, efficacy
and safety data, adverse event information, formulas, methods and processes,
specifications, pricing information (including discounts, rebates and other
price adjustments) and other terms and conditions of sales, customer
information, business plans, and all other intellectual property. This
restriction shall not apply to any information within the following
categories:
(i) information that is known to the receiving Party or its
Affiliates prior to the time of disclosure to it, to the extent
evidenced by written records or other competent proof;
(ii) information that is independently developed by employees, agents,
or independent contractors of the receiving Party or its
Affiliates without reference to or reliance upon the information
furnished by the disclosing Party, as evidenced by written
records or other competent proof;
42
<PAGE>
(iii) information disclosed to the receiving Party or its
Affiliates by a Third Party that has a right to make such
disclosure; or
(iv) any other information that becomes part of the public domain
through no fault or negligence of the receiving Party.
The receiving Party shall also be entitled to disclose the other Party's
Confidential Information (1) that is required to be disclosed in compliance
with applicable laws or regulations (including, without limitation, to comply
with SEC, NASDAQ or stock exchange disclosure requirements) or by order of
any governmental body or a court of competent jurisdiction, (2) as may be
necessary or appropriate in connection with the enforcement of this Agreement
or any Related Agreement, (3) as required in furtherance of a Party's
obligations under this Agreement or any Related Agreement; or (4) as may be
necessary for the conduct of clinical studies; PROVIDED, that the Party
required to disclose such information shall use commercially reasonable
efforts to obtain confidential treatment of such information by the agency or
court or other disclosee, and that, in the case of disclosures under (1)
shall provide the other Party with a copy of the proposed disclosure in
sufficient time to allow reasonable opportunity to comment thereon.
12.1.2 The obligations set forth in this Section 12.1 shall
survive the termination or expiration of this Agreement for five (5) years.
Nothing in this Article 12 shall be construed to create or imply any right or
license under any patent rights, trademarks, copyrights or other intellectual
property rights owned or controlled by a Party or its Affiliates except as
may be expressly set forth in other Articles of this Agreement.
12.1.3 The confidentiality obligations set forth in this Article
12 shall supersede the Confidential Disclosure Agreement dated as of July 22,
1998 between the Parties ("Confidentiality Agreement"), shall govern any and
all information disclosed by either Party to the other pursuant thereto, and
shall be retroactively effective to the date of such Confidential Disclosure
Agreement.
12.2 USE OF INFORMATION. Each Party shall use, and cause each of its
Affiliates to use, any Confidential Information obtained by it from the other
Party or their respective Affiliates, pursuant to this Agreement or
otherwise, solely in connection with the transactions contemplated hereby.
12.3 RELIEF. Each Party shall be entitled, in addition to any other
right or remedy it may have, at law or in equity, to an injunction, without
the posting of any bond or other security, enjoining or restraining any other
Party from any violation or threatened violation of this Article 12.
13. TERMINATION.
13.1 TERM. This Agreement shall become effective as of the effective
date of this Agreement first set forth above and, unless sooner terminated as
provided in this Article 13, shall terminate:
43
<PAGE>
13.1.1 As to Azactam-Registered Trademark- and all rights
granted hereunder with respect to said Product, on October 1, 2005 (the
"AZACTAM-Registered Trademark- TERM").
13.1.2 As to Maxipime-Registered Trademark- and all rights
granted hereunder with respect to said Product, on February 1, 2008 (the
"MAXIPIME-Registered Trademark- TERM").
13.2 BREACH.
13.2.1 Failure by either Party to comply with any of the
material obligations contained in this Agreement shall entitle the other
Party, if it is not in material default hereunder, to give to the Party in
default notice specifying the nature of the default and requiring it to cure
such default. If such default is not cured within 60 days after the receipt
of such notice (or, if such default cannot be cured within such 60-day
period, if the Party in default does not commence and diligently continue
substantive actions to cure such default), the notifying Party shall be
entitled, without prejudice to any of its other rights conferred on it by
this Agreement and in addition to any other remedies available to it by law
or in equity, to terminate this Agreement by giving written notice to take
effect immediately upon delivery of such notice.
13.2.2 Termination by a Party of the Supply Agreement, in whole
or as to a given Product, for failure on the part of the other Party to
comply with any of the material obligations contained in said Supply
Agreement shall entitle the terminating Party thereunder, without prejudice
to any of its other rights conferred on it by this Agreement and in addition
to any other remedies available to it by law or in equity, to terminate this
Agreement (provided that if such Supply Agreement is only terminated as to a
specific Product, then termination hereunder shall be as to such Product
only) by giving written notice to take effect immediately upon delivery of
such notice.
13.3 INSOLVENCY OR BANKRUPTCY. In the event that a Party shall have
become insolvent or bankrupt, or shall have made an assignment for the
benefit of its creditors, or there shall have been appointed a trustee or
receiver of such Party for all or a substantial part of its property, or any
case or proceeding shall have been commenced or other action taken by or
against such Party (as to which, if involuntary commenced against such Party,
such Party is not able to obtain dismissal within 90 days after commencement
thereof) in bankruptcy or seeking reorganization, liquidation, dissolution,
winding-up, arrangement, composition or readjustment of its debts or any
other relief under any bankruptcy, insolvency, reorganization or other
similar act or law of any jurisdiction now or hereafter in effect, then such
Party shall not be relieved in any respect of its obligations hereunder, and,
in addition to any other remedies available to it by law or in equity, the
other Party may terminate this Agreement, in whole or in part as the
terminating Party may determine, by written notice to such Party.
13.4 OTHER TERMINATION SITUATIONS. BMS may (without prejudice to any of
its other rights conferred on it by this Agreement or by law) terminate this
Agreement effective immediately by giving written notice to such effect to
44
<PAGE>
DURA in the event that:
13.4.1 DURA engages in illegal activities or illegal conduct
which materially and adversely damages the market or potential market for a
Product (i) in the Territory and/or (ii) in other countries of the world when
taken as a whole; or
13.4.2. BMS withdraws a given Product from the U.S. market for
safety reasons in connection with a withdrawal of such Product from its
markets worldwide generally for such reasons (in which event the termination
shall be limited to such Product only).
13.5 EFFECT OF TERMINATION.
13.5.1 Upon termination of this Agreement by BMS pursuant to
Section 13.2 (as to the entire Agreement), 13.3, or 13.4.1, DURA shall
promptly: (i) return to BMS all relevant records, materials or confidential
information relating to the Products in its (or any Affiliates or
contractors') possession or control; (ii) except as provided in Section
13.5.3, discontinue all marketing, sale, and distribution of the Products,
and, where BMS elects to purchase same pursuant to Section 13.5.3 or is
required to purchase same pursuant to Section 13.5.4, return in accordance
with Section 13.5.3 or 13.5.4, as the case may be, any inventory of Products
then on hand at DURA facilities or that of its designee (with BMS to
reimburse DURA for transportation charges of same to BMS); and (iii) except
as provided in Section 13.5.3, discontinue use of the Trademarks, destroy all
advertising or other printed materials bearing the Trademarks, cooperate with
BMS to execute such documents and take such actions as may be necessary to
cancel any registration of DURA, if applicable, as a Permitted User or
Registered User of the Trademarks, and DURA's right to use the Trademarks for
the Products in the Territory shall terminate.
13.5.2 Upon expiration of this Agreement or upon the termination
of this Agreement by BMS pursuant to Section 13.1, 13.2.2 (as to a given
Product), or 13.4.2, DURA shall promptly: (i) return to BMS all relevant
records, materials or confidential information relating to the affected
Product in its (or any Affiliates or contractors') possession or control;
(ii) except as provided in Section 13.5.3, discontinue all marketing, sale,
and distribution of the affected Product, and, where BMS elects to purchase
same pursuant to Section 13.5.3 or is required to purchase same pursuant to
Section 13.5.4, return in accordance with Section 13.5.3 or 13.5.4, as the
case may be, any inventory of the affected Product then on hand at DURA
facilities or that of its designee (with BMS to reimburse DURA for
transportation charges of same to BMS, except that, if terminated by BMS
pursuant to Section 13.2, then such transportation charges shall be at DURA's
expense); and (iii) except as provided in Section 13.5.3, discontinue use of
the Trademarks, destroy all advertising or other printed materials bearing
the Trademarks, cooperate with BMS to execute such documents and take such
actions as may be necessary to cancel any registration of DURA as a Permitted
User or Registered User of the Trademarks with respect to the affected
Product, and DURA's right to use the Trademarks for the affected Product in
the Territory shall terminate.
45
<PAGE>
13.5.3 Upon expiration of this Agreement or upon the termination
of this Agreement by BMS pursuant to any of Sections 13.1 or 13.3, DURA shall
be entitled, for three (3) months following such termination, to sell in the
Territory any Product then on hand and to use the Trademarks for such limited
purpose, subject to the following. Upon expiration of this Agreement or upon
the termination of this Agreement by BMS pursuant to any of Sections 13.1,
13.3, 13.4.1 or 13.4.2, BMS may elect in its sole and absolute discretion,
upon written notice given to DURA at any time prior to the end of said
3-month period, to purchase from DURA, and DURA shall (if such written notice
is provided by BMS) sell to BMS, such amount (including up to all) of the
Product then in DURA's inventory at the end of such 3-month period at the
price paid for each Product by DURA as BMS may elect to purchase; PROVIDED ,
however, that, where such written notice was provided by BMS, BMS shall not
be obligated to repurchase any Products which are not in good condition,
which are labeled as requiring storage under refrigerated or freezing
conditions, which are not in full, unopened, factory-sealed cases, whose
labeling or packaging have been altered or damaged, or which have at the time
of return a then remaining shelf life of less than twelve (12) months for any
Product.
13.5.4 Upon the termination of this Agreement by DURA pursuant
to Section 13.2 or 13.3, DURA shall be entitled, for three (3) months
following such termination, to sell in the Territory any Product then on hand
to which such termination applies and to use the Trademarks for such limited
purpose, subject to the following. DURA may elect upon written notice to BMS
given within said 3-month period, to require that BMS purchase from DURA, and
DURA shall sell to BMS, all Products then in DURA's inventory at the price
paid for such Product by DURA; PROVIDED, however, that where DURA provides
such written notice, BMS shall not be obligated to repurchase any such
Product which is not in good condition, which are labeled as requiring
storage under refrigerated or freezing conditions, which are not in full,
unopened, factory-sealed cases, whose labeling or packaging have been altered
or damaged, or which have at the time of return a then remaining shelf life
of less than twelve (12) months for any Product.
13.5.5 Neither BMS or DURA shall incur any liability to the
other by reason of the expiration or termination of this Agreement as
provided herein, nor for its non-renewal, whether for loss of goodwill,
anticipated profits or otherwise, and BMS and DURA shall accept all rights
granted and all obligations assumed hereunder, including those in connection
with such expiration or termination in full satisfaction of any claim
resulting from such expiration or termination.
13.5.6 Any acceptance by BMS of any order from DURA or the sale
of any Products by BMS to DURA after the expiration or termination of this
Agreement shall not be construed as a renewal or extension of this Agreement
or as a waiver of termination thereof.
13.5.7 Exercise by a Party of its rights as to return, sale and
resale of Products under this Section 13.5 shall preclude the exercise of
such rights a second time under Section 10.5 of the Supply Agreement.
13.5.8 Upon termination of this Agreement by either Party prior to
the expiration of the applicable
46
<PAGE>
Term for a given Product, all rights granted to DURA under Article 2 hereof
with respect to such Product shall terminate and revert solely in BMS, and
DURA shall cease all marketing, sale, promotion and distribution of such
Product, except as may be expressly set forth in this Section 13.5. Upon
expiration of this Agreement at the applicable Term for a given Product,
either Party may market such Product thereafter, subject to the rights
granted to DURA under Section 2.2 and 2.3 hereof.
13.6 ACCRUED RIGHTS, SURVIVING OBLIGATIONS.
13.6.1 Termination, relinquishment or expiration of this
Agreement for any reason shall be without prejudice to any rights which shall
have accrued to the benefit of either Party prior to such termination,
relinquishment or expiration. Such termination, relinquishment or expiration
shall not relieve either Party from obligations which are expressly indicated
to survive termination or expiration of this Agreement.
13.6.2 All of the Parties' rights and obligations under Articles
1, 10, 11, 12, and 17, and Sections 2.2.3 (where applicable following
expiration of the applicable Term for a Product), 2.3, 3.2, 3.3.1, 3.3.2,
3.5.1, 3.7 (where applicable), 3.8 (where applicable), 4.2, 4.4.3, 4.4.4,
4.5, 4.7, 4.8, 4.9, 4.10, 4.11, 4.12, 5.2.4, 5.2.7, 5.2.8, 6.1, 6.2, 6.4,
6.5, 6.6., 6.7, 8.3 (where applicable), 8.4, 9.4, 9.5, 13.5 and 13.6 shall
survive termination.
14. CONCURRENT TRANSACTIONS.
14.1 EXECUTION AND DELIVERY OF DOCUMENTS. Contemporaneously with the
execution and delivery of this Agreement, and in reliance upon the
representations and warranties set forth herein, the Parties hereto agree to
execute and deliver the following documents:
(i) The Supply Agreement attached as EXHIBIT 14.1.1 hereto; and
(ii) The Interim Services Agreement attached as EXHIBIT 14.1.2 hereto.
15. NOTICES.
15.1 NOTICES. Unless otherwise explicitly set forth herein, any notice
required or permitted to be given hereunder shall be in writing and shall be
delivered personally by hand, or sent by reputable overnight courier, signature
required, to the addresses of each Party set forth below or to such other
address or addresses as shall be designated in writing in the same matter:
(a) If to BMS:
47
<PAGE>
Bristol-Myers Squibb U.S. Pharmaceutical Group
777 Scudders Mill Road
Plainsboro, NJ 08536
Attention: President - U.S. Pharmaceuticals Group
with a copy to its Vice President and Senior Counsel, U.S. Pharmaceuticals
Group, at the same address.
(b) If to DURA:
Dura Pharmaceuticals, Inc.
7475 Lusk Boulevard
San Diego, CA 92121
Attention: President
with a copy to its General Counsel at the same address.
All notices shall be deemed given when received by the addressee.
16. NON-SOLICITATION.
16.1 NON-SOLICITATION. For a period of three (3) years following the
Effective Date, neither Party or its Affiliates shall employ, contract with,
or solicit, directly or indirectly, any employee of the other Party or any of
its Affiliates, wherever located, who was or is at any time a member of the
research and development group, franchise management group, manufacturing
group, financial group, or sales force or marketing group and whose duties
encompassed any duties pertaining to any Product, without the prior written
consent of the other Party; provided, that the foregoing restriction on
solicitation shall not apply to advertisements run in trade journals or other
publications or on the Internet that are targeted to qualified individuals
generally for the position in question.
17. MISCELLANEOUS PROVISIONS.
17.1 ASSIGNMENT. Neither Party shall assign or otherwise transfer this
Agreement or any interest herein or right hereunder without the prior written
consent of the other Party, and any such purported assignment, transfer or
attempt to assign or transfer any interest herein or right hereunder shall be
void and of no effect; except that each Party (i) may assign its rights and
obligations hereunder to an Affiliate without the prior consent of the other
Party (although, in such event, the assigning Party shall remain primarily
responsible for all of its obligations and agreements set forth herein,
notwithstanding such assignment) and (ii) may assign its rights and
obligations to a successor (whether by merger, consolidation, reorganization
or other similar event) or purchaser of all or substantially all of its
business assets relating to all Products, provided, that such successor or
purchaser has agreed in writing to assume all of such Party's rights and
obligations hereunder and a copy of such assumption is provided to the other
Party hereunder.
48
<PAGE>
17.2 NON-WAIVER. Any failure on the part of a Party to enforce at any
time or for any period of time any of the provisions of this Agreement shall
not be deemed or construed to be a waiver of such provisions or of any right
of such Party thereafter to enforce each and every such provision on any
succeeding occasion or breach thereof.
17.3 DISPUTE RESOLUTION.
17.3.1 The Parties recognize that disputes as to certain matters
may from time to time arise during the term of this Agreement which relate to
either Party's rights and/or obligations hereunder. It is the objective of
the Parties to establish procedures to facilitate the resolution of disputes
arising under or in connection with this Agreement, including without
limitation all financial disputes and any disputes as to the validity,
construction, performance, default, or breach hereof, in an expedient manner
by mutual cooperation and without resort to litigation. To accomplish this
objective, but subject to Section 17.3.3 below, the Parties agree to follow
the procedures set forth in this Section 17.3 if and when such disputes arise
under or in connection with this Agreement between the Parties (except as
provided in Section 14.3.4 of the Supply Agreement). If the Parties cannot
resolve the dispute within 30 days of formal request by either Party to the
other, any Party may, by written notice to the other, have such dispute
referred to the President of DURA and the President of the BMS U.S.
Pharmaceutical Group (or their designees) for attempted resolution by good
faith negotiations. If such personnel are unable to resolve such dispute
within thirty (30) days after such notice is received, then such dispute
shall be finally resolved, but only if written notice is thereafter served by
a Party on the other Party specifically requesting binding arbitration
pursuant to Section 17.3.2, by binding arbitration (except as set forth in
Section 14.3.4 of the Supply Agreement) under Section 17.3.2 hereof.
17.3.2 Where a Party has served a written notice upon the other
requesting binding arbitration of a dispute pursuant to this Section 17.3.2,
any such arbitration shall be held in New York, New York (if DURA was the
Party providing such written notice) or in San Diego, California (if BMS was
the Party providing such written notice), according to the Commercial
Arbitration Rules (the "Rules") of the American Arbitration Association. Any
arbitration herewith shall be conducted in the English language. The
arbitration shall be conducted by one arbitrator who is knowledgeable in the
subject matter which is at issue in the dispute and who is selected by mutual
agreement of the Parties or, failing such agreement, shall be selected
according to the AAA rules. The Parties shall have such discovery rights as
the arbitrator may allow, but in no event broader than that discovery
permitted under the Federal Rules of Civil Procedure. In conducting the
arbitration, the arbitrator shall apply the New York Rules of Evidence, and
shall be able to decree any and all relief of an equitable nature, including
but not limited to such relief as a temporary restraining order, a
preliminary injunction, a permanent injunction, or replevin of property, as
well as specific performance. The arbitrator shall also be able to award
direct, indirect and, where permitted by this Agreement, consequential
damages, but shall not award any other form of damage (e.g., punitive or
exemplary damages). The reasonable fees and expenses, of the arbitrators,
along with the reasonable legal fees and expenses of the prevailing Party
(including all expert witness fees and expenses), the fees and expenses of a
court reporter, and any expenses for a hearing room, shall be paid as
follows: If the arbitrators rule in favor of one Party on all disputed
issues in the arbitration, the losing Party shall pay 100% of
49
<PAGE>
such fees and expenses; if the arbitrators rule in favor of one Party on some
issues and the other Party on other issues, the arbitrators shall issue with
the rulings a written determination as to how such fees and expenses shall be
allocated between the Parties. The arbitrators shall allocate fees and
expenses in a way that bears a reasonable relationship to the outcome of the
arbitration, with the Party prevailing on more issues, or on issues of
greater value or gravity, recovering a relatively larger share of its legal
fees and expenses. The decision of the arbitrators shall be final and may be
entered, sued on or enforced by the Party in whose favor it runs in any court
of competent jurisdiction at the option of such Party. Whether a claim,
dispute or other matter in question would be barred by the applicable statute
of limitations, which statute of limitations also shall apply to any claim or
disputes subject to arbitration under this Section, shall be determined by
binding arbitration pursuant to this Section.
17.3.3 Notwithstanding anything to the contrary in this Section
17.3, either Party may seek immediate injunctive or other interim relief
without resort to arbitration from any court of competent jurisdiction as
necessary to enforce and prevent infringement of the patent rights, copyright
rights, trademarks, trade secrets, or other intellectual property rights
owned or controlled by a Party or its Affiliates or to prevent breach of
Article 12 hereof.
17.4 ENTIRETY OF AGREEMENT. This Agreement, the Exhibits attached
hereto, and the Related Agreements where herein referenced, contains the
entire understanding of the Parties with respect to the subject matter hereof
and thereof and supersedes all previous and contemporaneous verbal and
written agreements, representations and warranties with respect to such
subject matter. This Agreement (or any provision or term hereof) may be
released, waived, changed or supplemented only by a written agreement signed
by an officer or other authorized representative of the Party against whom
enforcement of any release, waiver, change or supplement is sought. This
Agreement shall not be strictly construed against either Party hereto.
17.5 PUBLIC ANNOUNCEMENTS. The form and content of any public
announcement to be made by one Party regarding this Agreement, or the subject
matter contained herein, shall be subject to the prior written consent of the
other Party (which consent may not be unreasonably withheld), except as may
be required by applicable law (including, without limitation, disclosure
requirements of the SEC, NASDAQ, or any other stock exchange) in which event
the other Party shall use commercially reasonable efforts to give the other
Party reasonable advance notice and reasonable opportunity to review any such
disclosure.
17.6 GOVERNING LAW. This Agreement shall be governed by and construed
in accordance with the internal laws of the State of New York, without regard
to its conflicts of law principles.
17.7 RELATIONSHIP OF THE PARTIES. In making and performing this
Agreement, the Parties are acting, and intend to be treated, as independent
entities and nothing contained in this Agreement shall be construed or
implied to create an agency, partnership, joint venture, or employer and
employee relationship between BMS and DURA. Except as otherwise provided
herein, neither Party may make any representation, warranty or commitment,
whether express or
50
<PAGE>
implied, on behalf of or incur any charges or expenses for or in the name of
the other Party. No Party shall be liable for the act of any other Party
unless such act is expressly authorized in writing by both Parties hereto.
17.8 COUNTERPARTS. This Agreement shall become binding when any one or
more counterparts hereof, individually or taken together, shall bear the
signatures of each of the Parties hereto. This Agreement may be executed in
any number of counterparts, each of which shall be deemed an original as
against the Party whose signature appears thereon, but all of which taken
together shall constitute but one and the same instrument.
17.9 SEVERABILITY. If any part of this Agreement is declared invalid by
any legally governing authority having jurisdiction over either Party, then
such declaration shall not affect the remainder of the Agreement and the
Parties shall revise the invalidated part in a manner that will render such
provision valid without impairing the Parties' original intent.
17.10 CUMULATIVE RIGHTS. Except as herein expressly provided, the
rights, powers and remedies hereunder shall be in addition to, and not in
limitation of, all rights, powers and remedies provided at law or in equity,
or under any other agreement between the Parties, and all of such rights,
powers and remedies shall be cumulative, and may be exercised successively or
cumulatively.
17.11 NO OTHER RIGHTS. No rights or licenses in or to either Party's
patent rights, know-how, copyrights or trademarks are granted by a Party to
the other, or shall be created or implied hereunder, except those licenses
and rights that are expressly granted in this Agreement.
17.12 EXPENSES. BMS and DURA shall each bear their own direct and
indirect expenses incurred in connection with the negotiation and preparation
of this Agreement and the Related Agreements and, except as set forth in this
Agreement or any Related Agreements, the performance of the obligations
contemplated hereby and thereby.
[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK-THE SIGNATURE PAGE FOLLOWS]
51
<PAGE>
IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed in multiple counterparts by its duly authorized representative.
DURA PHARMACEUTICALS, INC. BRISTOL-MYERS SQUIBB COMPANY
By: /s/ Julia Brown By: /s/ Donald J. Hayden, Jr.
---------------------------- -------------------------------------
Julia Brown Donald J. Hayden, Jr.
Title: Executive Vice President Title: President-Worldwide Medicines Group
------------------------- -----------------------------------
Date: December 21, 1998 Date:
------------------------- ------------------------------------
[SIGNATURE PAGE TO THE DISTRIBUTION AGREEMENT]
52
<PAGE>
EXHIBITS
Exhibit 1.1A - List of Products and Trademarks
Exhibit 1.1B - Specifications for the Products
Exhibit 3.5.2 - List of Bundled Contracts
Exhibit 6.1 - Adverse Event Reporting; Product Complaints
Exhibit 6.2 - Professional Services
Exhibit 8.1.3 - Credit or Payment Schedule upon Termination for Voluntary
Withdrawal of a Product for Safety Reasons
Exhibit 8.3.1 - Form of Other Payment Report
Exhibit 9.1 - Exceptions to Mutual Representations and Warranties
Exhibit 9.2 - Exceptions to Representations and Warranties of BMS
Exhibit 9.3 - Exceptions to Representations and Warranties of DURA
Exhibit 14.1.1 - Form of Supply Agreement
Exhibit 14.1.2 - Form of Interim Services Agreement
53
<PAGE>
Exhibit 2.2*
SUPPLY AGREEMENT
FOR MAXIPIME-Registered Trademark- AND AZACTAM-Registered Trademark-
This AGREEMENT is made between Bristol-Myers Squibb Company, a
corporation duly organized and existing under the laws of the state of
Delaware, having offices at Route 206 and Province Line Road, Princeton, New
Jersey 08543-4000 ("BMS") and Dura Pharmaceuticals, Inc., a corporation duly
organized and existing under the laws of the State of Delaware, and having
offices at 7475 Lusk Boulevard, San Diego, CA 92121 ("DURA").
RECITALS
A. BMS markets two products known as Maxipime-Registered
Trademark-(Cefepime Hydrochloride) and Azactam-Registered Trademark-
(Aztreonam).
B. By separate agreement of even date herewith, DURA has obtained the
right to distribute, market, and sell these two products in the United States
and to use BMS's trademarks for such two products in such country, and BMS
has granted such distribution rights to DURA, on the terms and conditions set
forth in said separate Agreement.
C. DURA also wishes to purchase from BMS, and BMS wishes to supply to
DURA, DURA's entire requirements of each Product (as hereinafter defined),
for use in the United States only, pursuant to the terms and conditions set
forth in this Agreement.
NOW, THEREFORE, in consideration of the foregoing recitals and the
mutual covenants and agreements of the Parties contained in this Agreement,
the Parties agree as follows:
1. DEFINITIONS.
For all purposes of this Agreement, (i) the terms defined in this
Article 1 will have those meanings set forth in this Article 1, unless the
context in the text of the Agreement dictates otherwise; and (ii) all dollar
amounts refer to United States dollars.
"ABBOTT LICENSE AGREEMENT" means the Agreement executed in 1985 between
Abbott Laboratories, Inc. ("Abbott") and Bristol-Myers Squibb Company, as
heretofore amended and as the same may be amended hereafter, covering, among
other matters, the license by Abbott to make and use ADD-Vantage-TM- Vials
containing certain BMS drugs, including Maxipime-Registered Trademark-,
within the Territory.
"AFFILIATE", with respect to any Party, means any Person controlling,
controlled by, or under common control with, such Party. For these purposes,
"control" shall refer to: (a) the possession, directly or indirectly, of the
power to direct the management or policies of a Person or to veto any
material decision relating to the management or policies
1
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
of a Person, in each case, whether through the ownership of voting
securities, by contract or otherwise, or (b) the ownership, directly or
indirectly, of at least 50% of the voting securities of a Person.
"AGREEMENT" means this agreement, together with all appendices, exhibits
and schedules hereto, and as the same may be amended or supplemented from
time to time hereafter by a written agreement duly executed by authorized
representatives of each Party hereto.
"AGREEMENT QUARTER" means each three-month period commencing on the
first day of January, April, July, or October, as the case may be, during the
Term.
"AGREEMENT YEAR" means each 12-month period commencing on January 1
during the Term.
"AZACTAM-Registered Trademark- TERM" has the meaning set forth in
Section 10.1 hereof.
"BAXTER SUPPLY AGREEMENT" means the Agreement dated June 6, 1986 between
Travenol Laboratories, Inc. ("Baxter") and E.R. Squibb & Sons, Inc., as
heretofore amended and as the same may be amended hereafter, covering, among
other matters, the supply by Baxter to BMS customers of Azactam-Registered
Trademark- in packaged, premixed, sterile filled and frozen form in Baxter's
VIAFLEX-Registered Trademark- plastic container delivery system (now know as
the GALAXY-Registered Trademark- system) within the Territory.
"BMS ENTITIES" means BMS and those BMS entities that (i) distribute,
sell, or market any of the Products in the Territory; (ii) own or control any
of the rights licensed to DURA hereunder; (iii) own or control any of the
assets that are used in and are material to the conduct of the Business;
and/or (iv) are party to any Third Party contracts that are material to the
conduct of the Business.
"BUSINESS" means the manufacture, distribution, sale and marketing of
the Products within the Territory as conducted by BMS and its Affiliates as
of the Execution Date. The Business does not include any of the operations,
technology, intellectual property rights, research or assets relating to (A)
any other product of BMS or any of its Affiliates or (B) the manufacture,
distribution, marketing or sale of the Products for use outside the Territory.
"COMMERCIALLY REASONABLE EFFORTS" of a Party shall mean those efforts
consistent with the exercise of its prudent scientific and business judgment
as applied to other research, development and commercialization efforts for
products of similar scientific and commercial potential within the research
programs and relevant product lines of such Party.
"CONFIDENTIAL INFORMATION" has the meaning set forth in Article 9
hereof.
"CONFIDENTIALITY AGREEMENT" has the meaning set forth in Section 9.1.3
hereof.
2
<PAGE>
"CONTROL" or "CONTROLLED BY" means, with respect to a right or license
granted hereunder, possession by a Party or its Affiliates of the ability to
grant a license or sublicense or to supply a Product in accordance with the
terms of this Agreement, and without violating the terms of any agreement by
such Party with any Third Party.
"DISTRIBUTION AGREEMENT" means the separate agreement of even date
herewith (as the same may be amended from time to time hereafter in
accordance with the terms thereof), under which DURA has obtained the right
to distribute, market, and sell the Products in the United States and BMS has
granted such distribution rights to DURA, pursuant to the terms and
conditions set forth in such separate agreement.
"EFFECTIVE DATE" means January 1, 1999.
"EXECUTION DATE" means the date that this Agreement is signed by the
last Party to sign below.
"FDA" means the United States Food and Drug Administration.
"FUJISAWA LICENSE AGREEMENT" means the Agreement dated September 1,
1984, as amended heretofore and from time to time hereafter, between Fujisawa
Pharmaceutical Company, Ltd, a Japanese corporation, and BMS covering the
license to BMS of certain U.S. and foreign patents covering certain
monocyclic beta-lactam compounds, including Aztreonam, starting materials,
intermediates and manufacturing processes thereof.
"IND" means an Investigational New Drug application filed with the FDA
for any Product requesting permission to perform human clinical studies in
accordance with 21 CFR Part 312, as the same may be amended or supplemented
from time to time hereafter.
"INTERIM SERVICES AGREEMENT" means the separate agreement of even date
herewith (as the same may be amended from time to time hereafter in
accordance with the terms thereof), under which BMS has agreed to provide
certain interim services and Product co-promotion services to DURA, as more
fully set forth therein.
"KNOW-HOW" means, for each Product, any and all technical data,
information, material and other know-how currently owned or controlled by BMS
and its Affiliates or that may hereafter during the relevant Term for such
Product be owned or controlled by BMS and its Affiliates and which relates to
preclinical and clinical development, use and marketing of such Product;
PROVIDED, however, that the foregoing shall not extend to any formulation or
Manufacturing Know-How (including without limitation manufacturing processes
and techniques and quality control assays and reference standards) owned or
controlled by BMS or any of its Affiliates.
"MANUFACTURING KNOW-HOW" means, for each Product, any and all technical
data, information, material and other know-how currently owned or controlled
by BMS and its Affiliates or that may hereafter during the relevant Term for
such Product be owned or controlled by BMS and its Affiliates and which
relates to the formulation or manufacture
3
<PAGE>
of such Product (including without limitation manufacturing processes and
techniques, bulk actives, intermediates and excipients, and quality control
assays and reference standards).
"MAXIPIME-Registered Trademark- TERM" has the meaning set forth in
Section 10.1 hereof.
"NDA" means a New Drug Application or Product License Application for
any Product, as appropriate, requesting permission to place a drug on the
market in accordance with 21 CFR Part 314, and all supplements filed pursuant
to the requirements of the FDA, including all documents, data and other
information concerning a Product which are necessary for FDA approval to
market a Product in the Territory.
"PARTY" means BMS or DURA and, when used in the plural, shall mean BMS
and DURA.
"PERSON" means any natural person, corporation, firm, business trust,
joint venture, association, organization, company, partnership or other
business entity, or any government or any agency or political subdivision
thereof.
"PRODUCT" means any of the products listed on EXHIBIT 1.1A, packaged and
labeled in accordance with applicable law and the applicable Product
Registration, including all strengths and packaging configurations of the
final finished dosage form presentations existing on the Effective Date, and
any new products comprising either of the compounds Cefepime Hydrochloride or
Aztreonam as may be added to this Agreement pursuant to Section 4.8 of the
Distribution Agreement.
"PRODUCT REGISTRATIONS" means the approvals or registrations for each
Product which have been received by BMS in the Territory, including without
limitation each IND, Drug Master File (DMF), and NDA for each Product.
"PURCHASE PRICE" for a Product has the meaning set forth in Section 3.1
hereof.
"RECALL" has the meaning set forth in Section 8.1 hereof.
"RELATED AGREEMENTS" means the Distribution Agreement and the Interim
Services Agreement.
"SPECIFICATIONS" for each Product means such specifications for each
Product as set forth in EXHIBIT 1.1B, as the same may be changed or
supplemented by mutual written agreement of the Parties from time to time
hereafter.
"TAKEDA LICENSE AGREEMENT" means the Agreement dated May 7, 1991, as
amended heretofore and from time to time hereafter, between Takeda Chemical
Industries, Ltd, a Japanese corporation and BMS covering the license to BMS
of certain U.S. and foreign patents covering cephalosporins, including
Cefepime, starting materials, intermediates and manufacturing processes
thereof.
4
<PAGE>
"TERM" means the last to expire or terminate of the Azactam-Registered
Trademark- Term or the Maxipime-Registered Trademark- Term, as set forth in
Article 10 hereof.
"TERRITORY" means the all fifty states of the United States of America.
For sake of clarity and avoidance of doubt, Puerto Rico and any U.S.
possessions and territories are not part of the Territory.
"THIRD PARTY" means any Person who or which is neither a Party nor an
Affiliate of a Party.
"TO THE KNOWLEDGE OF" of a specified entity or any similar term means to
the actual knowledge of the officers and key employees of the specified
entity having operating responsibility for the business of such entity.
"TRADEMARKS" means the trademarks registered by BMS for the marketing of
the Products in the Territory, as more fully set forth on EXHIBIT 1.1A
attached to the Distribution Agreement.
2. GENERAL TERMS OF SUPPLY.
2.1 SALE AND PURCHASE OF PRODUCT AND EXISTING INVENTORY. Subject to
Section 2.12 hereof:
2.1.1 In order to ensure the quality of the Product to be
distributed by DURA under the Distribution Agreement, BMS shall sell to DURA,
and DURA shall, and shall cause each of its Affiliates to, purchase from BMS,
all of their respective requirements for the Product for resale or use in the
Territory during the applicable Term for a given Product, pursuant to
purchase orders submitted by DURA to BMS from time to time in accordance with
Section 2.3 hereof, at price determined in accordance with Section 3.1, and
subject to the warranties set forth in Section 5.2. All Product purchased
hereunder shall be resold solely in the Territory by DURA and its Affiliates.
Except as provided in Section 2.11 hereof and Section 3.5 of the
Distribution Agreement, all Product(s) supplied under this Agreement shall be
in finished dosage form, filled, labeled and packaged for commercial sale by
DURA, and DURA shall not alter in any manner any Product or its packaging as
sold to it by BMS and shall resell such Product without alteration in the
form sold to it by BMS.
2.1.2 BMS shall sell to DURA, and DURA shall purchase from BMS,
BMS' finished goods inventory of each Product on hand as of the Effective
Date, at the Purchase Price set forth in Section 3.2 hereof and subject to
the warranties set forth in Section 5.2.1; PROVIDED, however, that the
warranty set forth in Section 5.2.1(iv) shall not apply; and provided,
further, that DURA shall not be obligated to purchase any Product inventory
that does not have a minimum remaining shelf life of at least eighteen (18)
months, nor shall DURA be required to purchase BMS finished inventory for a
Product that exceeds more than the first three (3) months of DURA's
requirements following the Effective Date for such Product (by SKU#) except
with DURA's prior written consent. All Product inventory purchased hereunder
shall be resold solely in the Territory by DURA and its Affiliates. Except
as provided in Section 2.11 hereof and Section 3.5 of the Distribution
Agreement, all Product inventory sold to DURA shall be in finished dosage
form, filled, labeled
5
<PAGE>
and packaged for commercial sale by DURA, and DURA shall not alter in any
manner any Product or its packaging as sold to it by BMS and shall resell
such Product without alteration in the form sold to it by BMS.
2.1.3 Once BMS has received all necessary governmental
approvals for such label, all Product manufactured after the Effective Date
will be sold under a label where the Product will be identified as a
BMS-manufactured Product with DURA identified as the distributor thereof.
BMS shall control all labeling (and any changes or supplements thereto) for
each Product in the Territory, and shall have the responsibility at its
expense for securing any approvals required by FDA to any such changes or
supplements thereto. DURA shall not at any time do, cause to be done, or
omit or permit any act inconsistent with the then existing labeling for any
Product in the Territory.
2.1.4 No terms and conditions contained in any purchase order,
acknowledgment, invoice, bill of lading, acceptance or other preprinted form
issued by either Party shall be effective to the extent they are inconsistent
with or modify the terms and conditions contained herein. All Product orders
under this Agreement shall be for not less than BMS' minimum order quantities
for a given batch of Product, as such minimum quantities are set forth on
Exhibit 1.1A.
2.2 FORECASTS. Upon execution of this Agreement, and thereafter on the
first business day of each calendar quarter during the applicable Term for a
given Product, DURA shall provide BMS with a good faith rolling forecast
("Forecast") of estimated quantities and anticipated delivery schedules, for
each Product, for the following 24-month period, by calendar quarters;
provided, that the first six (6) months of each such Forecast shall consist
of the 3-month firm order placed by DURA concurrently with such Forecast
pursuant to Section 2.3.2 (to be delivered within months 4-6 of such
Forecast) and the 3-month firm order placed on the date of the previous
Forecast (to be delivered within months 1-3 of the current Forecast) and the
first nine (9) months of such Forecast for frozen premixed forms of
Azactam-Registered Trademark- (to be shipped to DURA's customers by Baxter in
accordance with Section 2.11) shall consist of the firm orders placed by DURA
pursuant to Section 2.3.2. Subject to the foregoing, the Parties agree to
use commercially reasonable efforts to correspond and/or meet periodically,
at mutually convenient times and places, to coordinate delivery of necessary
supplies and to discuss each Party's requirements under this Agreement and
the mechanisms that can be established to assure that those requirements are
met on a timely basis.
With respect to two of the Azactam-Registered Trademark- formulations
(500 mg/vial, 15mL and 2g/btl, 100mL), the parties recognized that the BMS
minimum batch sizes will result in the purchase by DURA of Product that may
well result in the purchase by DURA of more Product than DURA will require to
meet its delivery requirements over the succeeding three months following
delivery as well to fulfill its minimum inventory maintenance requirements
under Section 2.4. The Parties agree to meet and confer following the
Execution Date to discuss means of managing DURA's inventory requirements for
these two Product SKU#s more effectively and to minimize potential write-offs
due to out-of-date inventory.
2.3 ORDERING. Subject to Section 2.12 hereof:
6
<PAGE>
2.3.1 Upon execution of this Agreement, DURA will provide BMS
with its best estimate of its requirements for the first six (6) months (nine
(9) months in the case of frozen premixed forms of Azactam-Registered
Trademark- to be shipped to DURA's customers by Baxter in accordance with
Section 2.11) after the Effective Date, which estimate shall be attached as
EXHIBIT 2.3.1 hereto. BMS will supply such Product quantities as set forth in
the BMS production schedule provided to DURA on December 18, 1998, and to the
extent such amounts do not meet DURA's requirements as set forth in its
estimated requirements for the first six months as set forth in EXHIBIT
2.3.1, BMS will use commercially reasonable efforts to supply same in
accordance with DURA's requirements therefor. DURA agrees to purchase such
quantities of each Product as supplied by BMS to meet DURA's requirements set
forth on EXHIBIT 2.3.1 (which Product shall be supplied by BMS either from
inventory purchased by DURA subject to and pursuant to Section 2.1.2 or from
Product manufactured after the Effective Date). Following the initial
six-month period (or 9-month period for Baxter supplied Products, as the case
may be), orders shall be filled in accordance with the Forecasts and orders
provided and placed by DURA pursuant to Section 2.3.2.
2.3.2 Except as provided in Section 2.3.1, three (3) months
(six (6) months in the case of frozen premixed forms of Azactam-Registered
Trademark- to be shipped to DURA's customers by Baxter in accordance with
Section 2.11) before the beginning of any calendar quarter during the
applicable Term for a given Product, DURA shall place a firm order in writing
to BMS of the Product quantities to be purchased by DURA with respect to such
calendar quarter (and specify the delivery schedule and destination for the
Products ordered). Except as provided in Section 2.3.4, BMS will supply any
such purchase order received by it where the quantity ordered for a given
Product is not in excess of one hundred fifteen percent (115%) of the
quantity for such calendar quarter that was contained in the Forecast
provided by DURA on the date that was six (6) months (nine (9) months in the
case of frozen or premixed forms of Azactam-Registered Trademark- to be
shipped to DURA's customers by Baxter in accordance with Section 2.11) prior
to such calendar quarter. Although BMS will use commercially reasonable to
supply such excess quantity, BMS shall not be liable, for whatever reason, if
it is unable to deliver any quantities ordered by DURA that are in excess of
one hundred fifteen percent (115%) of the quantity for such calendar quarter
that was contained in the Forecast provided by DURA on the date that was six
(6) months (nine (9) months in the case of frozen or premixed forms of
Azactam-Registered Trademark- to be shipped to DURA's customers by Baxter in
accordance with Section 2.11) prior to such calendar quarter. That portion
of the excess which BMS cannot deliver as requested by such purchase order
shall be delivered to and purchased by DURA in the first month thereafter as
BMS is able to effect delivery of same. Except as provided in Section 2.3.4,
in the event that the quantity ordered by DURA for a given Product is less
than eighty-five percent (85%) of the quantity for such calendar quarter that
was contained in the Forecast provided by DURA on the date that was six (6)
months (nine (9) months in the case of frozen premixed forms of
Azactam-Registered Trademark- to be shipped to DURA's customers by Baxter in
accordance with Section 2.11) prior to such calendar quarter, DURA shall be
obligated to pay to BMS such sum as it would have paid to BMS had it ordered
eighty-five percent (85%) of the quantity for such calendar quarter that was
contained in the Forecast provided by DURA on the date that was six (6)
months (nine (9) months in the case of frozen premixed forms of
Azactam-Registered Trademark- to be shipped to DURA's customers by Baxter in
accordance with Section 2.11) prior to such calendar quarter.
2.3.3 All Product ordered by DURA shall be consistent with BMS
batch sizes or multiples thereof,
7
<PAGE>
as set forth in EXHIBIT 3.1.
2.3.4 For deliveries to be made within the first year following
the Effective Date, the eighty-five percent (85%) floor and the one hundred
fifteen percent (115%) ceiling set forth in Section 2.3.2 shall be eighty
percent (80%) and one hundred twenty percent (120%), respectively.
2.3.5 Given that BMS' pricing for its Products will change on
* in accordance with Section 3.1, and in order to avoid a dispute over
the timing of price changes as they apply to orders, the Parties agree that once
DURA has placed its firm order for Product as of * of a given year,
the Purchase Price for Product firm-ordered by DURA thereafter shall be governed
by the new price that will apply on the following *.
2.4 MINIMUM INVENTORY.
2.4.1 DURA REQUIREMENT. Subject to Section 2.4.3, DURA will
use commercially reasonable efforts to maintain at least three (3) months'
inventory (based on one-fourth of its Forecast for the 12-month period
commencing on the first day of the calendar quarter for which such Forecast
is provided) of each Product at all times beginning January 1, 2000 through
the date that is three months prior to the end of the applicable Term for
such Product (unless DURA and BMS have agreed in writing prior to such date
that DURA will purchase any remaining stock of inventory on hand at the end
of such applicable Term).
2.4.2 BMS REQUIREMENT. Subject to Section 2.4.3, beginning
January 1, 2000, and subject to Section 2.12 hereof, BMS will use
commercially reasonable efforts to maintain at least three (3) months'
inventory of each Product at all times beginning January 1, 2000 through the
date that is three months prior to the end of the applicable Term for such
Product (unless DURA and BMS have agreed in writing prior to such date that
DURA will purchase any remaining stock of inventory on hand at the end of
such applicable Term). Said three month inventory shall be based on one-half
of the sum, as determined on the date that DURA places a firm order, of the
quantity of a Product (i) previously firm ordered by DURA pursuant to Section
2.3.2 for delivery within the 3-month period immediately preceding the date
of such firm order and (ii) previously firm ordered by DURA for delivery
within the 3-month period immediately following the date of such firm order.
2.5 SHIPMENTS. Except as provided in Section 2.11 hereof and Section
3.5 of the Distribution Agreement, BMS shall ship each order, F.O.B. the BMS
manufacturing facility for each Product, to DURA or its designee at the
location specified, as instructed by DURA. Freight and insurance shall be
for the account of DURA or shall be reimbursed by DURA, and BMS shall use
commercially reasonable efforts to assist DURA in arranging any desired
insurance. Title shall pass to DURA, and the risk of loss, delay or damage
in transit shall be with DURA, from and after delivery to the designated
carrier. BMS shall package each Product for shipment (and shall instruct
Baxter to package each premixed frozen Azactam-Registered Trademark- Product
for shipment) in accordance with its (or Baxter's, as the case may be)
customary practices therefor, unless otherwise specified by DURA, in which
event, any extra costs incurred by BMS or
8
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
Baxter on account of any changes requested by DURA shall be reimbursed by
DURA.
2.6 RECEIPT OF PRODUCT; ACCEPTANCE.
Except as provided in the Baxter Supply Agreement or as specifically
provided otherwise in Section 2.11 hereof or in any Related Agreement:
2.6.1 On or before the delivery of each shipment of each
Product, BMS will provide to DURA a Certificate of Analysis for the shipment
being delivered. DURA shall be entitled to reject any portion or all of any
such shipment that does not conform to the Certificate of Analysis (other
than as a result of damage in transit) or fails to comply in any material
respect with any other Specifications mutually agreed upon in writing for
such Product; PROVIDED, that DURA will notify BMS within fifteen (15)
business days after receipt of the shipment as to whether DURA is rejecting
such shipment. If no such notice is provided by DURA, then DURA shall be
deemed to have accepted the shipment ("Acceptance"); provided, that in the
case of Products having latent defects which upon diligent examination by
DURA upon receipt should not reasonably have been discovered, DURA must give
written notice of rejection within twenty (20) days after DURA discovers or
should reasonably have discovered such latent defect (and so long as DURA is
able to demonstrate that such defect was not attributable to any act or
omission of DURA or the common carrier once the Product shall have been
delivered by BMS to such common carrier). Any notice of rejection by DURA
shall be accompanied by a reasonably detailed statement of its reasons for
rejection and a report of any pertinent analysis performed by DURA on the
allegedly nonconforming Product, together with the methods and procedures
used. BMS shall notify DURA as promptly as reasonably possible, but in any
event within ten (10) days after receipt of such notice of rejection, whether
it accepts DURA's assertions of nonconformity.
2.6.2 Whether or not BMS accepts DURA's assertion of
nonconformity, promptly on receipt of a notice of rejection, BMS shall use
commercially reasonable efforts to provide replacement Product for that
rejected by DURA in the original shipment. However, if the Product rejected
by DURA from such original shipment ultimately is found to be nonconforming
(whether pursuant to Section 2.6.3 or if BMS acknowledges same in writing),
BMS shall, to the extent that DURA may previously have paid for such
nonconforming Product, bear its own expenses of such replacement Product
(including all transportation and/or disposal charges and cost of manufacture
for such nonconforming Product), and BMS shall determine if the nonconforming
Product shall be destroyed or returned to it. If DURA shall not previously
have paid for the allegedly nonconforming Product, and it is determined
subsequently that such Product was in fact conforming (whether pursuant to
Section 2.6.3 or if DURA acknowledges same in writing), then DURA shall be
responsible for the purchase price for the allegedly nonconforming Product
(including all transportation charges), as well as, upon receipt and
acceptance by DURA in accordance with the procedures (and at the same price
charged in the original shipment) set forth herein, the replacement Product.
Replacement shipments shall also be subject to the procedures contained in
this subparagraph. BMS shall be under no obligation to accept a return of
Product except as provided for in this subparagraph.
9
<PAGE>
2.6.3 If BMS disagrees with any alleged nonconformity, then an
independent GMP laboratory (or other expert) of recognized repute, selected
by BMS and reasonably acceptable to DURA, shall analyze an aliquot sample or
such other portions of a shipment, furnished by DURA from the shipment
received by DURA, as may be necessary to substantiate whether the shipment
rejected by DURA conformed in all material respects to the Certificate of
Analysis and/or any other pertinent Specifications. The laboratory (or
expert) shall use such procedures and tests as the laboratory may consider
necessary or appropriate to reach a conclusion. Both Parties agree to
cooperate with the independent laboratory's reasonable requests for
assistance in connection with its analysis hereunder. Both Parties shall be
bound by the laboratory's results of analysis, which, absent manifest error,
shall be deemed final as to any dispute over compliance of the Product in all
material respects with the Certificate of Analysis and/or any other pertinent
Specifications. The costs incurred by the laboratory shall be borne by the
losing Party, or if the laboratory cannot place the fault noticed and
complained about, then the Parties shall share equally the expenses connected
with the expert.
2.6.4 Where BMS accepts DURA's rejection of nonconformity (or
if not, then following the decision of the independent laboratory that the
shipment was nonconforming), BMS shall promptly make arrangements (but within
30 days thereafter) for the return or disposal, at BMS's option, of any
nonconforming Product. If BMS requests that DURA dispose of such
nonconforming Product, DURA shall lawfully destroy such Product promptly, and
provide BMS with written certification of such destruction. BMS shall pay
(or reimburse DURA for) any reasonable return shipping charges or
out-of-pocket costs incurred by DURA for such return shipment or lawful
disposal of such nonconforming Product.
2.6.5 All Products sold to DURA hereunder shall be used by DURA
in accordance with the terms and conditions of this Agreement and the
applicable terms and conditions of any applicable Related Agreement then in
force and effect.
2.7 QUALITY CONTROL; CHANGE IN SPECIFICATIONS OR SUPPLIER.
2.7.1 Except as provided in the Baxter Supply Agreement or as
specifically provided otherwise in Section 2.11 hereof or in any Related
Agreement, BMS shall conduct quality control testing of the Product prior to
shipment in accordance with the applicable NDAs and BMS' customary practices
therefor (for Product shipped by Baxter, BMS' quality control testing shall
be conducted solely on the bulk Product supplied by BMS prior to shipment to
Baxter). BMS shall retain records pertaining to such testing as required by
law.
2.7.2 BMS shall have the right, at its expense and in consultation
with DURA, to change the Specifications from time to time at any time during the
term of this Agreement or if BMS is required to do so by any regulatory agency
having jurisdiction over the Product, on not less than 120 days' prior written
notice to DURA. In such event, BMS shall be responsible at its expense for
ensuring that any such change is approved by each applicable regulatory
authority in the Territory, and DURA shall provide reasonable cooperation to
BMS in connection therewith. If a change requires prior approval by FDA, such
change will not be implemented in respect of such Product until such
10
<PAGE>
change has been so approved. BMS agrees to seek DURA's prior written consent
(not to be unreasonably withheld) for changes to the Specifications that BMS
may elect to make that would impose a material adverse cost upon DURA or that
would involve a change in form or potency of any Product set forth on Exhibit
1.1A.
2.7.3 BMS shall determine in its sole discretion, and may from
time to time change, the source of supply of the Product without the consent
of DURA, provided that BMS shall give DURA prior written notice of its
intention to do so, and that BMS shall be responsible for securing all
regulatory approvals at BMS' expense that may be required to effect such
change. DURA understands and accepts that BMS is planning to change its
manufacturing facility for the Azactam-Registered Trademark- Product from
BMS' New Brunswick, New Jersey facility to a BMS Affiliate's manufacturing
facility in Anagni, Italy.
2.7.4 BMS in its sole discretion shall determine, and may from
time to time change without the consent of or notice to DURA, the Affiliate
that shall invoice DURA for any Product supplied hereunder, and, subject to
Section 2.7.2 hereof and to Section 4.4.3, 4.4.4 and 4.12 of the Distribution
Agreement, any manufacturing processes used in manufacturing a given Product,
any intermediates, excipients, reagents or other compounds used in the
manufacture of any Product, and any suppliers of any components used in
making a Product.
2.8 RETENTION OF REGISTRATIONAL DOSSIER.
2.8.1 BMS shall retain all rights, title and interests in and
to the Product Registrations for each Product in the Territory. DURA shall
not at any time do, cause to be done, or omit or permit any act inconsistent
with the Product Registration for any Product in the Territory. In the event
that any filings are required to be made with or approvals required to be
obtained from applicable regulatory authorities in order to sell a Product to
DURA or for DURA to initiate marketing and sale of a Product in the
Territory, the Parties shall cooperate fully to ensure that such filings and
approvals are obtained or made as expeditiously as reasonably practicable.
2.8.2 BMS shall have sole responsibility for maintaining, and
shall use commercially reasonable efforts to maintain, the Product
Registrations in the Territory at its expense, including without limitation
filing IND and NDA Annual Reports. BMS shall keep DURA informed on a timely
basis as to any developments that would have a material adverse effect on a
Product Registration. Subject to such limitations as BMS may have under the
Abbott License Agreement and the Baxter Supply Agreement with respect to
access to and disclosure of information contained in the product
registrations filed by such Third Parties with respect to their plastic
container systems used in the manufacture of a Product, BMS shall provide
DURA, upon request after reasonable notice from DURA, with access to copies
of all filings submitted by BMS to the NDA for each Product (other than to
the CMC section) and, with respect to clinical trials for the Products
sponsored by BMS that are included in the NDA for a given Product, copies of
the Application Summary for such Product, which provides a comprehensive
summary of all clinical trials conducted under the NDA for such Product.
Nothing set forth herein shall permit DURA to photocopy or otherwise make a
reproduction of the NDAs without the prior written consent of a Vice
President of BMS. DURA shall cooperate with BMS with
11
<PAGE>
respect to obtaining and/or maintaining the Product Registrations, and shall
execute, acknowledge and deliver such further instruments at BMS' request and
expense, and use commercially reasonable efforts to do all such other acts,
as promptly as possible, which may be necessary or appropriate to obtain and
maintain the Product Registrations in the Territory. DURA shall, on a timely
basis, provide to BMS all information that DURA has from time to time during
the applicable Term for each Product that BMS does not have that is
reasonably necessary and relevant to BMS's obligations hereunder to fulfill
such Product Registration maintenance requirements (including, but not
limited to, providing sales distribution information concerning the
Products), and shall otherwise cooperate with BMS as reasonably necessary in
connection therewith. BMS shall have the final decision-making authority in
every case on whether and how to supplement, amend or otherwise alter the
Product Registrations and any other issues in connection with such Product
Registrations (including, but not limited to, decisions to recall the
Products) and on whether and how to communicate with the FDA and other
applicable governmental agencies or authorities in connection therewith;
PROVIDED, that BMS will not, except where required by, or to fulfill its
obligations under, applicable law or except where required by a governmental
agency or authority acting within the scope of its authority, supplement,
amend or otherwise alter a Product Registration so as to materially and
adversely alter the rights granted to DURA hereunder that are derived from
such Product Registration.
2.9 MATERIAL SAFETY DATA SHEETS. BMS shall provide DURA with all
material information currently known to BMS regarding handling precautions,
toxicity, and hazards associated with each Product as the same are set forth
in the applicable Material Safety Data Sheet for each Product provided by BMS
to its own employees as in effect from time to time.
2.10 BMS DISCRETION TO MAINTAIN MANUFACTURING PROCESS PATENTS,
FORMULATIONS, AND SUPPLY CONTRACTS.
2.10.1 Notwithstanding any other provision of this Agreement,
including without limitation Article 7 hereof, BMS shall have the sole right,
but not the obligation, at its sole discretion and expense, to prosecute,
maintain, enforce, defend or abandon any patent rights and know-how owned or
controlled by BMS covering the manufacture of a Product, except that BMS
shall use commercially reasonable efforts to maintain, at its cost and
expense (subject to Section 3.1 hereof), the patent rights licensed to it
under (i) the Takeda License Agreement, (ii) the Fujisawa License Agreement,
and (iii) the Abbott License Agreement. The foregoing shall not require BMS
to grant additional rights or to provide any additional consideration to
Takeda, Fujisawa or Abbott, as the case may be, beyond that which BMS is
obligated to pay or provide under the terms of the current applicable
agreement.
2.10.2 Notwithstanding any provision of this Agreement that may
imply or provide to the contrary, BMS shall have the sole right, but not the
obligation, at its sole discretion and expense, to maintain and enforce any
contract entered into by BMS covering the supply of any compounds,
intermediates, biomaterials, packaging components, containers and other
materials used in the manufacture of a Product, except that BMS shall use
commercially reasonable efforts to maintain, at its cost and expense, the
supply of Product under the Baxter Supply Agreement. The foregoing shall not
require BMS to extend such Agreement, to grant additional rights to Baxter,
or to
12
<PAGE>
provide any additional consideration to Baxter beyond that which BMS is
obligated to pay or provide under the terms of the current applicable
agreement.
2.10.3 BMS shall have no obligation, express or implied, to
develop new formulations, dosages, forms of administration, or preparations
for the Product, other than those in effect as of the Effective Date. DURA
acknowledges and accepts that BMS may, at BMS' discretion and expense, pursue
or conduct such studies as are necessary to convert Azactam-Registered
Trademark-(other than the frozen, premixed presentation prepared by Baxter)
from a lyophilized product to a crystalline, sterile dry powder fill product.
BMS shall be responsible for making any regulatory filings and conducting
any studies as are necessary, at its expense, to obtain regulatory approval
for such dry powder fill product for Azactam-Registered Trademark-. Upon
receipt of regulatory approval to market a sterile dry powder fill product
for Azactam-Registered Trademark-, such product shall replace the lyophilized
Azactam-Registered Trademark- product as set forth in the Exhibits attached
to this Agreement and to any Related Agreement.
2.11 BAXTER SUPPLY AGREEMENT. Pursuant to the terms of the Baxter
Supply Agreement, BMS provides Baxter with bulk Aztreonam, and Baxter then
fills, labels and packages the finished dosage form for all frozen premixed
presentations of the Azactam-Registered Trademark- Product. Although all
such presentations of the Azactam-Registered Trademark- Product are sold
under agreement between BMS and the ultimate customer, Baxter stores all
frozen premixed presentations of the Azactam-Registered Trademark- Product
and ships same to each BMS customer in accordance with instructions provided
by BMS. BMS does not test said frozen premixed presentations of the
Azactam-Registered Trademark- Product before the same are shipped to a
customer by Baxter. BMS will cooperate with DURA to ensure that such
presentations of the Azactam-Registered Trademark- Product are shipped to
DURA's customers in accordance with instructions provided by DURA and in
accordance with the terms of the Baxter Supply Agreement, until such time as
Baxter and DURA may enter into a separate agreement under which DURA shall
inform Baxter directly of DURA's customers and delivery instructions for
frozen premixed presentations of the Azactam-Registered Trademark- Product.
2.12 MAXIMUM CAPACITY. DURA acknowledges and agrees that BMS' supply
obligations under this Agreement shall be limited to BMS' existing supply
capacity for the supply of bulk compound for the Products for use in the
Territory. These supply capacities are set forth on Exhibit 2.12.
Notwithstanding any other provision in this Agreement or any Related
Agreement that may state or imply to the contrary, BMS shall not be obligated
to manufacture or provide supplies of a Product for use in the Territory in
excess of the bulk compound capacity for such Product as set forth on such
Exhibit. In the event that either Party believes that the market that DURA
is building for either or both of these Products will exceed said BMS
capacity for such Product, such Party shall so notify the other promptly, and
the Parties agree to meet and confer with a view to finding a mutually
agreeable solution to DURA's supply requirements.
In the event that BMS is able to improve both its bulk and finished
manufacturing processes for either Product in a manner that BMS believes may
enable it to increase the maximum capacity limitation set forth on Exhibit
2.12 without incurring any material additional cost (including without
limitation direct and indirect costs, including overhead), BMS will consider
in good faith (the decision for which shall be made at BMS' sole and absolute
discretion and without any obligation, express or implied, to make any such
change) adjusting the maximum capacity limitation on said Exhibit
13
<PAGE>
to reflect such increased capacity figure. DURA may request that BMS
undertake such a review not more than once per annum, but BMS shall not be
obligated to share the results of its analysis with DURA nor the data or
inputs comprising such analyses.
2.13 SUPPLY FOLLOWING APPLICABLE TERM FOR A PRODUCT.
2.13.1 Three and one-half years prior to the end of the
applicable Term for a given Product, the Parties will meet and confer for the
purpose of discussing whether, and upon what terms, BMS would be willing to
supply and DURA would be willing to purchase such Product following the
applicable Term for such Product (it being understood that neither Party
shall be obligated, expressly or impliedly, to agree to same). If the
Parties conclude that there is no mutual interest within three (3) months
thereafter or are unable to reach a mutually acceptable written agreement on
an extension of such supply by not later than three (3) years prior to the
end of the applicable Term for a given Product, then, where permitted by and
subject to the terms and conditions of Section 2.13.2, BMS shall provide to
DURA or such Third Party manufacturer as DURA may designate, under an
obligation of confidentiality (and any such Third Party contractor or
subcontractor shall be required to sign a confidentiality agreement with
respect to the nondisclosure and use of same), such Manufacturing Know-How
(including a copy of, and/or rights of reference to, BMS' Product
Registrations for such Product) as will enable DURA or such Third Party to
make such Product only, and no other product, following the applicable Term
for such Product; provided, that BMS shall not be obligated to provide more
than one hundred twenty (120) man-hours of on-site consulting advice
(including travel time) or devote any time or effort to the conduct of any
tests, studies or assays required for the transfer of such manufacturing or
the Product manufactured by or for DURA, unless BMS is reimbursed for its
fully-burdened costs (including without limitation its personnel) incurred to
provide such advice or services.
2.13.2 Following the expiration of BMS' supply obligation for a
Product, and provided that such supply obligation did not terminate as a
result of the termination of this Agreement (or BMS' supply obligation
hereunder as to such Product) prior to the end of the applicable Term for
such Product as a result of any action taken by BMS pursuant to any of
Sections 10.2, 10.3 or 10.4, BMS shall grant to DURA the nonexclusive right
and license under any patent rights owned or controlled by BMS or any of its
Affiliates, the nonexclusive right to reference BMS' Product Registrations
for such Product, and to use the Manufacturing Know-How for the sole purpose
of enabling DURA to make the Product (with right of sublicense solely to
enable a Third Party to manufacture the Product) for the sole purpose of
supplying DURA's requirements for marketing and sale of the Product within
the Territory, but not to make any other product or to make the Product for
sale outside the Territory; PROVIDED, that:
2.13.2.1 The foregoing shall not apply to any rights as may
be exclusively licensed to BMS under the Takeda License Agreement unless and
until BMS and DURA shall have reached a written agreement as to same as set
forth in Section 4.7 of the Distribution Agreement. DURA shall be jointly
and severally liable and responsible for all acts or omissions of any of its
sublicensees;
14
<PAGE>
2.13.2.2 DURA (and its permitted sublicensees under this
Section 2.13.2) shall comply with all terms and conditions of all agreements
("Third Party License Agreements") covering the license of any rights to BMS
that are sublicensed to DURA under this Section 2.13.2, in whole or in part,
and shall reimburse BMS for any payments to be made by BMS to such Third
Party licensor on account of the rights sublicensed by BMS to DURA, or on
account of the exercise by DURA of the rights sublicensed to it, under such
Third Party License Agreements (or, if BMS and DURA mutually agree in
writing, DURA shall make such payments required to be made by it to the Third
Party licensor directly). DURA shall be primarily responsible and liable for
the performance and compliance by its permitted sublicensees of the terms and
conditions of this Agreement and any Third Party License Agreement;
2.13.2.3 Each permitted sublicensee Party shall have first
agreed in writing with DURA and BMS to keep all necessary books and records
and to permit BMS to review such books and records pursuant to this Agreement
and to observe all other applicable obligations and terms imposed on DURA
under this Agreement or any Third Party License Agreement applicable to the
duties assigned, delegated and/or sublicensed to such Third Party by DURA.
2.13.2.4 DURA shall indemnify and hold BMS and its Affiliates
harmless from and against any liability, damages, loss, cost or expense
incurred by BMS arising out of or in connection with a breach by DURA or any
of its Affiliates (or any of its permitted sublicensees) of any of the terms
and conditions of a Third Party License Agreement. In the event of a breach
by a DURA Affiliate of the applicable terms of a Third Party License
Agreement, BMS, as well as such Third Party licensor (which shall be an
express third party beneficiary of DURA's obligations thereunder) shall be
entitled to proceed directly against DURA to enforce same or to pursue any
remedies available to it, at law or in equity;
As part of any transfer of manufacturing operations for a Product to
DURA, DURA and BMS will coordinate an appropriate phase-out of BMS' minimum
inventory holding under Section 2.4 with respect to such Product to be
manufactured by DURA so that BMS may avoid to the maximum practicable extent
a write-off of any such inventory upon transfer.
2.14 BACK-UP SUPPLY. With respect to Maxipime-Registered Trademark-,
BMS agrees to commercially reasonable efforts to qualify a back-up facility
or supplier for the finishing of packaged Maxipime-Registered Trademark-
Product, but not bulk compound, as promptly as reasonably practicable after
the Effective Date; PROVIDED, however, that BMS shall not be obligated to
qualify a back-up supplier or facility to finish or package any of the
Piggyback or ADD-Vantage-Registered Trademark- formulations for
Maxipime-Registered Trademark- or any back-up supplier of the frozen,
premixed formulation of Azactam-Registered Trademark- supplied by Baxter.
BMS estimates that, unless unanticipated regulatory problems are encountered,
BMS will be able to qualify a back-up BMS finishing facility with one year
after the Effective Date. With respect to Azactam-Registered Trademark-
(other than the frozen, premixed presentation prepared by Baxter), BMS has
already qualified a Third Party (Ben Venue) as of the Effective Date to
provide finished Product (but not bulk compound) for the lyophilized
Aztreonam product. If and when BMS switches to a crystalline, sterile dry
powder fill Aztreonam product and has transferred the finishing and packaging
for this Product
15
<PAGE>
to its Anagni, Italy facility, BMS will use commercially reasonable efforts
to qualify a back-up BMS facility or supplier of said finished, packaged
Product (but not the bulk compound) within one-year after BMS has so
transferred its finishing facility to Anagni, Italy to make the finished,
packaged, sterile dry powder Aztreonam Product. BMS will use commercially
reasonable efforts to maintain, once established, a back-up supplier or
back-up BMS finishing facility for packaging and finishing each Product
during the applicable Term for such Product. BMS shall be entitled to change
in its discretion its back-up supplier or back-up supply facility once all
necessary approvals have been obtained and shall give DURA prompt written
notice of any such change. It is understood that BMS is under no obligation
to qualify a back-up supplier or facility to make bulk cefepime hydrochloride
or bulk aztreonam.
2.15 PRIORITY TO DURA. In the event that BMS is unable to supply the
total demands of all of its customers for firm orders of the Product provided
for in this Agreement for any reason other than those covered by Article 11),
BMS shall first allocate any available Product among firm orders placed by
DURA and BMS' Third Party customers and licensees, excluding BMS' own
divisions and departments, proportionately to the amounts so firm-ordered by
DURA and by such Third Parties and licensees, with any balance then remaining
being available for BMS' own divisions and departments.
3. PURCHASE PRICE FOR PRODUCTS AND CLOSING INVENTORY.
3.1 PURCHASE PRICE.
3.1.1 The purchase price for each Product sold to DURA pursuant to
Article 2 hereof shall be equal to the price for such Product set forth on
EXHIBIT 3.1 for purchase orders received by BMS under Section 2.4 prior to
*, as such price is adjusted on each anniversary date thereafter
as set forth in this Section 3.1 (the "Purchase Price"). The price of each such
Product shall be adjusted as of *, and on each *
thereafter during the applicable Term for a Product, by such percentage
increase or decrease in the U.S. Producers Price Index for Finished Goods (or
successor index) as published by the U.S. Department of Labor, Bureau of
Statistics (or successor governmental entity), as shall have occurred for the
immediately preceding twelve-month (1/1-12/31) period, subject, however, to such
additional adjustments as may occur as set forth in Sections 3.1.2 and 3.1.3
below. The Purchase Price adjustment under this Section 3.1.1 shall be
retroactively effective to said *, even though the index figures needed
to calculate such change will not be available until published by the Bureau of
Statistics after *.
3.1.2 Subject to Section 3.3, BMS may elect in its discretion to
adjust for any given year that portion of the prior year's Purchase Price of a
Product that represents such Product's variable costs (including without
limitation costs of labor, cost of supplies, materials increases, and cost of
Third Party supplies and services, but excluding overhead) by the actual
percentage change in such variable costs incurred in that year, rather than
adjusting such portion by the change in the index set forth above. All other
components of the Purchase Price of such Product for such year shall be adjusted
by the index set forth above. For purposes of pricing Product ordered by DURA
on said * and
16
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
thereafter, all components of the Purchase Price of such Product shall be
adjusted as of * by the change in the index as set forth in Section 3.1.1,
until such time as BMS notifies DURA that it is electing to change said
portion of the annual adjustment to the Purchase Price attributable to
variable costs by said difference between the percentage change in the actual
variable cost component of such Product and the percentage change
attributable to the index. Once BMS has so notified DURA in writing that BMS
is electing, for such year, to change said portion of the annual adjustment
to the Purchase Price that is attributable to variable costs by such
difference between the percentage change in the actual variable cost
component of such Product and the percentage change attributable to the
index, then the Purchase Price with respect to firm orders placed by DURA
after such date shall be increased accordingly effective upon receipt of such
notice; however, for purposes of calculating future annual changes thereafter
to the Purchase Price of the Product under Section 3.1.1, such change shall
be deemed to have occurred retroactively to *. If BMS does not notify DURA
of any change under this Section 3.1.2 within the year following the * date
to which such change would be retroactively effective for purposes of
calculating future annual changes thereafter to the Purchase Price under
Section 3.1.1, BMS shall be deemed to have waived its right to apply this
section 3.1.2 with respect to the year that the change in costs occurred.
For sake of clarity and avoidance of doubt, the following example
is intended to illustrate how this Section 3.1.2 would work: Assuming that
the Purchase Price of a vial of Product for a given SKU# is $20.00 on *, and
the Producers Price Index increases by 5% between * and *, then the Purchase
Price of the Product shall be automatically adjusted to $21.00 on 1/1/2000,
both for purposes of calculating the price to be paid by DURA to BMS for firm
orders on or after such date, as well as for setting the baseline price on
which the following year's annual adjustment shall be made. Assume, too, that
the sum of all of BMS' variable costs for the Product as of * represented
$8.00 of the $20.00 Purchase Price, and that such variable costs actually
increased in the aggregate by 10% over the * period. If BMS notifies DURA
within one (1) year after * that its variable prices for the Product actually
rose by 10% for the period from * and that BMS is electing to adjust the
Purchase Price for such SKU# in accordance with this Section 3.1.2 (and
assume that BMS provides such notice on May 1, 2000), then: (i) the Purchase
Price of such Product SKU# shall be increased to $21.40 ($20.00 + ($12.00 x
.05) + ($8.00 x .10)) for firm orders placed by DURA after May 1, 2000; (ii)
for purposes of determining the annual price adjustment on *, the Purchase
Price of the Product on * shall be deemed to have been $21.40 (with variable
costs comprising $8.80 of such figure); and (iii) DURA shall be entitled to
exercise its audit rights under Section 3.3 with respect to such increase in
the variable price component only for the * period.
3.1.3 The Purchase Price of each such Product shall also be
adjusted, effective immediately, by any additional fees, royalties, costs or
other compensation as BMS may be required to pay to (i) Baxter in order to
retain Baxter's commitment to supply premixed frozen Azactam-Registered
Trademark- Product (beyond such fees, royalties, costs or other compensation as
BMS may be obligated to pay under the Baxter Supply Agreement as of the
Execution Date), provided that DURA shall have agreed to same in writing in
advance (it being understood that if DURA does not agree to pay all such
additional fees, royalties, costs or other compensation as BMS may be obligated
to pay in order to renew or extend the Baxter Supply Agreement or otherwise pay
in order to obtain Baxter's agreement to continue to supply premixed
17
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
frozen Azactam-Registered Trademark- Product, BMS shall be under no
obligation to so extend or renew the Baxter Supply Agreement or to negotiate
or enter into any other agreement with Baxter to supply same), and/or (ii)
Takeda, as more fully set forth in Section 4.7 of the Distribution Agreement.
3.2 PURCHASE PRICE FOR EXISTING INVENTORY. The purchase price for
finished Product inventory supplied to DURA pursuant to Section 2.1.2 hereof
shall be as set forth on EXHIBIT 3.2.
3.3 AUDIT OF COST RECORDS. DURA shall not be entitled to audit BMS'
cost records for a given Product, unless BMS has elected to adjust its price
for a Product in accordance with Section 3.1 above for a given year based on
the change in BMS' actual variable costs for the preceding year. In such
event, DURA shall have the right to audit (not more frequently than once with
respect to any given year for which BMS has so elected to adjust its price),
at its expense (which shall include reimbursement to BMS for the
administrative costs it incurs in connection with the review) at reasonable
times during normal business hours and upon reasonable notice, to have a "Big
Five" accounting firm review BMS' books and records relating to the
manufacture of the applicable Product(s), for the sole purpose of verifying
BMS' determination of its change in variable costs for the year in question
under Section 3.1.2. Such accounting firm shall sign an appropriate
confidentiality agreement reasonably acceptable to BMS, and shall not
disclose to DURA the individual cost records or figures or any information
that would result in a disclosure of information relating to Manufacturing
Know-how, but shall be entitled to disclose to DURA's its conclusion as a
result of its audit and, if necessary, disclose its work records to DURA to
the extent necessary to assist DURA in enforcing its rights under this
Agreement. A copy of the auditing entity's conclusions of its audit shall be
furnished to BMS at least ten (10) days prior to disclosure to DURA so that
BMS may determine if any BMS Confidential Information pertaining to its
Manufacturing Know-how would be disclosed thereby and to allow BMS an
opportunity to review the accuracy of the auditing firm's conclusions prior
to disclosure to DURA. DURA shall bear the full cost of such audit unless
such audit discloses a variance of more than five percent (5%) from the
amount due, in which event, BMS shall bear the full cost of such audit. Any
amounts that are determined to be due and owing by BMS to DURA or by DURA to
BMS following such audit shall be paid within ten (10) business days
thereafter, together with any interest due thereon from the date of
overpayment by DURA at the rate of twelve percent (12%) per annum; PROVIDED,
that in no event shall such rate exceed the maximum legal annual interest
rate. The payment of such interest shall not limit a Party from exercising
any other rights it may have as a consequence of the lateness of any payment.
4. PAYMENTS AND REPORTS.
4.1 PAYMENT. BMS shall submit invoices to DURA for Product promptly
after shipment. The invoices shall reflect the price for the Product as set
forth within Section 3.1. Payments shall be made by DURA within thirty (30)
days of receipt of the invoice.
4.2 MODE OF PAYMENT. DURA shall make all payments required under this
Agreement by wire transfer to a bank account designated by BMS in United
States Dollars.
18
<PAGE>
4.3 TAXES. Any and all transfer, sales, use, registration and other
taxes imposed upon or with respect to or measured by the sale or delivery by
BMS to DURA of any Product hereunder shall be the responsibility of and for
the account of DURA. Such amounts shall be included on BMS's invoices to
DURA for such Products. Anything to the contrary notwithstanding, DURA shall
have no obligation to pay any income tax imposed on BMS or any of its
Affiliates which may arise from the transactions contemplated by this
Agreement.
4.4 LATE PAYMENTS. In the event that any payment due hereunder is not
made when due, the payment shall accrue interest from the date due at the
rate of twelve percent (12%) per annum; provided that in no event shall such
rate exceed the maximum legal annual interest rate. The payment of such
interest shall not limit BMS from exercising any other rights it may have as
a consequence of the lateness of any payment.
5. COMPLIANCE WITH LAWS; COMPLIANCE AUDITS; REPRESENTATIONS AND WARRANTIES.
5.1 COMPLIANCE WITH LAW; COOPERATION; COMPLIANCE AUDITS.
5.1.1 COMPLIANCE WITH LAW. Each Party shall use commercially
reasonable efforts to maintain in full force and effect all necessary
licenses, permits and other authorizations required by law to carry out its
duties and obligations under this Agreement. Each Party shall comply with
all laws, ordinances, rules and regulations (collectively, "Laws") applicable
to its activities under this Agreement and each Related Agreement, including
without limitation, any requirements of any product license applicable to the
Products in the Territory; PROVIDED, that DURA shall be solely responsible
for compliance with those Laws pertaining to the activities conducted by it
hereunder and under any Related Agreement (including, without limitation,
those Laws that apply to documentation and records retention pertaining to
the distribution and use of Products within the Territory), notwithstanding
that FDA may, as a matter of law, be entitled to hold BMS accountable or
responsible (whether primarily or secondarily) for failure of DURA to comply
with such Laws. Without limiting the generality of the foregoing, Dura shall
not promote the Products for any indications not contained in the approved
NDAs or in any manner in conflict with the approved labeling and all
applicable Laws. DURA shall store the Products sold to it in compliance with
all applicable laws, including, without limitation, the PDMA. BMS and DURA
each shall keep all records and reports required to be kept by applicable
laws and regulations. The Parties will reasonably cooperate with one another
with the goal of ensuring full compliance with Laws. Each Party will
cooperate with the other to provide such letters, documentation and other
information on a timely basis as the other Party may reasonably require to
fulfill its reporting and other obligations under applicable Laws to
applicable regulatory authorities.
5.1.2 REASONABLE COOPERATION. BMS and DURA each hereby agrees
to use commercially reasonable efforts to take, or cause to be taken, all
actions and to do, or cause to be done, all things necessary or proper to
make effective the transactions contemplated by this Agreement, including
such actions as may be reasonably necessary to obtain approvals and consents
of governmental Persons and other Persons (including, without limitation, all
necessary notifications to the FDA and other governmental authorities
identifying DURA as a distributor of the
19
<PAGE>
Products); PROVIDED, that no Party shall be required to (i) pay money (other
than as expressly required pursuant to this Agreement or a Related
Agreement), or (ii) assume any other material obligation not otherwise
required to be assumed by this Agreement or any Related Agreement.
5.1.3 COMPLIANCE AUDITS.
5.1.3.1 From time to time as BMS may elect during the
applicable Term for a given Product, during normal business hours and upon
reasonable notice from BMS (but not less than 10 days notice), DURA shall
permit duly authorized representatives of BMS to review and inspect the
premises, facilities, Product inventory, records and documentation maintained
by DURA for the purpose of determining compliance by DURA with its
obligations under this Agreement and any Related Agreement.
5.1.3.2 From time to time as DURA may elect during the
applicable Term for a given Product, during normal business hours and upon
reasonable advance notice from DURA (but not less than 10 days notice), BMS
shall permit duly authorized representatives of DURA to inspect, on the
premises of BMS where such records and inventory are kept, finished Product
inventory and BMS's quality control records relating to the storage of the
finished Products to ensure compliance with quality control standards and the
labeling for each such Product and with applicable terms of this Agreement
pertaining to the use of the Trademarks; PROVIDED, that nothing in the
foregoing shall allow or be construed to allow DURA to have access to any
Manufacturing Know-How of BMS or any records containing or pertaining to same
(except where DURA has obtained right of access to such Know-How under
Sections 2.13 or 10.5.8 of this Agreement.
5.2 MANUFACTURING WARRANTIES.
5.2.1 BMS warrants that each Product manufactured by or for BMS
and sold to DURA under this Agreement:
(i) will not be adulterated or misbranded under applicable FDA
laws and regulations at the time the same is tendered to
the common carrier for delivery to DURA; and
(ii) will meet the Specifications therefor in all material
respects at the time the same is tendered to the common
carrier for delivery to DURA; and
(iii) shall be manufactured in accordance with Good
Manufacturing Practices (GMPs), as established by FDA;
and
(iv) will have a shelf life of not less than those months set
forth in EXHIBIT 1.1(A) at the time the same is tendered to
the common carrier for delivery to DURA.
5.2.2 THE LIMITED WARRANTY PROVIDED IN SECTION 5.2.1 IS BMS' SOLE
WARRANTY WITH RESPECT TO A PRODUCT THAT IS MADE BY BMS UNDER THIS AGREEMENT AND
20
<PAGE>
IS MADE IN LIEU OF ANY AND ALL OTHER WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING WARRANTIES OF QUALITY, PERFORMANCE, MERCHANTABILITY AND FITNESS FOR
A PARTICULAR USE OR PURPOSE. EXCEPT AS MAY BE EXPRESSLY SET FORTH IN THIS
ARTICLE 5 OR IN ANY RELATED AGREEMENT, BMS MAKES NO OTHER REPRESENTATIONS OR
WARRANTIES OF ANY KIND WITH RESPECT TO THE PRODUCT, INCLUDING WITHOUT
LIMITATION ANY WARRANTIES WITH RESPECT TO LACK OF THIRD PARTY INFRINGEMENT
THAT MAY RESULT FROM THE MANUFACTURE, USE OR SALE OF ANY PRODUCT.
5.2.3 Where DURA has acquired the right to make or have made a
Product under this Agreement, DURA warrants that each Product manufactured by
or for DURA under this Agreement:
(i) will not be adulterated or misbranded under applicable FDA
laws and regulations at the time the same is tendered to
the common carrier for delivery to DURA; and
(ii) will meet the Specifications therefor in all material
respects at the time the same is tendered by DURA to the
common carrier for delivery to a Third Party; and
(iii) shall be manufactured in accordance with Good
Manufacturing Practices (GMPs), as established by FDA;
and
(iv) will have a shelf life of not less than those months set
forth in EXHIBIT 1.1(A) at the time the same is tendered to
the common carrier for delivery by DURA.
5.2.4 THE LIMITED WARRANTY PROVIDED IN SECTION 5.2.3 IS DURA'S
SOLE WARRANTY WITH RESPECT TO A PRODUCT THAT IS MADE BY OR FOR DURA UNDER
THIS AGREEMENT AND IS MADE IN LIEU OF ANY AND ALL OTHER WARRANTIES, EXPRESS
OR IMPLIED, INCLUDING WARRANTIES OF QUALITY, PERFORMANCE, MERCHANTABILITY AND
FITNESS FOR A PARTICULAR USE OR PURPOSE. EXCEPT AS MAY BE EXPRESSLY SET
FORTH IN THIS ARTICLE 5 OR IN ANY RELATED AGREEMENT, DURA MAKES NO OTHER
REPRESENTATIONS OR WARRANTIES OF ANY KIND WITH RESPECT TO THE PRODUCT,
INCLUDING WITHOUT LIMITATION ANY WARRANTIES WITH RESPECT TO LACK OF THIRD
PARTY INFRINGEMENT THAT MAY RESULT FROM THE MANUFACTURE, USE OR SALE OF ANY
PRODUCT.
5.3 DURA PRODUCT WARRANTIES.
5.3.1 Subject to Section 5.2, DURA represents and warrants to BMS
that:
(i) DURA shall adhere to all applicable Laws relating to the
handling, storage, disposal, distribution and sale of each
Product in the Territory; and
(ii) DURA's sales force will not make any promotional or other
claims with respect to a Product that are not within the
Product Registrations and labeling for such Product
21
<PAGE>
as approved by FDA and that are not in compliance with
applicable law.
5.4 REPRESENTATIONS AND WARRANTIES OF BOTH PARTIES. Except as may be
set forth in EXHIBIT 5.4, each Party hereby represents and warrants that, as
of the Execution Date:
5.4.1 GOOD STANDING. Such Party is duly organized, validly
existing and in good standing under the laws of the state of its
incorporation, is duly qualified to transact the business in which it is
engaged in each jurisdiction where failure to be so qualified would have a
material adverse effect upon its business as currently conducted, and has
full corporate power and authority to enter into this Agreement and the
Related Agreements and to carry out the provisions of this Agreement and the
Related Agreements.
5.4.2 POWER AND AUTHORITY. Such Party has the requisite power
and authority and the legal right to own and operate its property and assets,
to license and lease the property and assets it operates or uses under lease
or license, and to carry on its business as it is now being conducted. Such
Party has the requisite power and authority and the legal right to enter into
this Agreement and the Related Agreements, and to perform its obligations
hereunder and thereunder, and has taken all necessary corporate action on its
part to authorize the execution and delivery of the Agreement and the Related
Agreements and the performance of its obligations hereunder and thereunder.
All persons who have executed this Agreement or a Related Agreement on behalf
of such Party, or who will execute on behalf of such Party any agreement or
instrument contemplated hereby or thereby, have been duly authorized to do so
by all necessary corporate action.
5.4.3 BINDING OBLIGATION. This Agreement and the Related
Agreements have been duly executed and delivered on its behalf and (assuming
the due execution and delivery hereof and thereof by the other Party) each
such agreement is a legal and valid obligation binding upon it and is
enforceable in accordance with its terms, except that (i) such enforcement
may be subject to bankruptcy, insolvency, reorganization, moratorium or other
similar laws now or hereafter in effect relating to creditors rights
generally and (ii) the remedy of specific performance and other forms of
equitable relief may be subject to equitable defenses and to the discretion
of the court or arbitrator before which any proceeding therefor may be
brought.
5.5 REPRESENTATIONS AND WARRANTIES OF BMS. Except as set forth in
EXHIBIT 5.5, BMS hereby represents and warrants to DURA that:
5.5.1 NO VIOLATION OF INSTRUMENTS OR CONTRACTS. The execution and
the delivery of this Agreement and the Related Agreements and the consummation
of the transactions contemplated hereby and thereby will not: (i) violate the
Certificate of Incorporation or By-Laws of any of the BMS Entities; (ii) to the
knowledge of BMS, materially conflict with or result in a material breach of any
of the material terms, conditions or provisions of, or constitute an express
event of default under, any material instrument, agreement, mortgage, judgment,
order, award, or decree specifically relating to the Business to which any BMS
Entity is a party or by which it is bound and which would have
22
<PAGE>
a material adverse effect upon the conduct of the Business as currently
conducted by such BMS Entity, (iii) to the knowledge of BMS, require the
affirmative approval, consent, authorization or other order or action of any
court, governmental authority or regulatory body or of any creditor of any of
the BMS Entities, or (iv) to the knowledge of BMS, give any Third Party the
right under any material instrument, agreement, mortgage, judgment, order,
award or decree specifically relating to the Business the right to terminate,
modify or otherwise change the rights or obligations of any of the BMS
Entities under such material instrument, agreement, mortgage, judgment,
order, award or decree, the effect of which would be materially adverse to
the conduct of the Business as currently conducted by such BMS Entity, or (v)
conflict with or result in any violation of or constitute a breach of any of
the terms or provisions of, or result in the acceleration of any obligation
under, or constitute a default under, any contract that is material to the
conduct of the Business and to which any BMS Entity is a party or to which it
is subject or bound, except for such conflict, acceleration, default, breach
or violation that is not reasonably likely to have a material adverse effect
on such BMS Entity's ability to perform its obligations under this Agreement
or any Related Agreement.
5.5.2 COMPLIANCE WITH LAW. Each BMS Entity is in compliance
with all requirements of applicable law within the Territory, except to the
extent that any noncompliance would not have a material adverse effect on the
conduct of the Business as currently conducted by such BMS Entity and would
not materially adversely affect BMS' ability to perform its obligations under
this Agreement or any Related Agreement.
5.5.3 LITIGATION AND CLAIMS. There is no litigation,
arbitration, claim, governmental or other proceeding (formal or informal),
or, to the knowledge of BMS, governmental investigation pending or threatened
in writing within the Territory relating to the Business (it being understood
that this sentence does not relate in any way to the subject matter of
Sections 5.2.5 and 5.2.6 of this Agreement), which, if adversely determined,
would have a material adverse effect upon BMS' ability to perform its
obligations under this Agreement or any Related Agreement. None of the BMS
Entities is in violation of, or in default with respect to, any law, rule,
regulation, order, judgment, or decree relating to the Business or to the
Trademarks, which violation or default would materially and adversely affect
the Business; nor is any of the BMS Entities required to take any action
outside of the ordinary course of business in order to avoid such violation
or default.
5.5.4 NO BROKER FEES. BMS has not incurred any liability or
obligation to any broker, finder, or agent for any brokerage fees, finder's
fees, or commissions with respect to the transactions contemplated by this
Agreement which may be directly or indirectly asserted against DURA.
5.6 REPRESENTATIONS AND WARRANTIES OF DURA. Except as set forth in
EXHIBIT 5.6, DURA hereby represents and warrants to BMS that:
5.6.1 NO VIOLATION OF INSTRUMENTS OR CONTRACTS. The execution and
the delivery of this Agreement and the Related Agreements and the consummation
of the transactions contemplated hereby and thereby will not: (i) violate the
Certificate of Incorporation or By-Laws of DURA; (ii) to the knowledge of DURA,
materially conflict with
23
<PAGE>
or result in a material breach of any of the material terms, conditions or
provisions of, or constitute an express event of default under, any material
instrument, agreement, mortgage, judgment, order, award, or decree to which
DURA is a party or by which it is bound and that would have a material
adverse effect upon DURA's ability to perform its obligations under this
Agreement or any Related Agreement, (iii) to the knowledge of DURA, require
the affirmative approval, consent, authorization or other order or action of
any court, governmental authority or regulatory body or of any creditor of
DURA or any of its Affiliates, or (iv) to the knowledge of DURA, give any
Third Party the right under any material instrument, agreement, mortgage,
judgment, order, award or decree the right to terminate, modify or otherwise
change the rights or obligations of DURA or any of its Affiliates under such
material instrument, agreement, mortgage, judgment, order, award or decree,
the effect of which would have a material adverse effect upon DURA's ability
to perform its obligations under this Agreement or any Related Agreement, or
(v) conflict with or result in any violation of or constitute a breach of
any of the terms or provisions of, or result in the acceleration of any
obligation under, or constitute a default under, any contract to which DURA
or any of its Affiliates is a party or to which it is subject or bound,
except for such conflict, acceleration, default, breach or violation that
would have a material adverse effect on DURA's ability to perform its
obligations under this Agreement or any Related Agreement.
5.6.2 COMPLIANCE WITH LAW. DURA and its Affiliates are in
compliance with all requirements of applicable law within the Territory,
except to the extent that any noncompliance would not have a material adverse
affect upon its ability to perform its obligations under this Agreement or
any Related Agreement.
5.6.3 LITIGATION AND CLAIMS. There is no litigation,
arbitration, claim, governmental or other proceeding (formal or informal),
or, to the knowledge of DURA, governmental investigation pending or
threatened in writing within the Territory against DURA or any of its
Affiliates where an adverse outcome would have a material adverse affect upon
DURA's ability to perform its obligations under this Agreement or any Related
Agreement. DURA and its Affiliates are not in violation of, or in default
with respect to, any law, rule, regulation, order, judgment, or decree, which
violation or default would have a material adverse affect upon DURA's ability
to perform its obligations under this Agreement or any Related Agreement; nor
is DURA or any of its Affiliates required to take any action outside of the
ordinary course of business in order to avoid such violation or default.
5.6.4 NO BROKER FEES. DURA has not incurred any liability or
obligation to any broker, finder, or agent for any brokerage fees, finder's
fees, or commissions with respect to the transactions contemplated by this
Agreement which may be directly or indirectly asserted against BMS.
5.7 DISCLAIMER OF WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS
AGREEMENT, THERE ARE NO OTHER REPRESENTATIONS OR WARRANTIES, EXPRESS OR
IMPLIED, MADE OR GIVEN BY EITHER PARTY HEREUNDER, INCLUDING, WITHOUT
LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OF ANY PRODUCT.
5.8 NO RELIANCE BY THIRD PARTIES. The representations and warranties of a
Party set forth in this Agreement
24
<PAGE>
are intended for the sole and exclusive benefit of the other Party hereto,
and may not be relied upon by any Third Party.
6. INDEMNIFICATION.
6.1 BMS INDEMNITY. Subject to Section 6.4 hereof, BMS shall defend,
indemnify and hold DURA, its Affiliates, and its and their employees, agents,
officers, and directors (a "DURA PARTY") harmless from and against any and
all losses, liabilities, damages, fees (including, until such time as BMS has
notified DURA in writing that it will assume control of a given DURA Claim,
reasonable attorneys fees and costs of litigation pertaining to such DURA
Claim), and expenses paid or payable by a DURA Party to a Third Party and
that result from or arise in connection with a claim, suit or other
proceeding made or brought by such Third Party against a DURA Party (a "DURA
CLAIM") based on (i) the breach of any obligation, covenant, agreement,
representation or warranty of BMS contained in this Agreement, (ii) any sale
of a Product by BMS or any of its Affiliates outside the Territory, and any
use outside the Territory of any such Product sold by BMS or any of its
Affiliates outside the Territory (including without limitation Claims based
on or relating to product liability), whether sold by BMS or its Affiliates
prior to or following the Effective Date, or (iii) infringement of a Third
Party's patent rights by reason of the manufacture of a Product by or for BMS
and/or its purchase by DURA under this Agreement (other than infringement of
Third Party patent rights or trademarks by reason of the manufacture, use or
sale of plastic containers, vials, or other components for any
Azactam-Registered Trademark- Product used or provided by Baxter under the
Baxter Supply Agreement and the manufacture, use or sale of the Abbott fluid
containers or vials for any Maxipime-Registered Trademark- Product pursuant
to the rights granted under the Abbott License Agreement); PROVIDED, however,
that BMS shall not be obligated to indemnify a DURA Party under (i) or (ii)
above for any loss, liability, damages, fees or expenses incurred by such
DURA Party to the extent attributable to a breach by DURA of any obligation,
covenant, agreement, representation or warranty of DURA contained in this
Agreement or any Related Agreement, to any act or omission constituting
negligence, recklessness, gross negligence, or wilful misconduct on the part
of DURA or a DURA Party, and/or to any failure of DURA to identify a Product
defect or nonconformity with Specifications known by or that should
reasonably have been known to DURA prior to the use of such Product by a
Third Party.
6.2 DURA INDEMNITY. DURA shall defend, indemnify and hold BMS, its
Affiliates, and its and their employees, agents, officers, and directors (a
"BMS PARTY") harmless from and against any and all losses, liabilities,
damages, fees (including, until such time as DURA has notified BMS in writing
that it will assume control of a given Claim, attorneys fees and costs of
litigation pertaining to such Claim), and expenses paid or payable by a BMS
Party to a Third Party (including without limitation payments that BMS may be
required to make to its licensors of any rights pertaining to any Product
(including without limitation Fujisawa, Abbott, and Takeda) and suppliers of
any components of any Product (including without limitation, Baxter)) that
result from or arise in connection with a claim, suit or other proceeding
made or brought by a Third Party ("BMS CLAIM") based on (i) the breach by
DURA of any obligation, covenant, agreement, representation or warranty of
DURA contained in this Agreement; and/or (ii) infringement of a Third Party's
trademarks by reason of the use of "DURA" or any variant thereof on the
labeling for a Product or any materials used in promoting or advertising a
Product; and/or (iii) infringement of a Third Party's patent rights by reason
of the manufacture of a Product by or for DURA or its Affiliates under this
Agreement or any Related Agreement (other
25
<PAGE>
than infringement of Third Party patent rights or trademarks by reason of the
manufacture, use or sale of plastic containers, vials, or other components
for any Azactam-Registered Trademark- Product used or provided by Baxter
under the Baxter Supply Agreement and the manufacture, use or sale of the
Abbott fluid containers or vials for any Maxipime-Registered Trademark-
Product pursuant to the rights granted under the Abbott License Agreement);
PROVIDED, however, that DURA shall not be obligated to indemnify a BMS Party
for any loss, liability, damages, fees or expenses incurred by such BMS Party
to the extent attributable to a breach by BMS of any obligation, covenant,
agreement, representation or warranty of BMS contained in this Agreement or
any Related Agreement, or to any act or omission constituting negligence,
recklessness, gross negligence, or wilful misconduct on the part of BMS or a
BMS Party.
6.3 CONTROL OF PROCEEDINGS. To receive the benefits of the indemnity
under Sections 6.1 or 6.2, as applicable, an indemnified Party must (i) give
the indemnifying Party written notice of any Claim or potential Claim
promptly after the indemnified Party receives written notice of any such
Claim; (ii) allow the indemnifying Party to assume exclusive control of the
defense and settlement (including all decisions relating to litigation,
defense and appeal) of any such Claim (so long as it has confirmed its
indemnification obligation responsibility to such indemnified Party under
this Section 6.3 with respect to a given Claim); PROVIDED THAT the
controlling Party may not settle such Claim in any manner that would require
payment by the other Party, or would materially adversely affect the rights
granted to the other Party hereunder, or would materially conflict with the
terms of this Agreement, without first obtaining the other Party's prior
written consent; and (iii) so long as such cooperation does not vitiate any
legal privilege to which it is entitled, reasonably cooperate with the
indemnifying Party in its defense of the Claim (including, without
limitation, making documents and records available for review and copying and
making persons within its/his/her control available for pertinent testimony).
If the indemnifying Party defends the claim, an indemnified Party may
participate in, but not control, the defense of such Claim using attorneys of
its/his/her choice and at its/his/her sole cost and expense. An indemnifying
Party shall have no obligation or liability under this Article 6 as to any
Claim for which settlement or compromise of such claim or an offer of
settlement or compromise of such Claim is made by an indemnified Party
without the prior written consent of the indemnifying Party.
If the Party entitled to control the defense of such Claim notifies
the other in writing that it will not defend the other Party against such
Claim asserted against the other Party, or if the Party entitled to control
the defense of such Claim fails to defend or take other reasonable, timely
action, in response to such Claim asserted against the other Party, the other
Party shall have the right, but not the obligation, to defend or take other
reasonable action to defend its interests in such proceedings, and shall have
the right to litigate, settle or otherwise dispose of any such Claim;
provided, however, that the other Party shall not have the right to settle
such Claim in a manner that adversely affects the rights granted to the other
Party hereunder, or would materially conflict with this Agreement, or would
require a payment by the Party entitled to control the defense to such Third
Party, without the prior written consent of Party entitled to control the
defense of such Claim.
6.4 SPECIFIC DAMAGES FOR BREACH OF SUPPLY.
26
<PAGE>
6.4.1 Subject to Sections 2.12, 6.4.2, 6.4.3, 6.4.4, and 6.4.5
below, in the event that:
(A) BMS continuously fails to supply DURA with any conforming Product
(for a given SKU#) such that DURA is unable to supply its
customers with conforming Product (for such given SKU#) from the
inventories maintained by BMS and DURA under Section 2.4 hereof
or from inventories maintained by DURA's wholesalers for a period
of *, and
(B) such failure to supply is not attributable in whole or in part to
an event covered by Article 11 hereof and/or to a failure of
Baxter to supply frozen, premixed Product under the Baxter Supply
Agreement (in which event the time period set forth in Section
6.4.1(A)(i) shall be extended by time period of delay or
non-performance reasonably occasioned by such event or failure),
then, if requested in writing by DURA ("Notice") within * after
the foregoing conditions have been met, * subject
to the following:
(C) Such Notice *
(D) Such Notice shall not apply, and may not be exercised or given,
with respect to any breaches hereunder or failure of supply (1)
* or (2) * and
(E) Once a Notice is given, DURA may not invoke the provisions of
this Section 6.4 again with respect to such SKU# until *
(F) * shall be offset or reduced by the amount of any damages paid
or payable by BMS to DURA on account of any such breach and any
payments that have been or will be made by BMS to DURA under
Section 6.1 on account of any such breach prior to the date of
payment.
27
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
6.4.2 Where a Notice has been served by DURA pursuant to
Section 6.4.1, DURA shall not be entitled to recover any other damages of any
nature from BMS with respect to any other breach of supply under this
Agreement to which DURA may be entitled to recover at law or in equity or to
receive or recover any amounts payable by BMS under its indemnification
obligation set forth in Section 6.1 hereof, where such damages or indemnity
payment arise out of or in connection with the breaches of supply for which
such Notice was served under Section 6.4.1, unless and until DURA is able to
clearly demonstrate to BMS' reasonable satisfaction that its damages and/or
the amounts required to be paid by BMS under Section 6.1 with respect to such
breaches of supply exceed the amount of reduction in the Purchase Price that
will be absorbed by BMS under Section 6.4.1.
6.4.3 If no written Notice is provided by DURA * set forth in
Section 6.4.1, any reduction in the Purchase Price to which DURA may be
entitled under this Section 6.4 shall lapse; provided, that the foregoing
shall not restrict or limit DURA's ability to recover any damages to which it
may be entitled at law or in equity with respect to such breach(es) of supply.
6.4.4 In the event that DURA failed to maintain the three-month
inventory required of it for a Product SKU# under Section 2.4 that is the
subject to a Notice under Section 6.1.1 or if such shortfall is attributable
to materially inaccurate forecasts provided by DURA, then the period of time
referenced in Section 6.4.1(A) shall be increased by the period of time that
DURA customers were unable to obtain Product by reason of such inventory
shortfall maintained by DURA or to the extent its forecast was materially
inaccurate as compared to the amounts firm-ordered.
6.5 INSURANCE. DURA shall maintain at all times during the period that
any Product is being distributed or sold by or through DURA hereunder, and
for fifteen (15) years thereafter, comprehensive general liability insurance,
with endorsements for contractual liability and product liability with
coverage limits of not less than Twenty Million Dollars ($20,000,000). The
minimum level of insurance set forth herein shall not be construed to create
a limit on DURA's liability with respect to its indemnification obligations
hereunder. Prior to the Effective Date (and each anniversary thereof
thereafter), DURA shall furnish to BMS a certificate of insurance evidencing
such coverage as of the Effective Date (and each anniversary thereof) and
upon request by BMS at any time hereafter. Each such certificate of
insurance shall include a provision whereby sixty (60) days' written notice
must be received by BMS prior to coverage modification or cancellation by
either DURA or the insurer.
BMS will maintain at all times during the period that any Product
is being supplied to DURA by BMS and is being manufactured by or for BMS, and
for fifteen (15) year thereafter, a commercially reasonable program of
self-insurance and insurance with respect to its obligations under this
Agreement and any Related Agreement.
7. INFRINGEMENT OF BMS PATENTS AND TRADEMARKS.
7.1 INFRINGEMENT BY THIRD PARTIES.
28
*Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has been
filed with the Secretary of the Commission without the Mark pursuant to the
Company's application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
<PAGE>
7.1.1 If either Party becomes aware that a Third Party is
infringing any rights in any patent rights owned or controlled by BMS or any
of its Affiliates covering the composition or use of a Product or any
Trademark used in connection with a Product, such Party shall give written
notice to the other Party describing in detail the nature of such
infringement. Subject to Section 7.1.2, BMS and its Affiliates shall have
the sole right, but not the obligation, to enforce any such BMS patent rights
and Trademarks against such Third Party infringer and to settle or compromise
any such possible infringement by taking such action as BMS or its Affiliates
may determine in their sole and absolute discretion; PROVIDED, however, that
BMS may not settle any such potential infringement in a manner that
materially adversely affects the rights granted to DURA hereunder or the
title, rights and interests in any patent rights, Trademarks or other
intellectual property rights owned or controlled by BMS or any of its
Affiliates relating to the composition or use of any such Products, or that
would materially conflict with this Agreement, or that would require a
payment by DURA to such Third Party, or that would require the grant of any
right or license by BMS to any Third Party in conflict with the rights
granted to DURA hereunder, without the prior written consent of DURA. So
long as such cooperation does not vitiate any legal privilege to which it is
entitled, DURA agrees to provide BMS all reasonable assistance (including,
without limitation, making documents and records available for review and
copying and making persons within its control available for pertinent
testimony), at BMS' expense, in such enforcement.
7.1.2 In the event that BMS fails to institute an infringement
suit or take other reasonable action in response to such infringement
referred to in 7.1.1 within one hundred eighty (180) days after notice of
such infringement has been brought to its attention, DURA shall have the
right, but not the obligation, to institute such suit or take other
appropriate action in its own name to enforce such BMS patent rights (but not
any BMS patents pertaining to the manufacture of a Product) against such
Third Party and to settle or compromise any such possible infringement by
taking such action as DURA or its Affiliates may determine in their sole and
absolute discretion; PROVIDED, however, that DURA may not settle any such
potential infringement in a manner that would materially adversely affect any
title, rights and interests in any patents, Trademarks or other intellectual
property rights owned or controlled by BMS or any of its Affiliates relating
to the composition or use of any Product, or that would materially conflict
with any terms of this Agreement, or that would require a payment by BMS to
such Third Party, or that would require the grant of any right or license by
BMS to any Third Party, without the prior written consent of BMS. So long
as such cooperation does not vitiate any legal privilege to which it is
entitled, BMS agrees to provide DURA all reasonable cooperation and
assistance (including, without limitation, making documents and records
available for review and copying and making persons within its control
available for pertinent testimony), at DURA's expense, in such enforcement.
7.1.3 Regardless of which Party brings an action to enforce a
BMS Patent or a Trademark that is being infringed by a Third Party as
provided in Section 7.1.1 or 7.1.2 above, the Party not bringing the action
shall have the right to participate in such action at its own expense with
its own counsel. Any damages or other recovery, whether by settlement or
otherwise, from an action hereunder to enforce such BMS Patents or Trademarks
shall be paid to the Party controlling the conduct of the litigation.
7.1.4 Upon assignment by BMS of a Trademark to DURA in accordance
with Section 2.2.2 of the
29
<PAGE>
Distribution Agreement, the Parties' rights and responsibilities under
Section 7.1.1 and 7.1.2 shall be reversed, MUTATIS MUTANDIS, with respect to
infringement of such Trademark by a Third Party following such assignment.
7.1.5 In the event that a Third Party files an ANDA for a
Product certifying that it does not infringe any patents owned or controlled
by BMS relating to such Product, the Party receiving a copy of such ANDA
shall promptly forward a copy of same to the other Party. The Parties shall
meet and confer within thirty (30) days following the filing of such ANDA for
the purpose of determining what action should be taken with respect to such
certification should both Parties conclude that such Third Party would
violate Patent Rights owned or controlled by BMS. As the NDA holder, BMS
shall be responsible for filing and coordinating any mutually agreed
responses to FDA. DURA shall reimburse BMS for any reasonable costs incurred
by BMS in connection with such filings, and will reimburse BMS for any
reasonable out-of-pocket costs incurred by BMS in any legal proceedings
undertaken by BMS based on the Parties mutually agreed upon course of action.
8. PRODUCT RECALL.
8.1 PRODUCT RECALL. In the event that DURA obtains information that
a Product or any portion thereof should be alleged or proven not to meet the
Specifications, the labeling, or the Product Registration for such Product
in the Territory, DURA shall notify BMS immediately and both Parties shall
cooperate fully regarding the investigation and disposition of any such
matter. BMS and Dura shall each maintain such traceability records as are
sufficient and as may be necessary to permit a recall or field correction of
any Products. In the event (a) any applicable regulatory authority of a state
or country in the Territory should issue a request, directive or order that
a Product be recalled, or (b) a court of competent jurisdiction orders such a
recall, or (c) BMS determines that any Product already in interstate commerce
in the Territory presents a risk of injury or gross deception or is otherwise
defective and that recall of such Product is appropriate (a "RECALL"), each
Party shall give telephonic notice (to be confirmed in writing) to the other
within twenty-four (24) hours of the receipt of any event. BMS shall have
sole responsibility for determining all corrective action to be taken and for
carrying out the Recall. DURA will provide full cooperation and assistance to
BMS in connection therewith as may be requested by BMS. BMS shall be
responsible for all expenses of any such Recall (including any out-of-pocket
expenses incurred by DURA in connection with such cooperation), except (i)
to the extent such Recall is attributable to any negligence on the part of
DURA or any breach by DURA of its obligations under this Agreement or any
other agreement then in force and effect between DURA and BMS, in which event
DURA will reimburse BMS for its costs and expenses incurred that are so
attributable to such actions by DURA or (ii) where the Product was
manufactured by or for DURA (other than by BMS), in which event DURA will
reimburse BMS for its costs and expenses incurred in effecting such Recall.
9. CONFIDENTIALITY.
9.1 CONFIDENTIALITY.
30
<PAGE>
9.1.1 Each Party acknowledges that it may receive confidential
or proprietary information of the other Party in the performance of this
Agreement. Each Party shall use commercially reasonable efforts to safeguard
and to hold such information received by it from the other Party in
confidence, and shall limit disclosure of the furnishing Party's information
to those employees and consultants of the receiving Party and its Affiliates
who are bound by a written obligation of confidentiality to the receiving
Party that is consistent with the terms of this Article 9. Each Party shall
not, directly or indirectly, disclose, publish or use for the benefit of any
Third Party or itself, except in carrying out its duties hereunder, any
confidential or proprietary information of the other Party, without first
having obtained the furnishing Party's written consent to such disclosure or
use. "CONFIDENTIAL INFORMATION" shall include, INTER ALIA, know-how,
scientific information, the terms of this Agreement, clinical data, efficacy
and safety data, adverse event information, formulas, methods and processes,
specifications, pricing information (including discounts, rebates and other
price adjustments) and other terms and conditions of sales, customer
information, business plans, and all other intellectual property. This
restriction shall not apply to any information within the following
categories:
(i) information that is known to the receiving Party or its
Affiliates prior to the time of disclosure to it, to the extent
evidenced by written records or other competent proof;
(ii) information that is independently developed by employees, agents,
or independent contractors of the receiving Party or its
Affiliates without reference to or reliance upon the information
furnished by the disclosing Party, as evidenced by written
records or other competent proof;
(iii) information disclosed to the receiving Party or its
Affiliates by a Third Party that has a right to make such
disclosure; or
(iv) any other information that becomes part of the public domain
through no fault or negligence of the receiving Party.
The receiving Party shall also be entitled to disclose the other Party's
Confidential Information (1) that is required to be disclosed in compliance
with applicable laws or regulations (including, without limitation, to comply
with SEC, NASDAQ or stock exchange disclosure requirements) or by order of
any governmental body or a court of competent jurisdiction, (2) as may be
necessary or appropriate in connection with the enforcement of this Agreement
or any Related Agreement, (3) as required in furtherance of a Party's
obligations under this Agreement or any Related Agreement; or (4) as may be
necessary for the conduct of clinical studies; PROVIDED, that the Party
required to disclose such information shall use commercially reasonable
efforts to obtain confidential treatment of such information by the agency or
court or other disclosee, and that, in the case of disclosures under (1)
shall provide the other Party with a copy of the proposed disclosure in
sufficient time to allow reasonable opportunity to comment thereon.
9.1.2 The obligations set forth in this Section 9.1 shall
survive the termination or expiration of this Agreement for five (5) years.
Nothing in this Article 9 shall be construed to create or imply any right or
license under any patent rights, trademarks, copyrights or other intellectual
property rights owned or controlled by a Party or its Affiliates except as
may be expressly set forth in other Articles of this Agreement.
31
<PAGE>
9.1.3 The confidentiality obligations set forth in this Article
9 shall supersede the Confidential Disclosure Agreement dated as of July 22,
1998 "Confidentiality Agreement") between the Parties, shall govern any and
all information disclosed by either Party to the other pursuant thereto, and
shall be retroactively effective to the date of such Confidential Disclosure
Agreement.
9.2 USE OF INFORMATION. Each Party shall use, and cause each of its
Affiliates to use, any Confidential Information obtained by it from the other
Party or their respective Affiliates, pursuant to this Agreement or
otherwise, solely in connection with the transactions contemplated hereby.
9.3 RELIEF. Each Party shall be entitled, in addition to any other
right or remedy it may have, at law or in equity, to an injunction, without
the posting of any bond or other security, enjoining or restraining any other
Party from any violation or threatened violation of this Article 9.
10. TERMINATION.
10.1 TERM. This Agreement shall become effective as of the Effective
Date and, unless sooner terminated as provided in this Article 10, shall
expire:
10.1.1 As to Azactam-Registered Trademark- and all rights
granted under the Distribution Agreement with respect to said Product, on
October 1, 2005 (the "AZACTAM-Registered Trademark- TERM").
10.1.2 As to Maxipime-Registered Trademark- and all rights
granted under the Distribution Agreement with respect to said Product, on
February 1, 2008 (the "MAXIPIME-Registered Trademark- TERM").
10.2 BREACH.
10.2.1 Failure by either Party to comply with any of the
material obligations contained in this Agreement shall entitle the other
Party, if it is not in material default hereunder, to give to the Party in
default notice specifying the nature of the default and requiring it to cure
such default. If such default is not cured within 60 days after the receipt
of such notice (or, if such default cannot be cured within such 60-day
period, if the Party in default does not commence and diligently continue
substantive actions to cure such default), the notifying Party shall be
entitled, without prejudice to any of its other rights conferred on it by
this Agreement and in addition to any other remedies available to it by law
or in equity (except as provided in Section 6.4), to terminate this Agreement
by giving written notice to take effect immediately upon delivery of such
notice.
10.2.2 Except as provided in Section 6.4, termination by a Party
of the Distribution Agreement, in whole or as to a given Product, for failure
on the part of the other Party to comply with any of the material obligations
contained in said Distribution Agreement shall entitle the terminating Party
thereunder, without prejudice to any of its
32
<PAGE>
other rights conferred on it by this Agreement and in addition to any other
remedies available to it by law or in equity, to terminate this Agreement
(provided that if such Distribution Agreement is only terminated as to a
specific Product, then termination hereunder shall be as to such Product
only) by giving written notice to take effect immediately upon delivery of
such notice.
10.3 INSOLVENCY OR BANKRUPTCY. In the event that a Party shall have
become insolvent or bankrupt, or shall have made an assignment for the
benefit of its creditors, or there shall have been appointed a trustee or
receiver of such Party for all or a substantial part of its property, or any
case or proceeding shall have been commenced or other action taken by or
against such Party (as to which, if involuntary commenced against such Party,
such Party is not able to obtain dismissal within 90 days after commencement
thereof) in bankruptcy or seeking reorganization, liquidation, dissolution,
winding-up, arrangement, composition or readjustment of its debts or any
other relief under any bankruptcy, insolvency, reorganization or other
similar act or law of any jurisdiction now or hereafter in effect, then such
Party shall not be relieved in any respect of its obligations hereunder, and,
in addition to any other remedies available to it by law or in equity, the
other Party may terminate this Agreement, in whole or in part as the
terminating Party may determine, by written notice to such Party.
10.4 OTHER TERMINATION SITUATIONS. BMS may (without prejudice to any of
its other rights conferred on it by this Agreement or by law) terminate this
Agreement effective immediately by giving written notice to such effect to
DURA in the event that:
10.4.1 DURA engages in illegal activities or illegal conduct
which materially and adversely damages the market or potential market for a
Product (i) in the Territory and/or (ii) in other countries of the world when
taken as a whole; or
10.4.2. BMS withdraws a given Product from the U.S. market for
safety reasons in connection with a withdrawal of the Product from its
markets worldwide generally for such reasons (in which event the termination
shall be limited to such Product only).
10.5 EFFECT OF TERMINATION.
10.5.1 Upon termination of this Agreement by BMS pursuant to
Section 10.2 (as to the entire Agreement), 10.3, or 10.4.1, DURA shall
promptly: (i) return to BMS all relevant records, materials or confidential
information relating to the Products in its (or any Affiliates or
contractors') possession or control; (ii) except as provided in Section
10.5.3, discontinue all marketing, sale, and distribution of the Products,
and return where BMS elects to purchase same pursuant to Section 10.5.3 or is
required to purchase same pursuant to Section 10.5.4, return in accordance
with Section 10.5.3 or 10.5.4, as the case may be, any inventory of Products
then on hand at DURA facilities or that of its designee (with BMS to
reimburse DURA for transportation charges of same to BMS); and (iii) except
as provided in Section 10.5.3, discontinue use of the Trademarks, destroy all
advertising or other printed materials bearing the
33
<PAGE>
Trademarks, cooperate with BMS to execute such documents and take such
actions as may be necessary to cancel any registration of DURA as a Permitted
User or Registered User of the Trademarks, and DURA's right to use the
Trademarks for the Products in the Territory shall terminate.
10.5.2 Upon expiration of this Agreement (as to a given Product)
or upon the termination of this Agreement by BMS pursuant to Section 10.2.2
(as to a given Product) or 10.4.2 (as to a given Product), DURA shall
promptly: (i) return to BMS all relevant records, materials or confidential
information relating to the affected Product in its (or any Affiliates or
contractors') possession or control; (ii) except as provided in Section
10.5.3, discontinue all marketing, sale, and distribution of the affected
Product, and return, where BMS elects to purchase same pursuant to Section
10.5.3 or is required to purchase same pursuant to Section 10.5.4, return in
accordance with Section 10.5.3 or 10.5.4, as the case may be, any inventory
of the affected Product then on hand at DURA facilities or that of its
designee (with BMS to reimburse DURA for transportation charges of same to
BMS, except that, if terminated by BMS pursuant to Section 10.2, then such
transportation charges shall be at DURA's expense); and (iii) except as
provided in Section 10.5.3, discontinue use of the Trademarks, destroy all
advertising or other printed materials bearing the Trademarks, cooperate with
BMS to execute such documents and take such actions as may be necessary to
cancel any registration of DURA as a Permitted User or Registered User of the
Trademarks with respect to the affected Product, and DURA's right to use the
Trademarks for the affected Product in the Territory shall terminate.
10.5.3 Upon expiration of this Agreement or upon the
termination of this Agreement by BMS pursuant to any of Sections 10.1, 10.3,
10.4.1 or 10.4.2, DURA shall be entitled, for three (3) months following such
termination, to sell in the Territory any Product then on hand and to use the
Trademarks for such limited purpose, subject to the following. BMS may elect
in its sole and absolute discretion, upon written notice given to DURA at any
time prior to the end of said 3-month period, to purchase from DURA, and DURA
shall (if such written notice is provided by BMS) sell to BMS, such amount
(including up to all) of the Product then in DURA's inventory at the end of
such 3-month period at the price paid for each Product by DURA as BMS may
elect to purchase; PROVIDED, however, that, where such written notice was
provided by BMS, BMS shall not be obligated to repurchase any Products which
are not in good condition, which are labeled as requiring storage under
refrigerated or freezing conditions, which are not in full, unopened,
factory-sealed cases, whose labeling or packaging have been altered or
damaged, or which have at the time of return a then remaining shelf life of
less than twelve (12) months for any Product.
10.5.4 Upon the termination of this Agreement by DURA pursuant
to Section 10.2 or 10.3, DURA shall be entitled, for three (3) months
following such termination, to sell in the Territory any Product then on hand
to which such termination applies and to use the Trademarks for such limited
purpose, subject to the following. DURA may elect upon written notice to BMS
given within said 3-month period, to require that BMS purchase from DURA, and
DURA shall sell to BMS, all Products then in DURA's inventory at the price
paid for such Product by DURA; PROVIDED, however, that where DURA provides
such written notice, BMS shall not be obligated to repurchase any Products
which are not in good condition, which are labeled as requiring storage under
refrigerated or freezing conditions, which are not in full, unopened,
factory-sealed cases, whose labeling or packaging have been altered or
damaged, or which have at the
34
<PAGE>
time of return a then remaining shelf life of less than twelve (12) months
for any Product.
10.5.5 Neither BMS or DURA shall incur any liability to the
other by reason of the expiration or termination of this Agreement as
provided herein, nor for its non-renewal, whether for loss of goodwill,
anticipated profits or otherwise, and BMS and DURA shall accept all rights
granted and all obligations assumed hereunder, including those in connection
with such expiration or termination in full satisfaction of any claim
resulting from such expiration or termination.
10.5.6 Any acceptance by BMS of any order from DURA or the sale
of any Products by BMS to DURA after the expiration or termination of this
Agreement shall not be construed as a renewal or extension of this Agreement
or as a waiver of termination thereof.
10.5.7 Exercise by a Party of its rights as to return, sale and
resale of Products under this Section 10.5 shall preclude the exercise of
such rights a second time under the Distribution Agreement.
10.5.8 Upon termination of this Agreement by DURA in accordance
with the terms hereof, and provided that DURA does not thereafter elect to
terminate its rights under the Distribution Agreement, BMS shall, if
requested in writing by DURA (and so long as DURA certifies to BMS that DURA
intends to manufacture, or have a Third Party manufacture for DURA, the
Product for marketing in the Territory), promptly provide Manufacturing
Know-How to DURA and grant DURA the rights and licenses set forth in Section
2.13 hereof, subject to the terms and conditions set forth in said Section
2.13, as though DURA were intending to manufacture the Product for marketing
the Territory following the Applicable Term.
10.6 ACCRUED RIGHTS, SURVIVING OBLIGATIONS.
10.6.1 Termination, relinquishment or expiration of this
Agreement for any reason shall be without prejudice to any rights which shall
have accrued to the benefit of either Party prior to such termination,
relinquishment or expiration. Such termination, relinquishment or expiration
shall not relieve either Party from obligations which are expressly indicated
to survive termination or expiration of this Agreement.
10.6.2 Termination of this Agreement, in whole or in part, shall
not terminate DURA's obligation to pay the Purchase Price for Product which
has been sold to it or firm ordered by it hereunder prior to the effective
date of termination. All of the Parties' rights and obligations under
Articles 1, 4 , 6, 7, 8, 9, 11, 12, 13 (where applicable), and 14 and
Sections 2.5, 2.6, 2.8, 2.11, 2.13, 5.1, 5.2, 5.3, 5.7, 5.8, 10.5 (as
applicable), and 10.6 shall survive termination.
11. FORCE MAJEURE.
Any delays in performance by any Party under this Agreement shall not be
considered a breach of this
35
<PAGE>
Agreement if and to the extent caused by occurrences beyond the reasonable
control of the Party affected, including but not limited to acts of God,
embargoes, governmental restrictions, materials shortages or failure of any
supplier, where such shortage or failure is attributable to a supplier's
breach of its agreement with BMS or with a Third Party subcontractor or to an
event of force majeure suffered by such supplier), fire, flood, earthquake,
hurricanes, storms, tornados, explosion, riots, wars, civil disorder, failure
of public utilities or common carriers, failure of Baxter to supply Product,
labor disturbances, rebellion or sabotage. The Party suffering such
occurrence shall immediately notify the other Party as soon as practicable of
such inability and of the period for which such inability is expected to
continue, and any time for performance hereunder shall be extended by the
actual time of delay caused by the occurrence; provided, that the Party
suffering such occurrence uses commercially reasonable efforts to mitigate.
The Party giving such notice shall thereupon be excused from such of its
obligations under this Agreement as it is thereby disabled from performing,
and shall have no liability for such non-performance, for so long as it is so
disabled and the 30 days thereafter. During any period when BMS is unable to
supply the total demands of all of its customers for firm orders of a Product
SKU# for any reason covered by this Article 11, BMS may allocate any
available Product among the firm orders placed by DURA and BMS' Third Party
customers and licensees, excluding BMS' own divisions and departments,
proportionately to the amounts so firm-ordered by DURA and such Third Parties
and licensees. Notwithstanding the foregoing, nothing in this Article 11
shall excuse or suspend the obligation to make any payment due under this
Agreement or in any Related Agreement in the manner and at the time provided.
12. NOTICES.
Unless otherwise explicitly set forth herein, any notice required or
permitted to be given hereunder shall be in writing and shall be delivered
personally by hand, or sent by reputable overnight courier, signature
required, to the addresses of each Party set forth below or to such other
address or addresses as shall be designated in writing in the same matter:
(a) If to BMS:
Bristol-Myers Squibb U.S. Pharmaceutical Group
777 Scudders Mill Road
Plainsboro, NJ 08536
Attention: President, U.S. Pharmaceuticals Group
with a copy to its Vice President and Senior Counsel, U.S. Pharmaceuticals Group
at the same address
(b) If to DURA:
Dura Pharmaceuticals, Inc.
7475 Lusk Boulevard
San Diego, CA 92121
36
<PAGE>
Attention: President
with a copy to its General Counsel at the same address
All notices shall be deemed given when received by the addressee.
13. NON-SOLICITATION.
13.1 NON-SOLICITATION. For a period of three (3) years following the
Effective Date, neither Party or its Affiliates shall employ, contract with,
or solicit, directly or indirectly, any employee of the other Party or any of
its Affiliates, wherever located, who was or is at any time a member of the
research and development group, franchise management group, manufacturing
group, financial group, or sales force or marketing group and whose duties
encompassed any duties pertaining to any Product, without the prior written
consent of the other Party; provided, that the foregoing restriction on
solicitation shall not apply to advertisements run in trade journals or other
publications or on the Internet that are targeted to qualified individuals
generally for the position in question.
14. MISCELLANEOUS PROVISIONS.
14.1 ASSIGNMENT. Neither Party shall assign or otherwise transfer this
Agreement or any interest herein or right hereunder without the prior written
consent of the other Party, and any such purported assignment, transfer or
attempt to assign or transfer any interest herein or right hereunder shall be
void and of no effect; except that each Party (i) may assign its rights and
obligations hereunder to an Affiliate without the prior consent of the other
Party (although, in such event, the assigning Party shall remain primarily
responsible for all of its obligations and agreements set forth herein,
notwithstanding such assignment) and (ii) may assign its rights and
obligations to a successor (whether by merger, consolidation, reorganization
or other similar event) or purchaser of all or substantially all of its
business assets relating to all Products, provided, that such successor or
purchaser has agreed in writing to assume all of such Party's rights and
obligations hereunder and a copy of such assumption is provided to the other
Party hereunder.
14.2 NON-WAIVER. Any failure on the part of a Party to enforce at any
time or for any period of time any of the provisions of this Agreement shall
not be deemed or construed to be a waiver of such provisions or of any right
of such Party thereafter to enforce each and every such provision on any
succeeding occasion or breach thereof.
14.3 DISPUTE RESOLUTION.
14.3.1 The Parties recognize that disputes as to certain matters
may from time to time arise during the term of this Agreement which relate to
either Party's rights and/or obligations hereunder. It is the objective of
the Parties to establish procedures to facilitate the resolution of disputes
arising under or in connection with this Agreement, including without
limitation all financial disputes and any disputes as to the validity,
construction, performance, default,
37
<PAGE>
or breach hereof, in an expedient manner by mutual cooperation and without
resort to litigation. To accomplish this objective, but subject to Section
14.3.3 below, the Parties agree to follow the procedures set forth in this
Section 14.3 if and when such disputes arise under or in connection with this
Agreement between the Parties (except as provided in Section 14.3.4 below).
If the Parties cannot resolve the dispute within 30 days of formal request by
either Party to the other, any Party may, by written notice to the other,
have such dispute referred to the President of DURA and the President of the
BMS U.S. Pharmaceutical Group (or their designees) for attempted resolution
by good faith negotiations. If such personnel are unable to resolve such
dispute within thirty (30) days after such notice is received, then such
dispute shall be finally resolved, but only if written notice is thereafter
served by a Party on the other Party specifically requesting binding
arbitration pursuant to Section 14.3.2, by binding arbitration (except as set
forth in Section 14.3.4 below) under Section 14.3.2 hereof.
14.3.2 Where a Party has served a written notice upon the other
requesting binding arbitration of a dispute pursuant to this Section 14.3.2,
any such arbitration shall be held in New York, New York (if DURA was the
Party providing such written notice) or in San Diego, California (if BMS was
the Party providing such written notice), according to the Commercial
Arbitration Rules (the "Rules") of the American Arbitration Association. Any
arbitration herewith shall be conducted in the English language. The
arbitration shall be conducted by one arbitrator who is knowledgeable in the
subject matter which is at issue in the dispute and who is selected by mutual
agreement of the Parties or, failing such agreement, shall be selected
according to the AAA rules. The Parties shall have such discovery rights as
the arbitrator may allow, but in no event broader than that discovery
permitted under the Federal Rules of Civil Procedure. In conducting the
arbitration, the arbitrator shall apply the New York Rules of Evidence, and
shall be able to decree any and all relief of an equitable nature, including
but not limited to such relief as a temporary restraining order, a
preliminary injunction, a permanent injunction, or replevin of property, as
well as specific performance. The arbitrator shall also be able to award
direct, indirect and, where permitted by this Agreement, consequential
damages, but shall not award any other form of damage (e.g., punitive or
exemplary damages). The reasonable fees and expenses, of the arbitrators,
along with the reasonable legal fees and expenses of the prevailing Party
(including all expert witness fees and expenses), the fees and expenses of a
court reporter, and any expenses for a hearing room, shall be paid as
follows: If the arbitrators rule in favor of one Party on all disputed
issues in the arbitration, the losing Party shall pay 100% of such fees and
expenses; if the arbitrators rule in favor of one Party on some issues and
the other Party on other issues, the arbitrators shall issue with the rulings
a written determination as to how such fees and expenses shall be allocated
between the Parties. The arbitrators shall allocate fees and expenses in a
way that bears a reasonable relationship to the outcome of the arbitration,
with the Party prevailing on more issues, or on issues of greater value or
gravity, recovering a relatively larger share of its legal fees and expenses.
The decision of the arbitrators shall be final and may be entered, sued on
or enforced by the Party in whose favor it runs in any court of competent
jurisdiction at the option of such Party. Whether a claim, dispute or other
matter in question would be barred by the applicable statute of limitations,
which statute of limitations also shall apply to any claim or disputes
subject to arbitration under this Section, shall be determined by binding
arbitration pursuant to this Section 14.3.
14.3.3 Notwithstanding anything to the contrary in this Section
14.3, either Party may seek immediate
38
<PAGE>
injunctive or other interim relief without resort to arbitration from any
court of competent jurisdiction as necessary to enforce and prevent
infringement of the patent rights, copyright rights, trademarks, trade
secrets, or other intellectual property rights owned or controlled by a Party
or its Affiliates or to prevent breach of Article 9 hereof.
14.3.4 Notwithstanding anything to the contrary in this Section
14.3, DURA shall be entitled to seek damages without resort to arbitration
from any court of competent jurisdiction with respect to any breach by BMS of
its supply obligations hereunder, and if so elected by DURA, BMS shall be
entitled, but not obligated, to pursue such damages as it may have against
DURA in any such proceeding without resort to arbitration.
14.4 ENTIRETY OF AGREEMENT. This Agreement, the Exhibits attached
hereto, and the Related Agreements where herein referenced, contains the
entire understanding of the Parties with respect to the subject matter hereof
and thereof and supersedes all previous and contemporaneous verbal and
written agreements, representations and warranties with respect to such
subject matter. This Agreement (or any provision or term hereof) may be
released, waived, changed or supplemented only by a written agreement signed
by an officer or other authorized representative of the Party against whom
enforcement of any release, waiver, change or supplement is sought. This
Agreement shall not be strictly construed against either Party hereto.
14.5 PUBLIC ANNOUNCEMENTS. The form and content of any public
announcement to be made by one Party regarding this Agreement, or the subject
matter contained herein, shall be subject to the prior written consent of the
other Party (which consent may not be unreasonably withheld), except as may
be required by applicable law (including, without limitation, disclosure
requirements of the SEC, NASDAQ, or any other stock exchange) in which event
the other Party shall use commercially reasonable efforts to give the other
Party reasonable advance notice and reasonable opportunity to review any such
disclosure.
14.6 GOVERNING LAW. This Agreement shall be governed by and construed
in accordance with the internal laws of the State of New York, without regard
to its conflicts of law principles.
14.7 RELATIONSHIP OF THE PARTIES. In making and performing this
Agreement, the Parties are acting, and intend to be treated, as independent
entities and nothing contained in this Agreement shall be construed or
implied to create an agency, partnership, joint venture, or employer and
employee relationship between BMS and DURA. Except as otherwise provided
herein, neither Party may make any representation, warranty or commitment,
whether express or implied, on behalf of or incur any charges or expenses for
or in the name of the other Party. No Party shall be liable for the act of
any other Party unless such act is expressly authorized in writing by both
Parties hereto.
14.8 COUNTERPARTS. This Agreement shall become binding when any one or
more counterparts hereof, individually or taken together, shall bear the
signatures of each of the Parties hereto. This Agreement may be executed in
any number of counterparts, each of which shall be deemed an original as
against the Party whose signature appears thereon, but all of which taken
together shall constitute but one and the same instrument.
39
<PAGE>
14.9 SEVERABILITY. If any part of this Agreement is declared invalid by
any legally governing authority having jurisdiction over either Party, then
such declaration shall not affect the remainder of the Agreement and the
Parties shall revise the invalidated part in a manner that will render such
provision valid without impairing the Parties' original intent.
14.10 CUMULATIVE RIGHTS. Except as herein expressly provided, the
rights, powers and remedies hereunder shall be in addition to, and not in
limitation of, all rights, powers and remedies provided at law or in equity,
or under any other agreement between the Parties, and all of such rights,
powers and remedies shall be cumulative, and may be exercised successively or
cumulatively.
14.11 NO OTHER RIGHTS. No rights or licenses in or to either
Party's patent rights, know-how, copyrights or trademarks are granted by a
Party to the other, or shall be created or implied hereunder, except those
licenses and rights that are expressly granted in this Agreement.
14.12 EXPENSES. BMS and DURA shall each bear their own direct and
indirect expenses incurred in connection with the negotiation and preparation
of this Agreement and the Related Agreements and, except as set forth in this
Agreement or any Related Agreements, the performance of the obligations
contemplated hereby and thereby.
[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK - THE SIGNATURE PAGE FOLLOWS]
40
<PAGE>
IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed in multiple counterparts by its duly authorized representative.
DURA PHARMACEUTICALS, INC. BRISTOL-MYERS SQUIBB COMPANY
By: /s/ Cam L. Garner By: /s/ Donald J. Hayden, Jr.
----------------------------- ----------------------------------------
Donald J. Hayden, Jr.
Title: President & Chief Executive Title: President-Worldwide Medicines Group
Officer -----------------------------------
---------------------------
Date: 12/21/98 Date:
----------------------------- ------------------------------------
[SIGNATURE PAGE TO THE SUPPLY AGREEMENT]
41
<PAGE>
EXHIBITS
Exhibit 1.1A - List of Products and Trademarks
Exhibit 1.1B - Specifications for the Products
Exhibit 2.3.1 - Initial Order of Product for First Six Months After
Effective Date
Exhibit 2.12 - Maximum Annual Capacity
Exhibit 3.1 - Purchase Price for Product Ordered 1/1/99-12/31/99; Minimum
Batch Sizes
Exhibit 3.2 - Purchase Price for Finished Product Inventory
Exhibit 5.4 - Exceptions to Mutual Representations and Warranties
Exhibit 5.5 - Exceptions to Representations and Warranties of BMS
Exhibit 5.6 - Exceptions to Representations and Warranties of DURA
42
<PAGE>
EXHIBIT 99.1
CONTACT: CAM L. GARNER
CHAIRMAN AND CHIEF EXECUTIVE OFFICER
DURA PHARMACEUTICALS, INC.
(619) 457-2553
DURA PHARMACEUTICALS ANNOUNCES ACQUISITION OF EXCLUSIVE DISTRIBUTION RIGHTS FOR
TWO PATENTED ANTIBIOTIC PRODUCTS, MAXIPIME-Registered Trademark- AND
AZACTAM-Registered Trademark-, FROM BRISTOL-MYERS SQUIBB
SAN DIEGO, CA -- December 22, 1998 -- Dura Pharmaceuticals, Inc.
(NASDAQ NNM: DURA) (Dura) today announced that it has signed an agreement for
exclusive U.S. distribution rights for the patented hospital antibiotic
products Maxipime-Registered Trademark- IV/IM (cefepime HCl) and
Azactam-Registered Trademark- IV/IM (aztreonam) from Bristol-Myers Squibb
Company (NYSE:BMY) for an initial payment of $60 million, a payment of $70
million due in 2003 and additional contingent payment amounts. In addition,
the companies have entered into a transitional co-promotion agreement in
which Bristol-Myers Squibb will dedicate a hospital sales force to promote
the products in 1999. The transaction will be effective January 1, 1999.
Bristol-Myers Squibb will be responsible for the manufacture and supply of
the products for Dura. Dura expects that Maxipime-Registered Trademark- and
Azactam-Registered Trademark- could generate combined sales of $60 - $65
million in 1999. The market for intravenous (IV) antibiotics in the U.S.
totaled approximately $1.4 billion in 1997.
"With the potential for peak annual combined revenues to be more than
twice our first year expectations, Maxipime-Registered Trademark- and
Azactam-Registered Trademark- are strategically and financially significant
for Dura," said Cam L. Garner, Dura's Chairman and CEO. "They support our
respiratory-focused business strategy while funding our expansion into the
hospital market, which offers substantial opportunity for additional product
acquisitions and represents an important distribution channel for our
Spiros-Registered Trademark- products, pending FDA approval. Importantly,
these products will not detract from our promotional efforts that have
provided solid growth momentum for Ceclor-Registered Trademark- CD (cefaclor
extended release tablets) and Nasarel-Registered Trademark-(flunisolide).
Indeed, they allow us to apply our expertise and knowledge base of antibiotic
therapies and respiratory infection to the hospital market, as the products
are indicated in part for acute respiratory infection such as pneumonia, the
most frequently treated hospital infection."
<PAGE>
In addition to the strategic fit of the products, Dura expects
Maxipime-Registered Trademark- and Azactam-Registered Trademark- to have
positive financial impact. "In 1999, we expect that the products will be
mildly accretive to earnings as we will simultaneously co-promote the
products with Bristol-Myers Squibb and invest in building our own hospital
sales force. Sales of Maxipime-Registered Trademark- and Azactam-Registered
Trademark- in the year 2000 will support our goal to deliver 35% growth in
earnings-per-share, even if major pre-launch or launch expenses are incurred
for our Spiros-Registered Trademark- products during that time," said Mr.
Garner.
Dura Pharmaceuticals is a San Diego-based developer and marketer of
prescription pharmaceutical products for the treatment of allergies, asthma
and related respiratory conditions, and is developing a pulmonary drug
delivery system. Dura's mission is to be the leading pharmaceutical company
with a focus in the high-growth U.S. respiratory market. The Company is
pursuing that goal through two major strategies: (1) acquiring late-stage
prescription pharmaceuticals and/or companies with rights to such
pharmaceuticals for marketing to high-prescribing respiratory physicians and
(2) developing Spiros-Registered Trademark-, a proprietary dry powder
pulmonary drug delivery system.
Bristol-Myers Squibb is a diversified worldwide health and personal care
company whose principal businesses are pharmaceuticals, consumer medicines,
beauty care, nutritionals and medical devices. It is a leading maker of
innovative therapies for cardiovascular, metabolic and infectious diseases,
central nervous and dermatological disorders, and cancer. The company is a
leader in consumer medicines, orthopaedic devices, ostomy care, wound
management, nutritional supplements, infant formulas, and hair and skin care
products.
Except for the historical and factual information contained herein, the
matters discussed in this press release may contain forward-looking
statements which involve risks and uncertainties, including market
conditions, competitive products and pricing, seasonality, the ability of the
Company to add qualified sales representatives in a timely manner, the timely
establishment of a hospital sales force, the timely development of the
Spiros-Registered Trademark- system, the timely receipt of FDA approval of
Spiros-Registered Trademark- products, if at all, Dura's limited
manufacturing experience, dependency upon third parties and their successful
development efforts and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission. Actual results
may differ materially from those projected. Any forward-looking statements
represent the Company's judgment as of the date of this release. The Company
disclaims, however, any intent or obligation to update these forward-looking
statements.
# # #
